100286-90-6 | Irinotecan hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
25mg	95%	in stock	$69.00	$48.00
250mg	95%	in stock	$74.00	$52.00
1g	95%	in stock	$203.00	$142.00
5g	95%	in stock	$667.00	$467.00
10g	95%	in stock	$1,132.00	$793.00
25g	95%	in stock	$2,004.00	$1,403.00

Description

• Catalog Number: AI04877
• Chemical Name: Irinotecan hydrochloride
• CAS Number: 100286-90-6
• Molecular Formula: C33H39ClN4O6
• Molecular Weight: 623.1389600000001
• MDL Number: MFCD01862255
• SMILES: CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(cc4c(c3Cn1c2=O)CC)OC(=O)N1CCC(CC1)N1CCCCC1.Cl

Computed Properties

• Complexity: 1200
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 44
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5

Literature

• Plasma citrulline is a sensitive safety biomarker for small intestinal injury in rats.

  Toxicology letters 20181001

• Impact of diet on irinotecan toxicity in mice.

  Chemico-biological interactions 20180801

• Dual effect of silymarin on experimental non-alcoholic steatohepatitis induced by irinotecan.

  Toxicology and applied pharmacology 20170715

• Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.

  Toxicology in vitro : an international journal published in association with BIBRA 20170601

• Inhibition of NF-κB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38.

  Environmental toxicology 20170201

• Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activation.

  Chemico-biological interactions 20161225

• OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.

  International journal of cancer 20161101

• The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.

  Oncotarget 20160119

• Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression.

  Toxicology and applied pharmacology 20160115

• CPT-11 activates NLRP3 inflammasome through JNK and NF-κB signalings.

  Toxicology and applied pharmacology 20151201

• Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.

  Drug design, development and therapy 20150101

• ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.

  Cancer research 20141201

• Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.

  Molecules (Basel, Switzerland) 20140217

• Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.

  Toxicology and applied pharmacology 20140201

• Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).

  Proceedings of the National Academy of Sciences of the United States of America 20131119

• Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).

  Medical oncology (Northwood, London, England) 20121201

• Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.

  Investigational new drugs 20121201

• Fabrication of biodegradable micelles with sheddable poly(ethylene glycol) shells as the carrier of 7-ethyl-10-hydroxy-camptothecin.

  Colloids and surfaces. B, Biointerfaces 20121201

• Molecular structure and vibrational spectra of Irinotecan: a density functional theoretical study.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20121201

• A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20121201

• A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.

  Journal of drug targeting 20121201

• BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.

  Molecular pharmaceutics 20121105

• Relapsed hepatoblastoma.

  Pediatric blood & cancer 20121101

• Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.

  Pediatric blood & cancer 20121101

• A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20121101

• Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods.

  Biochimica et biophysica acta 20121101

• The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.

  International journal of molecular medicine 20121101

• Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20121101

• Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20121101

• Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.

  Cancer chemotherapy and pharmacology 20121101

• Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.

  Neuro-oncology 20121101

• Creation of pure nanodrugs and their anticancer properties.

  Angewandte Chemie (International ed. in English) 20121008

• Irinotecan induces senescence and apoptosis in colonic cells in vitro.

  Toxicology letters 20121002

• Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.

  Investigational new drugs 20121001

• Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20121001

• Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume.

  Magnetic resonance in medicine 20121001

• Second-line chemotherapy for advanced gastric cancer in Korea.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20121001

• UPLC and LC-MS studies on degradation behavior of irinotecan hydrochloride and development of a validated stability-indicating ultra-performance liquid chromatographic method for determination of irinotecan hydrochloride and its impurities in pharmaceutical dosage forms.

  Journal of chromatographic science 20121001

• Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20121001

• Preparation and in vitro characterization of SN-38-loaded, self-forming polymeric depots as an injectable drug delivery system.

  Journal of pharmaceutical sciences 20121001

• Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20121001

• Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.

  Journal of vascular and interventional radiology : JVIR 20121001

• Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.

  JOP : Journal of the pancreas 20120910

• Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma.

  Journal of gastrointestinal cancer 20120901

• Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC).

  Journal of cancer research and clinical oncology 20120901

• N-glycan biosynthesis inhibitors induce in vitro anticancer activity in colorectal cancer cells.

  Journal of cellular biochemistry 20120901

• Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20120901

• Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.

  Annals of surgical oncology 20120901

• AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

  Cancer chemotherapy and pharmacology 20120901

• Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity.

  AAPS PharmSciTech 20120901

• MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120901

• Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).

  Acta oncologica (Stockholm, Sweden) 20120901

• S-1 for the treatment of gastrointestinal cancer.

  Expert opinion on pharmacotherapy 20120901

• Evaluation of predictive markers for patients with advanced colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20120901

• Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.

  Anticancer research 20120901

• Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.

  Anticancer research 20120901

• [A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120901

• [A case of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix successfully treated by postoperative CPT-11+CDDP chemotherapy after non-curative surgery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120901

• [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].

  Magyar onkologia 20120901

• Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120810

• Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

  Investigational new drugs 20120801

• A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

  Investigational new drugs 20120801

• Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.

  Investigational new drugs 20120801

• Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.

  Cancer treatment reviews 20120801

• What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive preoperative chemotherapy?

  Annals of surgical oncology 20120801

• Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20120801

• Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.

  Journal of biomolecular screening 20120801

• Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20120801

• Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).

  Oncology reports 20120801

• Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.

  Molecular cancer therapeutics 20120801

• The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.

  Cancer gene therapy 20120801

• Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.

  Japanese journal of clinical oncology 20120801

• Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.

  Cancer chemotherapy and pharmacology 20120801

• Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.

  Japanese journal of clinical oncology 20120801

• Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer.

  Anticancer research 20120801

• Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia.

  The Indian journal of medical research 20120801

• The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.

  Journal of chemotherapy (Florence, Italy) 20120801

• Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

  British journal of cancer 20120724

• Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.

  International journal of cancer 20120715

• Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.

  Pediatric blood & cancer 20120715

• Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients.

  British journal of cancer 20120710

• In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20120701

• Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.

  Nanomedicine : nanotechnology, biology, and medicine 20120701

• Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120701

• FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120701

• Enhanced intracellular accumulation of a non-nucleoside anti-cancer agent via increased uptake of its valine ester prodrug through amino acid transporters.

  Xenobiotica; the fate of foreign compounds in biological systems 20120701

• Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.

  Acta oncologica (Stockholm, Sweden) 20120701

• Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics.

  Methods (San Diego, Calif.) 20120701

• Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.

  Annals of surgical oncology 20120701

• Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.

  Anti-cancer drugs 20120701

• A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.

  Acta oncologica (Stockholm, Sweden) 20120701

• A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics.

  Journal of pharmaceutical and biomedical analysis 20120701

• Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.

  Cancer chemotherapy and pharmacology 20120701

• Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.

  Cancer chemotherapy and pharmacology 20120701

• Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).

  Anti-cancer drugs 20120701

• Fertility-sparing management for bulky cervical cancer using neoadjuvant transuterine arterial chemotherapy followed by vaginal trachelectomy.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20120701

• Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients.

  Journal of vascular and interventional radiology : JVIR 20120701

• Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.

  Cell cycle (Georgetown, Tex.) 20120701

• [A case of gastric cancer with peritoneal dissemination who achieved long survival from control of ascites for over 2 years by successive treatments with S-1 in combination with docetaxel as first-line followed by irinotecan in combination with cisplatin as second-line].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120701

• Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.

  Cancer 20120615

• Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.

  Journal of medicinal chemistry 20120614

• Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

  Investigational new drugs 20120601

• The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan.

  Investigational new drugs 20120601

• Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.

  Cancer 20120601

• Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.

  Clinical colorectal cancer 20120601

• TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

  Cancer chemotherapy and pharmacology 20120601

• Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20120601

• The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.

  Oncology reports 20120601

• Conventional chemotherapy of advanced pancreatic cancer.

  Current drug targets 20120601

• MRI-monitored long-term therapeutic hydrogel system for brain tumors without surgical resection.

  Biomaterials 20120601

• ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.

  Molecular oncology 20120601

• The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.

  Cancer chemotherapy and pharmacology 20120601

• Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.

  Cancer chemotherapy and pharmacology 20120601

• Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20120601

• Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.

  Pharmacogenomics 20120601

• SN-38 loaded polymeric micelles to enhance cancer therapy.

  Nanotechnology 20120525

• Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120515

• Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer.

  British journal of cancer 20120508

• An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120501

• Peri-operative chemotherapy for resectable colorectal liver metastasis: does timing of systemic therapy matter?

  Journal of surgical oncology 20120501

• Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.

  The Journal of pathology 20120501

• Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery.

  International journal of radiation oncology, biology, physics 20120501

• Clinical development of new formulations of cytotoxics in solid tumors.

  Current opinion in oncology 20120501

• A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20120501

• Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.

  Cancer chemotherapy and pharmacology 20120501

• FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

  Neuro-oncology 20120501

• Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

• Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20120501

• Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120501

• Modulation of irinotecan-induced genomic DNA damage by theanine.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20120501

• Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

• A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.

  Japanese journal of clinical oncology 20120501

• Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells.

  The Journal of pharmacy and pharmacology 20120501

• Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120501

• Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

  British journal of clinical pharmacology 20120501

• Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy.

  HPB : the official journal of the International Hepato Pancreato Biliary Association 20120501

• Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.

  Neuro-oncology 20120501

• [Monitoring and evaluation tools for irinotecan and bevacizumab in glioblastoma: from prescription to patient's information].

  Bulletin du cancer 20120501

• Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors.

  Cell cycle (Georgetown, Tex.) 20120501

• [A case of an advanced gastric cancer patient on hemodialysis achieving long-term progression-free survival after CPT-11+CDDP therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120501

• [A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120501

• [Two cases of CPT-11 and CDDP chemotherapy for advanced pancreatic cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120501

• Cetuximab in metastatic colorectal cancer.

  Expert review of anticancer therapy 20120501

• Infused chemotherapy use in the elderly after patent expiration.

  The American journal of managed care 20120501

• Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer.

  Human molecular genetics 20120415

• Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

  The Journal of clinical investigation 20120402

• Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.

  Investigational new drugs 20120401

• Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

  Investigational new drugs 20120401

• Irinotecan injures tight junction and causes bacterial translocation in rat.

  The Journal of surgical research 20120401

• A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.

  Investigational new drugs 20120401

• A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.

  The British journal of radiology 20120401

• Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.

  International journal of clinical oncology 20120401

• Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120401

• The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120401

• Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?

  Annals of surgical oncology 20120401

• Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation.

  Cancer chemotherapy and pharmacology 20120401

• Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel.

  The Journal of pharmacology and experimental therapeutics 20120401

• Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.

  Oncology reports 20120401

• Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.

  Cancer chemotherapy and pharmacology 20120401

• Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies.

  Anti-cancer drugs 20120401

• Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells.

  Oncology reports 20120401

• Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20120401

• Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.

  European journal of gastroenterology & hepatology 20120401

• First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.

  Journal of clinical gastroenterology 20120401

• Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.

  Neurosurgery clinics of North America 20120401

• [Successful management of liver metastasis from gastric adenosquamous carcinoma with adjuvant chemotherapy and radiofrequency ablation].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20120401

• Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study.

  Anticancer research 20120401

• Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung.

  Anticancer research 20120401

• A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model.

  Small (Weinheim an der Bergstrasse, Germany) 20120326

• Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.

  Journal of pharmaceutical and biomedical analysis 20120325

• Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.

  International journal of radiation oncology, biology, physics 20120315

• Postoperative adjuvant chemotherapy in rectal cancer operated for cure.

  The Cochrane database of systematic reviews 20120314

• Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.

  British journal of cancer 20120313

• Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer.

  Medical oncology (Northwood, London, England) 20120301

• Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

  Pediatric blood & cancer 20120301

• Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces.

  Analytical and bioanalytical chemistry 20120301

• Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

  Clinical colorectal cancer 20120301

• Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.

  Clinical colorectal cancer 20120301

• Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.

  Clinical colorectal cancer 20120301

• Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

  Journal of neuro-oncology 20120301

• The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer.

  Journal of surgical oncology 20120301

• Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.

  Cancer chemotherapy and pharmacology 20120301

• Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.

  Scandinavian journal of gastroenterology 20120301

• Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.

  Scandinavian journal of gastroenterology 20120301

• Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.

  Journal of cancer research and clinical oncology 20120301

• Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.

  European journal of cancer (Oxford, England : 1990) 20120301

• Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120301

• Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer.

  Current drug delivery 20120301

• Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.

  Japanese journal of clinical oncology 20120301

• Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.

  Pharmacogenomics 20120301

• Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.

  Advances in therapy 20120301

• SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha.

  Anticancer research 20120301

• [A case of S-1-resistant resected advanced gastric cancer with para-aortic lymph node recurrence responding to bi-weekly CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120301

• A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.

  Acta gastro-enterologica Belgica 20120301

• Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.

  Journal of controlled release : official journal of the Controlled Release Society 20120227

• Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120220

• Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120215

• RAFT-derived polymer-drug conjugates: poly(hydroxypropyl methacrylamide) (HPMA)-7-ethyl-10-hydroxycamptothecin (SN-38) conjugates.

  ChemMedChem 20120206

• Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.

  Investigational new drugs 20120201

• Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.

  Investigational new drugs 20120201

• Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.

  International journal of radiation oncology, biology, physics 20120201

• Successful treatment of an intra-abdominal desmoid tumor with irinotecan, fluorouracil, and leucovorin plus bevacizumab in a patient with familial adenomatous polyposis.

  International journal of colorectal disease 20120201

• In vitro cytotoxic effect of ethanol extract prepared from sporophyll of Undaria pinnatifida on human colorectal cancer cells.

  Phytotherapy research : PTR 20120201

• Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer.

  International journal of radiation oncology, biology, physics 20120201

• Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.

  Annals of surgical oncology 20120201

• Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas.

  Biochimie 20120201

• Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.

  Cancer science 20120201

• Human neural stem cell tropism to metastatic breast cancer.

  Stem cells (Dayton, Ohio) 20120201

• Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120201

• Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

  Cancer research 20120201

• Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120201

• Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.

  Molecular cancer therapeutics 20120201

• Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20120201

• An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120201

• [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].

  Bulletin du cancer 20120201

• Viewing metastatic colorectal cancer as a curable chronic disease.

  American journal of clinical oncology 20120201

• [A case of cecal cancer with abdominal wall abscess].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120201

• [A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120201

• Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).

  British journal of cancer 20120131

• Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120120

• Comparison of the predictive ability of several second-order multivariate methods in the simultaneous determination of two therapeutic drugs in human urine.

  Talanta 20120115

• Total synthesis of camptothecin and SN-38.

  The Journal of organic chemistry 20120106

• Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.

  International journal of radiation oncology, biology, physics 20120101

• Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

  International journal of radiation oncology, biology, physics 20120101

• A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.

  Molecular biology reports 20120101

• Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.

  Cancer chemotherapy and pharmacology 20120101

• Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.

  International journal of oncology 20120101

• Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.

  Oncology reports 20120101

• Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.

  Cancer science 20120101

• A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.

  Molecular cancer therapeutics 20120101

• Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.

  Neuro-oncology 20120101

• In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis.

  Molecular medicine (Cambridge, Mass.) 20120101

• Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.

  Molecular cancer therapeutics 20120101

• Kampo medicine 'Dai-kenchu-to' prevents CPT-11-induced small-intestinal injury in rats.

  Surgery today 20120101

• Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.

  Neoplasma 20120101

• The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients.

  Surgery today 20120101

• Usefulness of multidisciplinary therapy combining neoadjuvant chemotherapy with S-1 plus cisplatin and postoperative sequential chemotherapy in patients with scirrhous gastric cancer.

  Hepato-gastroenterology 20120101

• TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.

  Scandinavian journal of gastroenterology 20120101

• Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.

  Pharmacogenomics 20120101

• Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.

  Drug metabolism and pharmacokinetics 20120101

• Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence.

  Anticancer research 20120101

• Involvement of specific transport system on uptake of lactone form of SN-38 in human intestinal epithelial cell line Caco-2.

  Biological & pharmaceutical bulletin 20120101

• Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20120101

• The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20120101

• [Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20120101

• Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.

  Oncology 20120101

• Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.

  BMC cancer 20120101

• Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.

  European journal of gynaecological oncology 20120101

• Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab.

  Journal of translational medicine 20120101

• The developing clinical problem of chemotherapy-induced hepatic injury.

  ANZ journal of surgery 20120101

• A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.

  Oncology 20120101

• A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.

  Oncology 20120101

• Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.

  Asian Pacific journal of cancer prevention : APJCP 20120101

• A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

  BMC cancer 20120101

• Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma.

  Biological & pharmaceutical bulletin 20120101

• Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

  PloS one 20120101

• [Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment].

  Bulletin du cancer 20120101

• XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.

  BMC cancer 20120101

• Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.

  Oncology 20120101

• DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.

  Current medicinal chemistry 20120101

• Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.

  Oncology 20120101

• Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.

  PloS one 20120101

• Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats.

  PloS one 20120101

• Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.

  European journal of gynaecological oncology 20120101

• [Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].

  Voprosy onkologii 20120101

• p53 Dimers associate with a head-to-tail response element to repress cyclin B transcription.

  PloS one 20120101

• Preclinical combination therapy of thiarabine plus various clinical anticancer agents.

  Nucleosides, nucleotides & nucleic acids 20120101

• Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.

  Asian Pacific journal of cancer prevention : APJCP 20120101

• Nedaplatin and irinotecan for patients with recurrent small cell lung cancer.

  Journal of experimental therapeutics & oncology 20120101

• Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.

  Oncology 20120101

• Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer.

  Onkologie 20120101

• EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

  PloS one 20120101

• Neurodevelopmental disorders. New hope for a devastating neurological disorder.

  Science (New York, N.Y.) 20111223

• Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.

  Cancer letters 20111208

• Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.

  The pharmacogenomics journal 20111201

• High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.

  The Journal of surgical research 20111201

• Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.

  Medical oncology (Northwood, London, England) 20111201

• Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

  Cancer 20111201

• Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20111201

• Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.

  Lung cancer (Amsterdam, Netherlands) 20111201

• Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20111201

• Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

  Journal of neuro-oncology 20111201

• Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.

  Current drug metabolism 20111201

• Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells.

  Biochemical pharmacology 20111201

• The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.

  Cancer chemotherapy and pharmacology 20111201

• Novel activity of acriflavine against colorectal cancer tumor cells.

  Cancer science 20111201

• A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20111201

• Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20111201

• Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.

  Annals of surgery 20111201

• Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20111201

• Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111201

• The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.

  Clinical colorectal cancer 20111201

• Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority.

  Drug safety 20111201

• Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.

  American journal of clinical oncology 20111201

• Contrast-enhanced ultrasonography with intraarterial administration of SonoVue for guidance of transarterial chemoembolization: an initial experience.

  Medical ultrasonography 20111201

• When do you need a validated assay?

  Bioanalysis 20111201

• Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).

  Anticancer research 20111201

• Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study.

  Anticancer research 20111201

• Salvage chemotherapy for ovarian carcinoma recurring during or after consolidation chemotherapy with paclitaxel.

  Anticancer research 20111201

• [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].

  Zhonghua fu chan ke za zhi 20111201

• Inflammatory macrophages induce Nrf2 transcription factor-dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection.

  The Journal of biological chemistry 20111125

• Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.

  British journal of cancer 20111122

• Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111120

• Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses.

  Biochemical and biophysical research communications 20111118

• MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.

  European journal of pharmacology 20111116

• KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.

  International journal of radiation oncology, biology, physics 20111115

• An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.

  British journal of cancer 20111108

• Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.

  International journal of radiation oncology, biology, physics 20111101

• [An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].

  Revue neurologique 20111101

• Synergistic effects of irinotecan and flavonoids on Ehrlich ascites tumour-bearing mice.

  Basic & clinical pharmacology & toxicology 20111101

• The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.

  Journal of surgical oncology 20111101

• Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence?

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20111101

• Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.

  European journal of cancer (Oxford, England : 1990) 20111101

• PDZK1 regulates breast cancer resistance protein in small intestine.

  Drug metabolism and disposition: the biological fate of chemicals 20111101

• The polypyrimidine/polypurine motif in the mouse mu opioid receptor gene promoter is a supercoiling-regulatory element.

  Gene 20111101

• Therapeutic targeting of subdural medulloblastomas using human neural stem cells expressing carboxylesterase.

  Cancer gene therapy 20111101

• Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.

  Cancer biology & therapy 20111101

• MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.

  Stem cells (Dayton, Ohio) 20111101

• Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.

  NMR in biomedicine 20111101

• Looking through the vascular normalization window: timing antiangiogenic treatment and chemotherapy with (99m)Tc-annexin A5.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20111101

• Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.

  The oncologist 20111101

• (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20111101

• [Molecular determinants of response to topoisomerase I inhibitors].

  Bulletin du cancer 20111101

• Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.

  Nanomedicine (London, England) 20111101

• [A case of advanced gastric cancer with splenic vein thrombus successfully treated with S-1 plus CPT-11 neoadjuvant chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• [A case of gastric neuroendocrine cell carcinoma successfully treated by neoadjuvant chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• [A case report of pathologically complete response of rectal cancer after preoperative treatment of CPT-11, S-1, and radiation therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• Identification of carboxylesterases expressed in rat intestine and effects of their hydrolyzing activity in predicting first-pass metabolism of ester prodrugs.

  Die Pharmazie 20111101

• Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.

  Cancer letters 20111028

• Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111015

• NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines.

  Biochemical and biophysical research communications 20111014

• Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.

  British journal of cancer 20111011

• Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.

  Investigational new drugs 20111001

• Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.

  Investigational new drugs 20111001

• Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study.

  International journal of clinical oncology 20111001

• Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.

  Cancer chemotherapy and pharmacology 20111001

• A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.

  Cancer chemotherapy and pharmacology 20111001

• Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.

  Cancer chemotherapy and pharmacology 20111001

• Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?

  Cancer 20111001

• Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat.

  International journal of experimental pathology 20111001

• Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.

  Cancer science 20111001

• Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.

  Gynecologic oncology 20111001

• Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

  European journal of cancer (Oxford, England : 1990) 20111001

• Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit.

  Molecular cancer therapeutics 20111001

• [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20111001

• Transient elevation of international normalized ratio during cisplatin-based chemotherapy in patients who are taking warfarin.

  The Annals of pharmacotherapy 20111001

• [Chemotherapy and rectal cancer].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20111001

• Intraperitoneally administered irinotecan with 5-fluorouracil impair wound healing of colonic anastomoses in a rat model: an experimental study.

  Techniques in coloproctology 20111001

• FOLFIRINOX: a small step or a great leap forward?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111001

• Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.

  The Lancet. Oncology 20111001

• Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.

  Chinese journal of cancer 20111001

• ERas enhances resistance to CPT-11 in gastric cancer.

  Anticancer research 20111001

• Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer.

  Anticancer research 20111001

• A safety and toxicity assessment of the administration of multiple intracerebral injections of irinotecan or doxorubicin drug-eluting beads.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20111001

• Localized skin necrosis of steroid-induced striae distensae: an unusual complication of bevacizumab and irinotecan therapy.

  Archives of dermatology 20111001

• Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue.

  Bioconjugate chemistry 20110921

• Total synthesis of 7-ethyl-10-hydroxycamptothecin (SN38) and its application to the development of C18-functionalized camptothecin derivatives.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20110905

• Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.

  Critical reviews in oncology/hematology 20110901

• Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid.

  Cancer chemotherapy and pharmacology 20110901

• Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20110901

• Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.

  Annals of surgical oncology 20110901

• Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.

  Angiogenesis 20110901

• Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience.

  Journal of surgical oncology 20110901

• Activity of aspirin analogues and vanillin in a human colorectal cancer cell line.

  Oncology reports 20110901

• Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110901

• Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.

  Cancer science 20110901

• Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a 'real world' analysis using Surveillance, Epidemiology, and End Results-Medicare data.

  Journal of the American Geriatrics Society 20110901

• Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.

  Japanese journal of clinical oncology 20110901

• An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

  Clinical colorectal cancer 20110901

• Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.

  Clinical colorectal cancer 20110901

• Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.

  Clinical colorectal cancer 20110901

• Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.

  The oncologist 20110901

• Five hundred patients with Merkel cell carcinoma evaluated at a single institution.

  Annals of surgery 20110901

• Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.

  Anticancer research 20110901

• Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.

  Surgery today 20110901

• [CPT-11 chemotherapy for a hemodialysis patient with small-cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110901

• [Irinotecan as second-line chemotherapy for 5-FU-resistant gastric cancer with disseminated intravascular coagulation: a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110901

• A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery.

  PLoS computational biology 20110901

• Diarrhea.

  Disease-a-month : DM 20110901

• Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.

  Gan to kagaku ryoho. Cancer & chemotherapy 20110901

• [A relapse of small-cell lung cancer ten years after concomitant chemoradiotherapy followed by high-dose chemotherapy with autologous peripheral blood stem cell transfusion].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20110901

• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  The New England journal of medicine 20110825

• Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.

  Journal of controlled release : official journal of the Controlled Release Society 20110810

• Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110810

• Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110810

• [Pathological changes of rectal cancer after irinotecan, 5-fluorouracil or combined short-term radiotherapy].

  Zhonghua yi xue za zhi 20110809

• Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.

  Journal of the National Cancer Institute 20110803

• Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS.

  Investigational new drugs 20110801

• UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20110801

• The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.

  Cancer chemotherapy and pharmacology 20110801

• Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura.

  International journal of clinical oncology 20110801

• A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110801

• Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer.

  International journal of clinical oncology 20110801

• A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.

  Cancer letters 20110801

• A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110801

• Second-line chemotherapy in patients with primary unknown cancer.

  Journal of cancer research and clinical oncology 20110801

• Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.

  Expert opinion on drug metabolism & toxicology 20110801

• Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.

  Cancer research 20110801

• Pulmonary artery chemoembolization in a sheep model: Evaluation of performance and safety of irinotecan eluting beads (DEB-IRI).

  Journal of biomedical materials research. Part B, Applied biomaterials 20110801

• Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].

  European journal of cancer (Oxford, England : 1990) 20110801

• Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.

  Cancer biology & therapy 20110801

• Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones.

  Bioorganic & medicinal chemistry 20110801

• Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.

  Annals of surgery 20110801

• Using bevacizumab in the fight against malignant glioma: first results in Asian patients.

  Hong Kong medical journal = Xianggang yi xue za zhi 20110801

• [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110801

• [A case of advanced gastric cancer with multiple liver metastasis responding to S-1 and irinotecan combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110801

• [A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110801

• Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.

  Cancer 20110715

• Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.

  British journal of cancer 20110712

• Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110710

• Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?

  Nature reviews. Clinical oncology 20110705

• Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20110701

• Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.

  Gastroenterology 20110701

• New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots.

  Cancer science 20110701

• Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301).

  Anti-cancer drugs 20110701

• Adjuvant treatment of colon cancer: what is next?

  Current opinion in oncology 20110701

• Cetuximab in the treatment of patients with colorectal cancer.

  Expert opinion on biological therapy 20110701

• Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.

  Anti-cancer drugs 20110701

• Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

  Molecular cancer therapeutics 20110701

• Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.

  Journal of pediatric hematology/oncology 20110701

• Development of thermosensitive poly(n-isopropylacrylamide-co-((2-dimethylamino) ethyl methacrylate))-based nanoparticles for controlled drug release.

  Nanotechnology 20110701

• Comparative proteomic analysis of irinotecan-sensitive colorectal carcinoma cell line and its chemoresistant counterpart.

  Anti-cancer drugs 20110701

• [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110701

• [Protective effects of d-chlorpheniramine maleate pre-treatment against acute side effects of Irinotecan(CPT- 11)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110701

• [A case of interstitial pneumonia induced by CPT-11 for local recurrence of rectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110701

• A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.

  British journal of cancer 20110628

• The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110615

• Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

  Critical reviews in oncology/hematology 20110601

• A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

  Cancer chemotherapy and pharmacology 20110601

• Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.

  Journal of neuro-oncology 20110601

• Capecitabine-based chemotherapy for metastatic colorectal cancer.

  Journal of cancer research and clinical oncology 20110601

• Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110601

• Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.

  Annals of surgical oncology 20110601

• Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110601

• Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110601

• Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110601

• Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.

  Cancer gene therapy 20110601

• Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 20110601

• Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.

  Biochemical pharmacology 20110601

• Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.

  Molecular cancer therapeutics 20110601

• CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.

  Current cancer drug targets 20110601

• Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.

  Molecular imaging 20110601

• Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.

  The Journal of pharmacy and pharmacology 20110601

• O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110601

• Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

  The oncologist 20110601

• Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.

  The oncologist 20110601

• [Clinical efficacy and safety of CPT-11+CDDP therapy as third-line chemotherapy for advanced and recurrent gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110601

• [Primary adenocarcinoma of small intestine with peritoneal dissemination treated with S-1 and CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110601

• Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.

  Anticancer research 20110601

• Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer.

  Anti-cancer drugs 20110601

• A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.

  Clinical colorectal cancer 20110601

• Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.

  British journal of cancer 20110524

• Use of irinotecan for treatment of small cell carcinoma of the prostate.

  The Prostate 20110515

• Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

• A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.

  Cancer 20110515

• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  The New England journal of medicine 20110512

• Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs.

  Cancer chemotherapy and pharmacology 20110501

• Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20110501

• Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110501

• Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110501

• Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.

  European journal of cancer (Oxford, England : 1990) 20110501

• Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.

  European journal of cancer (Oxford, England : 1990) 20110501

• Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.

  International journal of cancer 20110501

• Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20110501

• A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110501

• [A resected case of advanced gastric cancer with multiple liver metastasis successfully treated by preoperative and postoperative S-1/CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110501

• [Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110501

• Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.

  Anticancer research 20110501

• A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.

  Clinical lung cancer 20110501

• Sex and dosing-time dependencies in irinotecan-induced circadian disruption.

  Chronobiology international 20110501

• DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study.

  World journal of gastroenterology 20110414

• Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110410

• Few positives for triple-negative breast cancer.

  Journal of the National Cancer Institute 20110406

• Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma.

  Molecular pharmaceutics 20110404

• A model of primary culture of colorectal cancer and liver metastasis to predict chemosensitivity.

  The Journal of surgical research 20110401

• Dietary glycine protects from chemotherapy-induced hepatotoxicity.

  Amino acids 20110401

• Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110401

• Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20110401

• ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.

  Neuroradiology 20110401

• Irinotecan and radiosensitization in rectal cancer.

  Anti-cancer drugs 20110401

• The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™.

  Pharmaceutical research 20110401

• Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.

  Brain tumor pathology 20110401

• Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.

  European journal of cancer (Oxford, England : 1990) 20110401

• Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy.

  Cancer science 20110401

• Long-term survival in a patient with small-cell lung cancer undergoing hemodialysis who received multiple courses of chemotherapy.

  Japanese journal of clinical oncology 20110401

• R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20110401

• Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.

  Japanese journal of clinical oncology 20110401

• Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.

  Japanese journal of clinical oncology 20110401

• Barking up the wrong genome--we are not alone.

  Journal of clinical pharmacy and therapeutics 20110401

• Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

  Expert opinion on pharmacotherapy 20110401

• Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.

  The American journal of pathology 20110401

• [A case of recurrent gastric cancer with lymph node metastasis successfully treated by CPT-11/CDDP therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110401

• [A case report of primary duodenal adenocarcinoma responding to chemotherapy with S-1 and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110401

• Acneiform eruption following molecular targeted chemotherapy.

  Internal medicine journal 20110401

• APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population.

  Pharmacogenomics 20110401

• [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110401

• [Chemotherapy for advanced colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• [Importance and practice of UGT1A1 polymorphisms].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• [Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• [Treatment with CPT-11 based on the UGT1A1 genetic polymorphism].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity.

  Journal of controlled release : official journal of the Controlled Release Society 20110330

• Lipopolysaccharide down-regulates carbolesterases 1 and 2 and reduces hydrolysis activity in vitro and in vivo via p38MAPK-NF-κB pathway.

  Toxicology letters 20110325

• Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect.

  Advanced drug delivery reviews 20110318

• Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study.

  International journal of radiation oncology, biology, physics 20110315

• Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38.

  International journal of pharmaceutics 20110315

• Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110310

• Three-drug combination regimen in pancreatic cancer treatment: are we there yet?

  JOP : Journal of the pancreas 20110309

• Treatment for refractory pancreatic cancer. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011.

  JOP : Journal of the pancreas 20110309

• Cytokeratin expression patterns in multiple infundibulocystic basal cell carcinoma.

  Journal of cutaneous pathology 20110301

• Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.

  Medical oncology (Northwood, London, England) 20110301

• Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.

  Journal of neurosurgery 20110301

• Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.

  Cancer chemotherapy and pharmacology 20110301

• Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.

  Cancer chemotherapy and pharmacology 20110301

• Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.

  Annals of surgical oncology 20110301

• A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.

  International journal of radiation oncology, biology, physics 20110301

• High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.

  Pediatric blood & cancer 20110301

• Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.

  Pediatric blood & cancer 20110301

• Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.

  Japanese journal of clinical oncology 20110301

• A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.

  Cancer chemotherapy and pharmacology 20110301

• Effect of kaempferol on lipid peroxidation and antioxidant status in 1,2-dimethyl hydrazine induced colorectal carcinoma in rats.

  European journal of pharmacology 20110301

• Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

  Cancer research 20110301

• The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.

  European journal of cancer (Oxford, England : 1990) 20110301

• Feasibility of EUS-guided injection of irinotecan-loaded microspheres into the swine pancreas.

  Gastrointestinal endoscopy 20110301

• Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.

  Asia-Pacific journal of clinical oncology 20110301

• Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110301

• Spectrofluorimetric determination of SN-38, a promising new anti-tumor agent, in the presence and absence of organized media.

  Applied spectroscopy 20110301

• Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110301

• Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.

  Neoplasia (New York, N.Y.) 20110301

• [A case of spindle cell carcinoma of the breast, in which irinotecan was effective against respiratory failure due to pulmonary metastases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• [Palliative anti-cancer chemotherapy is safely executable in a hemodialytic patient with unresectable advanced gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• [A case of drug-induced interstitial pneumonia caused by S-1 and CPT-11 combination therapy for advanced colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.

  Clinical colorectal cancer 20110301

• Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.

  Clinical colorectal cancer 20110301

• Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.

  The pharmacogenomics journal 20110201

• Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.

  Cancer chemotherapy and pharmacology 20110201

• Acute thrombocytopenia: an unusual complication occurring after drug-eluting microspheres transcatheter hepatic chemoembolization.

  Cardiovascular and interventional radiology 20110201

• Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival.

  Annals of surgical oncology 20110201

• Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.

  Japanese journal of clinical oncology 20110201

• Delayed elimination of SN-38 in cancer patients with severe renal failure.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients.

  Clinics and research in hepatology and gastroenterology 20110201

• Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.

  Cancer research 20110201

• Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.

  International journal of colorectal disease 20110201

• Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft.

  Cancer science 20110201

• Changing management and survival in patients with stage IV colorectal cancer.

  Diseases of the colon and rectum 20110201

• Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110201

• Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

  Neurology 20110201

• [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110201

• Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110110

• Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.

  Cancer chemotherapy and pharmacology 20110101

• Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.

  Cancer chemotherapy and pharmacology 20110101

• Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding.

  Cancer chemotherapy and pharmacology 20110101

• Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.

  Cancer chemotherapy and pharmacology 20110101

• Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.

  Cancer chemotherapy and pharmacology 20110101

• Effects of methimazole on the elimination of irinotecan.

  Cancer chemotherapy and pharmacology 20110101

• Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.

  Annals of surgical oncology 20110101

• A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.

  Japanese journal of clinical oncology 20110101

• The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1.

  Cancer chemotherapy and pharmacology 20110101

• Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.

  The Journal of pathology 20110101

• Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.

  Biochemical pharmacology 20110101

• 18Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer.

  Journal of surgical oncology 20110101

• High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma.

  European journal of cancer (Oxford, England : 1990) 20110101

• Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20110101

• FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?

  The Lancet. Oncology 20110101

• Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110101

• Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110101

• The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.

  The oncologist 20110101

• A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.

  BMC medicine 20110101

• Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis.

  Chemotherapy 20110101

• Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110101

• [Analysis of gene expression patterns in an irinotecan-resistance colon cancer cell by cDNA microarray].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20110101

• EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.

  BMC cancer 20110101

• Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study.

  Chemotherapy 20110101

• A fully integrated and automated detection system for single nucleotide polymorphisms of UGT1A1 and CYP2C19.

  Oncology research 20110101

• Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.

  BMC cancer 20110101

• Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing.

  Medical science monitor : international medical journal of experimental and clinical research 20110101

• Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer: an analysis in Western patients.

  Tumori 20110101

• Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer.

  Asian Pacific journal of cancer prevention : APJCP 20110101

• Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment.

  BMC medical genomics 20110101

• Esophageal small-cell carcinoma with syndrome of inappropriate secretion of antidiuretic hormone.

  Internal medicine (Tokyo, Japan) 20110101

• Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.

  Chemotherapy 20110101

• Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.

  Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20110101

• Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer.

  Tumori 20110101

• Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

  Clinics and research in hepatology and gastroenterology 20110101

• Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).

  Oncology 20110101

• Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum.

  PloS one 20110101

• Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

• Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.

  Oncology 20110101

• Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.

  Oncology 20110101

• Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.

  Molecular cancer 20110101

• In Situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20110101

• Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma.

  Onkologie 20110101

• First-order multivariate calibration applied to the simultaneous fluorometric determination of the anticancer agents CPT-11 and SN-38 in serum and urine samples.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20110101

• Common side effects and interactions of colorectal cancer therapeutic agents.

  The Journal of practical nursing 20110101

• First-line therapy for metastatic colorectal carcinoma: modified FOLFOX4 or FOLFIRI-bevacizumab.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

• 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

  Oncology 20110101

• Irinotecan as a second-line monotherapy for small cell lung cancer.

  Asian Pacific journal of cancer prevention : APJCP 20110101

• [Chemotherapy in patients with non-resectable colorectal cancer metastases to the liver: systemic or regional?].

  Voprosy onkologii 20110101

• Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.

  BMC cancer 20110101

• Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.

  BMC cancer 20110101

• A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.

  BMC cancer 20110101

• Effect of 5-fluorouracil treatment on SN-38 absorption from intestine in rats.

  Biological & pharmaceutical bulletin 20110101

• The efficacy of chemotherapy in patients with high-grade metastatic colon cancer.

  Hepato-gastroenterology 20110101

• Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.

  Oncology 20110101

• High-density real-time PCR-based in vivo toxicogenomic screen to predict organ-specific toxicity.

  International journal of molecular sciences 20110101

• The continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer offers a survival benefit.

  Hepato-gastroenterology 20110101

• [Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110101

• Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?

  European journal of gynaecological oncology 20110101

• Immunogenicity of panitumumab in combination chemotherapy clinical trials.

  BMC clinical pharmacology 20110101

• Long-term survival and improved quality of life after chemoradiotherapy to treat esophageal small cell carcinoma: a report of two cases.

  Hepato-gastroenterology 20110101

• Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents.

  Drug metabolism and drug interactions 20110101

• A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer.

  Chang Gung medical journal 20110101

• Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.

  World journal of surgical oncology 20110101

• SN-38:β-cyclodextrin inclusion complex for in situ solidifying injectable polymer implants.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20110101

• HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.

  Asian Pacific journal of cancer prevention : APJCP 20110101

• Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.

  Cancer 20101215

• Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials.

  World journal of gastroenterology 20101214

• Guesstimates are not good enough for determining what is happening in routine care.

  British journal of cancer 20101207

• MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.

  Medical oncology (Northwood, London, England) 20101201

• Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan.

  Medical oncology (Northwood, London, England) 20101201

• A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.

  American journal of clinical oncology 20101201

• Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.

  International journal of cancer 20101201

• Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.

  European journal of cancer (Oxford, England : 1990) 20101201

• P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.

  Drug metabolism letters 20101201

• Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.

  European journal of clinical pharmacology 20101201

• CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8.

  Clinical & experimental metastasis 20101201

• Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.

  Cancer investigation 20101201

• [Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases].

  Cirugia espanola 20101201

• Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.

  Oncology reports 20101201

• An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.

  Oncology reports 20101201

• Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.

  Cancer science 20101201

• A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20101201

• Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.

  Molecular cancer therapeutics 20101201

• Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.

  Anticancer research 20101201

• Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.

  Clinical colorectal cancer 20101201

• Proteomic analysis of cell lines to identify the irinotecan resistance proteins.

  Journal of biosciences 20101201

• Laser induced fluorescence and photochemical derivatization for trace determination of camptothecin.

  Talanta 20101115

• Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.

  British journal of cancer 20101109

• Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.

  British journal of cancer 20101109

• Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.

  British journal of cancer 20101109

• Cancer. Targeting bacteria to improve cancer therapy.

  Science (New York, N.Y.) 20101105

• Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.

  Science (New York, N.Y.) 20101105

• The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany.

  European journal of cancer care 20101101

• Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.

  Head & neck 20101101

• Molecular predictive and prognostic markers in colon cancer.

  Cancer treatment reviews 20101101

• Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20101101

• Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy.

  Gynecologic oncology 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Expression of phosphorylated Akt in patients with small cell carcinoma of the lung indicates good prognosis.

  Pathology international 20101101

• A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.

  Cancer chemotherapy and pharmacology 20101101

• [Effects of irinotecan and 5-FU combination therapy in gastric cancer--is combination therapy synergic?].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Risk associated with severe hematological toxicity in patients with advanced or recurrent colonic cancer receiving combination chemotherapy of S-1 and irinotecan hydrochloride].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of complete resection of a squamous cell lung cancer invading diaphragm after neoadjuvant chemotherapy of nedaplatin and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron after chemotherapy including irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20101101

• XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.

  Anticancer research 20101101

• Maintenance therapy in colon cancer.

  Cancer treatment reviews 20101101

• Update on capecitabine alone and in combination regimens in colorectal cancer patients.

  Cancer treatment reviews 20101101

• Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.

  Chinese medical journal 20101101

• [Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of small cell carcinoma of esophagus treated by chemotherapy with CDDP plus CPT-11 and radiotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of pneumocystis pneumonia during chemotherapy for gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A clinical case of lymph node recurrence after resection of gastric cancer successfully treated by combination chemotherapy with irinotecan and cisplatin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A successful case with CPT-11 + CDDP chemotherapy for recurrent gastric cancer of the remnant stomach].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A long-term survival case of bilateral ovarian metastasis of progressive gastric cancer treated by chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Two cases of gastric endocrine cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of gastric endocrine cell carcinoma with liver metastases treated with S-1/CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [The efficacy of cetuximab for metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Adrenalectomy for solitary adrenal metastasis from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A long-term survival case of rectal cancer with Virchow's lymph node metastasis by multimodality therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [An experience of curative resection of local recurrent rectal cancer with high-level sacrectomy after preoperative chemo-radiation therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of synchronous double cancer of stomach and lung responding to neoadjuvant chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

  British journal of cancer 20101026

• Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.

  British journal of cancer 20101026

• Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation.

  Bioconjugate chemistry 20101020

• Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020

• Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.

  International journal of cancer 20101015

• Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101015

• Cetuximab in small bowel adenocarcinoma: a new friend?

  British journal of cancer 20101012

• Genotoxic effects of irinotecan combined with the novel platinum(II) complexes in human cancer cells.

  Chemico-biological interactions 20101006

• A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20101001

• Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.

  Cancer chemotherapy and pharmacology 20101001

• The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.

  Cancer chemotherapy and pharmacology 20101001

• Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.

  Lung cancer (Amsterdam, Netherlands) 20101001

• Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.

  American journal of clinical oncology 20101001

• Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.

  The pharmacogenomics journal 20101001

• Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.

  Annals of surgical oncology 20101001

• Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis.

  Annals of surgical oncology 20101001

• A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).

  Japanese journal of clinical oncology 20101001

• The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.

  Cancer 20101001

• Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.

  International journal of colorectal disease 20101001

• A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20101001

• Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry.

  Cardiovascular and interventional radiology 20101001

• Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat.

  Experimental biology and medicine (Maywood, N.J.) 20101001

• Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype.

  Therapeutic drug monitoring 20101001

• Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101001

• Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly.

  Pharmaceutical research 20101001

• [Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].

  RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 20101001

• Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101001

• Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.

  Oncology reports 20101001

• [mRNA quantification. The next challenge in routine diagnostics].

  Der Pathologe 20101001

• Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20101001

• Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20101001

• Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.

  The oncologist 20101001

• Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).

  Best practice & research. Clinical gastroenterology 20101001

• Induction chemoradiation therapy with cisplatin plus irinotecan followed by surgical resection for superior sulcus tumor.

  Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 20101001

• Synergistic effects of topoisomerase I inhibitor, SN38, on Fas-mediated apoptosis.

  Anticancer research 20101001

• Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).

  Anticancer research 20101001

• Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.

  Anticancer research 20101001

• A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.

  Anticancer research 20101001

• [A rare case of large cell neuroendocrine carcinoma of the thymus].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20101001

• [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101001

• [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101001

• A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.

  British journal of cancer 20100928

• Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).

  Journal of chromatography. A 20100910

• Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.

  Medical oncology (Northwood, London, England) 20100901

• Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.

  Medical oncology (Northwood, London, England) 20100901

• Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme.

  Current stem cell research & therapy 20100901

• Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents.

  International journal of cancer 20100901

• Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.

  Journal of neuro-oncology 20100901

• Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts.

  Cancer chemotherapy and pharmacology 20100901

• Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.

  Journal of neuro-oncology 20100901

• Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma.

  Journal of neuro-oncology 20100901

• Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100901

• A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100901

• Bevacizumab in recurrent high-grade pediatric gliomas.

  Neuro-oncology 20100901

• Canine spontaneous glioma: a translational model system for convection-enhanced delivery.

  Neuro-oncology 20100901

• Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.

  Cancer 20100901

• Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

  Cancer science 20100901

• Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.

  Journal of materials science. Materials in medicine 20100901

• Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.

  Anti-cancer drugs 20100901

• Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.

  Anti-cancer drugs 20100901

• A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100901

• Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.

  The American journal of surgical pathology 20100901

• Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.

  The Lancet. Oncology 20100901

• Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

  The Lancet. Oncology 20100901

• Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.

  British journal of clinical pharmacology 20100901

• [Metastatic gastric cancer: does second-line chemotherapy make sense?].

  Deutsche medizinische Wochenschrift (1946) 20100901

• Are herbal medicines ripe for the cancer clinic?

  Science translational medicine 20100818

• The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity.

  Science translational medicine 20100818

• Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes.

  Life sciences 20100814

• Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.

  World journal of gastroenterology 20100814

• Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100810

• UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.

  British journal of cancer 20100810

• Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.

  American journal of clinical oncology 20100801

• A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.

  American journal of clinical oncology 20100801

• Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.

  Cancer chemotherapy and pharmacology 20100801

• Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.

  Journal of neuro-oncology 20100801

• A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery.

  International journal of clinical oncology 20100801

• Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.

  Cancer chemotherapy and pharmacology 20100801

• Choroidal metastases from esophageal adenocarcinoma responding to chemotherapy with cisplatin and irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100801

• Pharmacogenetics of irinotecan disposition and toxicity: a review.

  Current clinical pharmacology 20100801

• Different DNA immobilization strategies for the interaction of anticancer drug irinotecan with DNA based on electrochemical DNA biosensors.

  Combinatorial chemistry & high throughput screening 20100801

• BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization.

  Cancer science 20100801

• Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100801

• Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20100801

• Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.

  British journal of pharmacology 20100801

• Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

  British journal of clinical pharmacology 20100801

• Consequences of chemotherapy on resection of colorectal liver metastases.

  Journal of visceral surgery 20100801

• Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).

  The Journal of pharmacy and pharmacology 20100801

• Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20100801

• When more is worse in clinical research and clinical practice.

  American journal of clinical oncology 20100801

• Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100801

• [A case of gastric adenosquamous carcinoma successfully treated with second-line chemotherapy (CPT-11 and CDDP)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100801

• [A case of irinotecan-induced interstitial pneumonia during treatment of recurrent colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100801

• Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20100801

• Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20100801

• Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.

  British journal of cancer 20100727

• Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.

  Cancer chemotherapy and pharmacology 20100701

• Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100701

• Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression.

  International journal of colorectal disease 20100701

• Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.

  Japanese journal of clinical oncology 20100701

• Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.

  European journal of cancer (Oxford, England : 1990) 20100701

• Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.

  Anti-cancer drugs 20100701

• Cytotoxicity and topo I targeting activity of substituted 10--nitrogenous heterocyclic aromatic group derivatives of SN-38.

  European journal of medicinal chemistry 20100701

• Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.

  Pediatric blood & cancer 20100701

• Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma.

  Expert opinion on pharmacotherapy 20100701

• Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701

• Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.

  Advances in therapy 20100701

• Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer.

  Journal of surgical oncology 20100701

• The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.

  European journal of cancer (Oxford, England : 1990) 20100701

• Irinotecan pharmacogenomics.

  Pharmacogenomics 20100701

• Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan.

  Journal of vascular and interventional radiology : JVIR 20100701

• Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.

  Clinical lung cancer 20100701

• [Recent developments of pharmacogenomics in the treatment of colorectal cancers].

  Annales pharmaceutiques francaises 20100701

• [A resected case of effective treatment with S-1+CPT-11 combination chemotherapy for advanced gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer.

  Anticancer research 20100701

• Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620

• Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38.

  International journal of cancer 20100615

• Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100601

• A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.

  American journal of clinical oncology 20100601

• Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.

  Lung cancer (Amsterdam, Netherlands) 20100601

• A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.

  American journal of clinical oncology 20100601

• Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines.

  Nanomedicine : nanotechnology, biology, and medicine 20100601

• The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.

  Journal of cancer research and clinical oncology 20100601

• Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer.

  International journal of radiation oncology, biology, physics 20100601

• Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20100601

• Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.

  International journal of clinical oncology 20100601

• Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11).

  International journal of clinical oncology 20100601

• Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.

  American journal of clinical oncology 20100601

• Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

  European journal of cancer (Oxford, England : 1990) 20100601

• Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy.

  The American journal of surgical pathology 20100601

• Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.

  Oncology reports 20100601

• Pharmacokinetics of intraperitoneal irinotecan in a pig model.

  Journal of surgical oncology 20100601

• A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100601

• [Transition of chemotherapy for metastatic colorectal cancer and recent advances].

  Nihon rinsho. Japanese journal of clinical medicine 20100601

• Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.

  Chemotherapy 20100601

• [Third-line CPT-11 chemotherapy for gastric cancer cases of non-curative gastrectomy or recurrence].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100601

• [Utility of CPT-11 as salvage chemotherapy for progressive or recurrent breast cancer patients with multiple drug resistance].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100601

• Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer.

  Anticancer research 20100601

• Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100520

• Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.

  Cancer 20100515

• Thermodynamic studies and loading of 7-ethyl-10-hydroxycamptothecin into mesoporous silica particles MCM-41 in strongly acidic solutions.

  The journal of physical chemistry. B 20100506

• Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.

  Cancer chemotherapy and pharmacology 20100501

• The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100501

• Irinotecan as maintenance therapy in high-risk hepatoblastoma.

  Pediatric blood & cancer 20100501

• Oral irinotecan for treatment of pediatric solid tumors: ready for prime time?

  Pediatric blood & cancer 20100501

• Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy.

  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20100501

• A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.

  Drug metabolism and disposition: the biological fate of chemicals 20100501

• Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53.

  Carcinogenesis 20100501

• [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review].

  Bulletin du cancer 20100501

• Operating characteristics of two independent sample design in phase I trials in paediatric oncology.

  European journal of cancer (Oxford, England : 1990) 20100501

• Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial.

  Gynecologic oncology 20100501

• Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100501

• Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

  Neuro-oncology 20100501

• Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.

  International journal of clinical pharmacology and therapeutics 20100501

• [A case of gastric large cell neuroendocrine carcinoma (LCNEC) for whom chemotherapy of CDDP+CPT-11 proved very effective].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100501

• [Hematological toxicity of some combined chemotherapy schemes involving aranoza].

  Eksperimental'naia i klinicheskaia farmakologiia 20100501

• Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100420

• Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.

  Biochemical pharmacology 20100415

• Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100415

• Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.

  Cancer chemotherapy and pharmacology 20100401

• Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100401

• Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.

  The pharmacogenomics journal 20100401

• Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin.

  Colloids and surfaces. B, Biointerfaces 20100401

• Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.

  Pediatric blood & cancer 20100401

• Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.

  Annals of surgical oncology 20100401

• An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles.

  Biomaterials 20100401

• Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.

  Cancer 20100401

• Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model.

  Journal of materials science. Materials in medicine 20100401

• Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.

  International journal of clinical oncology 20100401

• Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?

  Acta oncologica (Stockholm, Sweden) 20100401

• Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.

  Journal of clinical gastroenterology 20100401

• Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100401

• Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?

  Nature reviews. Clinical oncology 20100401

• Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100401

• Palliative chemotherapy for pancreatic malignancies.

  The Surgical clinics of North America 20100401

• Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

  Molecular cancer therapeutics 20100401

• [Prognostic factors and survival of metastatic colorectal cancer in the Sousse University Hospital (Tunisia): comparative study of two treatment period of 200 patients].

  Bulletin du cancer 20100401

• [Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100401

• [A case of fluoropyrimidine-resistant recurrent colon cancer successfully treated with weekly administration of irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100401

• [Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100401

• Glutathione modulators reverse the pro-tumour effect of growth factors enhancing WiDr cell response to chemotherapeutic agents.

  Anticancer research 20100401

• Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis.

  Cancer science 20100401

• Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.

  Cancer science 20100401

• Chemotherapy for advanced gastric cancer.

  The Cochrane database of systematic reviews 20100317

• Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.

  British journal of cancer 20100316

• Simple liquid chromatography method for the quantification of irinotecan and SN38 in sheep plasma: application to in vivo pharmacokinetics after pulmonary artery chemoembolization using drug eluting beads.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100315

• An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.

  Medical oncology (Northwood, London, England) 20100301

• Stability of irinotecan-loaded drug eluting beads (DC Bead) used for transarterial chemoembolization.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20100301

• N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100301

• Genotoxicity of irinotecan and its modulation by vitamins A, C and E in human lymphocytes from healthy individuals and cancer patients.

  Toxicology in vitro : an international journal published in association with BIBRA 20100301

• Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.

  Cancer science 20100301

• Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.

  Cancer 20100301

• Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100301

• In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats.

  Biotechnology journal 20100301

• An overview of the recent progress in irinotecan pharmacogenetics.

  Pharmacogenomics 20100301

• [A case of small cell lung cancer (extensive disease) with liver metastasis acquiring stable disease by hepatic arterial infusion chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100301

• [A case of effective chemotherapy using S-1 and CPT-11 following chemoradiotherapy with UFT and Leucovorin for unresectable advanced sigmoid colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100301

• [A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100301

• Assessment of cyto/genotoxicity of irinotecan in v79 cells using the comet, micronucleus, and chromosome aberration assay.

  Arhiv za higijenu rada i toksikologiju 20100301

• Establishment and characterization of multidrug-resistant gastric cancer cell lines.

  Anticancer research 20100301

• Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract.

  Toxicology 20100227

• Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100220

• Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice.

  Toxicology letters 20100215

• Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.

  Journal of immunology (Baltimore, Md. : 1950) 20100215

• Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100210

• Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.

  Cancer chemotherapy and pharmacology 20100201

• Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients.

  Cancer chemotherapy and pharmacology 20100201

• A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100201

• Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.

  Cancer immunology, immunotherapy : CII 20100201

• Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.

  Journal of cancer research and clinical oncology 20100201

• A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.

  American journal of clinical oncology 20100201

• Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.

  American journal of clinical oncology 20100201

• Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression.

  The Prostate 20100201

• Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine.

  The Journal of pharmacology and experimental therapeutics 20100201

• Irinotecan and mismatch repair deficiency.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100201

• Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour.

  European journal of cancer (Oxford, England : 1990) 20100201

• Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab.

  Bulletin du cancer 20100201

• [Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100201

• [A case of early poorly-differentiated neuroendocrine carcinoma of stomach].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100201

• [Clinical study of irinotecan plus cisplatin for advanced non-small cell lung cancer].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100201

• Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20100201

• [Clinical features of patients with brain metastasis from testicular germ cell tumor].

  Hinyokika kiyo. Acta urologica Japonica 20100201

• Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer.

  Acta medica Okayama 20100201

• Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.

  Acta medica Okayama 20100201

• Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study.

  HPB : the official journal of the International Hepato Pancreato Biliary Association 20100201

• Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.

  HPB : the official journal of the International Hepato Pancreato Biliary Association 20100201

• Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100120

• Individualizing dosing of irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

  Neurology 20100112

• PTEN status in advanced colorectal cancer treated with cetuximab.

  British journal of cancer 20100105

• A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.

  Cancer chemotherapy and pharmacology 20100101

• Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.

  Cancer chemotherapy and pharmacology 20100101

• Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.

  Cancer chemotherapy and pharmacology 20100101

• Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan.

  Glycoconjugate journal 20100101

• A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100101

• Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.

  Annals of surgical oncology 20100101

• A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.

  Japanese journal of clinical oncology 20100101

• Attenuation of cytogenetic effects by erythropoietin in human lymphocytes in vitro and P388 ascites tumor cells in vivo treated with irinotecan (CPT-11).

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20100101

• Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives.

  Biomedical chromatography : BMC 20100101

• No effect of irinotecan in patients with resistant desmoplastic small round cell tumor.

  Pediatric blood & cancer 20100101

• An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate.

  Cancer 20100101

• CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients.

  Oncology reports 20100101

• Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens.

  Cancer investigation 20100101

• Palliative treatment of unresectable metastatic colorectal cancer.

  Expert opinion on pharmacotherapy 20100101

• Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.

  Methods in molecular biology (Clifton, N.J.) 20100101

• The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.

  Molecular cancer therapeutics 20100101

• The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.

  The oncologist 20100101

• Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma.

  Zeitschrift fur Gastroenterologie 20100101

• [Retrospective analysis of generalized chemotherapy for unresectable advanced gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [A case of advanced gastric cancer with a complete response to S-1 plus CPT-11 chemotherapy for eight years].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [Successful treatment with S-1 + CPT-11 for hepatic metastasis from gastric cancer--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [S-1 + CPT-11 combination therapy with continuing 30-month CR in a recurrent gastric cancer with para-aortic lymph node metastasis in adjuvant chemotherapy with S-1--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [A case of S-1-resistant gastric cancer with multiple bone metastases and disseminated intravascular coagulation--effective treatment by combined chemotherapy with CDDP and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [Liver metastasis from sigmoid colon cancer showed a complete response to S-1 after recurrence with FOLFOX6 treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• Usefulness of staging laparoscopy for advanced gastric cancer.

  Surgery today 20100101

• Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.

  Onkologie 20100101

• Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.

  Cancer journal (Sudbury, Mass.) 20100101

• Gene expression profile of colon cancer cell lines treated with SN-38.

  Chemotherapy 20100101

• Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.

  Molecular cancer 20100101

• Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.

  Drug metabolism and pharmacokinetics 20100101

• [Prognostic analysis of patients with liver metastases from colorectal cancer treated with different modes of therapy].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20100101

• The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.

  Oncology research 20100101

• Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.

  Chemotherapy 20100101

• Metastatic colorectal cancer: from improved survival to potential cure.

  Oncology 20100101

• Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.

  Onkologie 20100101

• Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).

  Onkologie 20100101

• Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.

  Oncology research 20100101

• Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.

  BMC cancer 20100101

• Efficacy of combination treatment and influence of schedule with irinotecan and amrubicin in human lung carcinoma cells in vivo and in vitro.

  Biological & pharmaceutical bulletin 20100101

• Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20100101

• Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.

  Transactions of the American Clinical and Climatological Association 20100101

• A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract.

  Oncology 20100101

• Treatment of colorectal cancer with and without bevacizumab: a phase III study.

  Oncology 20100101

• [Pharmacogenomics and chemotherapy].

  Recenti progressi in medicina 20100101

• Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.

  Asian Pacific journal of cancer prevention : APJCP 20100101

• 'Poker' association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.

  BMC cancer 20100101

• Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma.

  Tumori 20100101

• Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.

  Oncology 20100101

• Effect of erythropoietin, 5-fluorouracil and SN-38 on the growth of DLD-1 cells.

  Pharmacological reports : PR 20100101

• Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.

  Onkologie 20100101

• Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.

  Asian Pacific journal of cancer prevention : APJCP 20100101

• Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.

  BMC cancer 20100101

• A patient with metastatic colon cancer to the liver presenting with cardiac arrest status post receiving combination irinotecan-panitumumab: a case report.

  Journal of experimental therapeutics & oncology 20100101

• Irinotecan as a maintenance therapy for hepatoblastoma: a comment.

  Journal of cancer research and therapeutics 20100101

• Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.

  Oncology 20100101

• Complete resection of unresectable liver metastases from colorectal cancer without deterioration of liver function after cetuximab and irinotecan: two case reports.

  Hepato-gastroenterology 20100101

• En bloc resection for right colon cancer directly invading duodenum or pancreatic head.

  Yonsei medical journal 20091231

• The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.

  International journal of cancer 20091215

• Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?

  Pediatric blood & cancer 20091215

• Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.

  British journal of cancer 20091215

• KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091210

• Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20091201

• Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20091201

• Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.

  Journal of neuro-oncology 20091201

• Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.

  International journal of radiation oncology, biology, physics 20091201

• A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20091201

• Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.

  Archives of disease in childhood 20091201

• Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma.

  Leukemia & lymphoma 20091201

• Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.

  Pediatric blood & cancer 20091201

• Irinotecan side effects relieved by the use of HI-6 oxime: in vivo experimental approach.

  Basic & clinical pharmacology & toxicology 20091201

• In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.

  Cytokine 20091201

• Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.

  Cancer treatment reviews 20091201

• A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.

  Japanese journal of clinical oncology 20091201

• Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.

  Japanese journal of clinical oncology 20091201

• Treatment of metastatic colorectal cancer in the elderly.

  Current treatment options in oncology 20091201

• Comeback for the camptothecins?

  Leukemia & lymphoma 20091201

• Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091201

• The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells.

  International journal of oncology 20091201

• Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.

  Targeted oncology 20091201

• KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091201

• [Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].

  Ai zheng = Aizheng = Chinese journal of cancer 20091201

• [Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• [A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].

  Bulletin du cancer 20091201

• Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

  Anticancer research 20091201

• Treatment of childhood sarcoma with irinotecan: bilirubin level as a predictor of gastrointestinal toxicity.

  Journal of chemotherapy (Florence, Italy) 20091201

• Expression of HSP27, HSP72 and MRP proteins in in vitro co-culture of colon tumour cell spheroids with normal cells after incubation with rhTGF- beta1 and/or CPT-11.

  Journal of biosciences 20091201

• Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.

  The American journal of geriatric pharmacotherapy 20091201

• [Allicin enhances cytotoxicity of CPT-11 to colon cancer LoVo cell in vitro].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20091201

• Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.

  British journal of cancer 20091117

• XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.

  Advanced drug delivery reviews 20091112

• Experimental study of combination therapy with S-1 against pancreatic cancer.

  Cancer chemotherapy and pharmacology 20091101

• Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.

  Cancer science 20091101

• Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.

  Cancer science 20091101

• UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?

  Anti-cancer drugs 20091101

• Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.

  International journal of radiation oncology, biology, physics 20091101

• Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

  The Lancet. Oncology 20091101

• Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer.

  Cancer investigation 20091101

• Treatment of gastric cancer in Asia: the missing link.

  The Lancet. Oncology 20091101

• [Intestinal absorption and secretion mechanism of carboxylate drugs].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20091101

• [Histological complete response in a case of advanced gastric endocrine carcinoma treated by irinotecan plus cisplatin].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20091101

• Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.

  Journal of natural products 20091101

• The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20091101

• Hypoxia-induced downregulation of autophagy mediator Beclin 1 reduces the susceptibility of malignant intestinal epithelial cells to hypoxia-dependent apoptosis.

  Autophagy 20091101

• [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of advanced gastric cancer that a medical therapy effect was provided grade 3 by a histopathological diagnosis after long-term chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A successful two-stage treatment with CDDP and CPT-11 for pancreatic neuroendocrine carcinoma with liver metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Huge ascending colon carcinoma, treated successfully with S-1 plus CPT-11, followed by significant tumor reduction and curative resection--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of advanced rectal cancer that responded to S-1 with an extended complete response].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of rectal cancer with lung metastases responding to cetuximab].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case report of metastatic liver tumor from rectosigmoid colon cancer demonstrating a pathological complete response with FOLFOX and FOLFIRI treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Intermittent hepatic arterial infusion with systemic chemotherapy for metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case report of multiple liver metastases from colorectal cancer effectively treated with systemic chemotherapy and hepatic arterial infusion].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Treatment for intrapelvic recurrence of rectal cancer--resection versus chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A long term survivor of advanced gastric cancer treated with multi-drug combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of bilateral pulmonary metastasis from gastric cancer performed radical thoracoscopic lobectomy after neoadjuvant chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

  World journal of gastroenterology 20091028

• Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.

  British journal of cancer 20091006

• Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.

  Cancer chemotherapy and pharmacology 20091001

• Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20091001

• Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents.

  Cancer chemotherapy and pharmacology 20091001

• Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.

  Journal of cancer research and clinical oncology 20091001

• Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20091001

• Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.

  Cancer 20091001

• Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001

• Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.

  European journal of pharmacology 20091001

• Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.

  Journal of human genetics 20091001

• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091001

• Long-term outcome of unresectable metastatic colorectal cancer: does 'adjuvant' chemotherapy play a role after resection?

  Annals of surgery 20091001

• [Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel].

  Bulletin du cancer 20091001

• Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.

  International journal of experimental pathology 20091001

• Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.

  Nature reviews. Clinical oncology 20091001

• Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?

  Nature reviews. Clinical oncology 20091001

• CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091001

• [Progress in chemotherapy for advanced gastric cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20091001

• [A case of recurrent rectal cancer with multiple lung metastases successfully treated with S-1 and CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091001

• [A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091001

• [A case of recurrent gastric cancer during adjuvant chemotherapy with S-1, treated by S-1 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091001

• Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.

  International journal of clinical oncology 20091001

• Advanced hepatocellular carcinoma treated effectively with irinotecan via hepatic arterial infusion followed by proton beam therapy.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20091001

• Small cell carcinoma of the breast.

  Journal of the National Medical Association 20091001

• [Combination with SN-38 on human colon cancer LoVo cells].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20091001

• Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920

• Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).

  British journal of cancer 20090915

• Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.

  World journal of gastroenterology 20090914

• Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.

  Cancer chemotherapy and pharmacology 20090901

• In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20090901

• Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver.

  Drug metabolism and disposition: the biological fate of chemicals 20090901

• Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.

  Acta radiologica (Stockholm, Sweden : 1987) 20090901

• Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.

  Cancer 20090901

• A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.

  Japanese journal of clinical oncology 20090901

• Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20090901

• Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer.

  Oncology reports 20090901

• Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?

  European journal of cancer (Oxford, England : 1990) 20090901

• Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer.

  The British journal of surgery 20090901

• Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901

• Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901

• Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090901

• Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?

  Nature reviews. Gastroenterology & hepatology 20090901

• Is there a role for second-line chemotherapy in advanced gastric cancer?

  The Lancet. Oncology 20090901

• [Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20090901

• [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].

  Ai zheng = Aizheng = Chinese journal of cancer 20090901

• [Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090901

• [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090901

• [A case of superficial small cell carcinoma of the esophagus].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090901

• Chemotherapy, which drugs and when.

  European journal of cancer (Oxford, England : 1990) 20090901

• [The development of the first line treatment of metastatic colorectal cancer (mCRC)].

  Magyar onkologia 20090901

• Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.

  World journal of gastroenterology 20090821

• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

  British journal of cancer 20090818

• Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.

  International journal of cancer 20090815

• Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.

  World journal of gastroenterology 20090807

• DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

  Cell stem cell 20090807

• Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.

  Investigational new drugs 20090801

• A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20090801

• A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.

  Cancer chemotherapy and pharmacology 20090801

• Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.

  International journal of radiation oncology, biology, physics 20090801

• Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour.

  The British journal of nutrition 20090801

• Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.

  Anti-cancer drugs 20090801

• Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

  Annals of oncology : official journal of the European Society for Medical Oncology 20090801

• Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.

  Anti-cancer drugs 20090801

• Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.

  Expert opinion on biological therapy 20090801

• 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation.

  Bioorganic & medicinal chemistry letters 20090801

• Differentiation-related gene-1 decreases Bim stability by proteasome-mediated degradation.

  Cancer research 20090801

• Irinotecan use during pregnancy.

  Obstetrics and gynecology 20090801

• A novel K-ras mutation in colorectal cancer. A case report and literature review.

  Anticancer research 20090801

• Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

  Molecular cancer therapeutics 20090801

• [Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• [Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• [A case of advanced colon cancer treated with preoperative chemotherapy (IRIS) leading to clinical complete response].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• [Effectiveness of S-1 plus CPT-11 therapy for an elderly patient with recurrent colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.

  British journal of cancer 20090721

• Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090720

• Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.

  JOP : Journal of the pancreas 20090706

• Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.

  Journal of neuro-oncology 20090701

• Can cetuximab affect paraneoplastic myopathy?

  Journal of neuro-oncology 20090701

• Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.

  Pediatric blood & cancer 20090701

• Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090701

• A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.

  Anti-cancer drugs 20090701

• Intracellular dynamics of topoisomerase I inhibitor, CPT-11, by slit-scanning confocal Raman microscopy.

  Histochemistry and cell biology 20090701

• Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles.

  Biomaterials 20090701

• Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.

  Cancer 20090701

• Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090701

• Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.

  Anti-cancer drugs 20090701

• Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701

• Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701

• Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

  European journal of cancer (Oxford, England : 1990) 20090701

• A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

  European journal of cancer (Oxford, England : 1990) 20090701

• Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090701

• Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.

  Molecular cancer therapeutics 20090701

• Genetic prognostic and predictive markers in colorectal cancer.

  Nature reviews. Cancer 20090701

• Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090701

• Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab.

  The Annals of pharmacotherapy 20090701

• [Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].

  Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20090701

• Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.

  Pharmacogenomics 20090701

• Individual differences in rate-limiting reactions during metabolism of irinotecan hydrochloride.

  Gan to kagaku ryoho. Cancer & chemotherapy 20090701

• [Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090701

• [A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090701

• TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.

  Cancer letters 20090628

• Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.

  Journal of medicinal chemistry 20090625

• Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.

  Oncogene 20090618

• Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.

  Cancer 20090615

• Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090610

• Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride.

  Cancer letters 20090608

• Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.

  Chinese medical journal 20090605

• A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.

  British journal of cancer 20090602

• A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.

  Investigational new drugs 20090601

• Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients.

  Investigational new drugs 20090601

• Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.

  Cancer chemotherapy and pharmacology 20090601

• Irinotecan-induced mucositis is associated with changes in intestinal mucins.

  Cancer chemotherapy and pharmacology 20090601

• DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090601

• Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090601

• Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090601

• Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.

  International journal of cancer 20090601

• Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.

  International journal of cancer 20090601

• Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment.

  International journal of colorectal disease 20090601

• Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities.

  The Journal of pharmacology and experimental therapeutics 20090601

• Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.

  Cancer chemotherapy and pharmacology 20090601

• A landmark point analysis with cytotoxic agents for advanced NSCLC.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090601

• Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer.

  Journal of cancer research and clinical oncology 20090601

• Irinogenetics: how many stars are there in the sky?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601

• Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601

• PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601

• Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.

  Therapeutic drug monitoring 20090601

• A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.

  Cancer prevention research (Philadelphia, Pa.) 20090601

• [Pharmacogenomics].

  Nihon rinsho. Japanese journal of clinical medicine 20090601

• Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells.

  Anticancer research 20090601

• [A case of marked response to CPT-11+CDDP neoadjuvant chemotherapy for advanced gastric cancer with paraaortic lymph node metastasis enabling curative resection and over 10-year survival].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090601

• [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090601

• Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.

  Acta pharmaceutica (Zagreb, Croatia) 20090601

• [Chemotherapy of elderly patients with colorectal cancer].

  Magyar onkologia 20090601

• Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.

  Diseases of the colon and rectum 20090601

• Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance.

  Electrophoresis 20090601

• Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC).

  International journal of clinical oncology 20090601

• [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20090601

• Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.

  Journal of controlled release : official journal of the Controlled Release Society 20090521

• Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520

• UGT1A and irinotecan toxicity: keeping it in the family.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520

• Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.

  British journal of cancer 20090519

• Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog.

  Bioorganic & medicinal chemistry letters 20090515

• Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

  Neurology 20090505

• Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.

  Cancer chemotherapy and pharmacology 20090501

• Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer.

  Cancer chemotherapy and pharmacology 20090501

• Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl.

  Drug development and industrial pharmacy 20090501

• Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.

  Cancer chemotherapy and pharmacology 20090501

• The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090501

• Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.

  Cancer investigation 20090501

• Different inhibitory effects in rat and human carboxylesterases.

  Drug metabolism and disposition: the biological fate of chemicals 20090501

• Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?

  World journal of surgery 20090501

• A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.

  Japanese journal of clinical oncology 20090501

• Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).

  Japanese journal of clinical oncology 20090501

• PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090501

• Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer.

  Nature reviews. Clinical oncology 20090501

• Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.

  Japanese journal of clinical oncology 20090501

• High therapeutic effectiveness of postoperative irinotecan chemotherapy in a typical case of radiographically and pathologically diagnosed pleuropulmonary blastoma.

  Journal of pediatric hematology/oncology 20090501

• UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.

  Pharmacogenomics 20090501

• [Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• [A case of recurrent endocrine cell carcinoma of the common bile duct successfully treated by hepatic artery infusion with CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• [CDDP+CPT-11 therapy is useful for stage IVb esophageal small cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.

  Cancer 20090415

• Second-line chemotherapy in advanced and metastatic CRC.

  The Cochrane database of systematic reviews 20090415

• Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090410

• 'Natural history' of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20090401

• A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.

  Cancer chemotherapy and pharmacology 20090401

• Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.

  Investigational new drugs 20090401

• A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20090401

• Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.

  European radiology 20090401

• Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon?

  Biomedical chromatography : BMC 20090401

• Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.

  Journal of neuro-oncology 20090401

• Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis.

  International journal of colorectal disease 20090401

• Gemcitabine, irinotecan and celecoxib in patients with biliary cancer.

  Anti-cancer drugs 20090401

• A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

  Annals of oncology : official journal of the European Society for Medical Oncology 20090401

• Need for a new treatment strategy: leptomeningeal carcinomatosis from gastric cancer.

  Anti-cancer drugs 20090401

• Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure.

  Anti-cancer drugs 20090401

• Irinotecan-induced ovarian follicular apoptosis is attenuated by deleting the kinase domain of death-associated protein kinase.

  International journal of oncology 20090401

• Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.

  Oncology reports 20090401

• NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis.

  Proteomics 20090401

• Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.

  Nature reviews. Clinical oncology 20090401

• [Colorectal cancers: prognostic and predictive factors of response to treatment].

  Bulletin du cancer 20090401

• Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.

  Molecular cancer therapeutics 20090401

• [Risk associated with severe hematological toxicity in patients with advanced or recurrent gastric cancer receiving primary combination chemotherapy of cisplatin and S-1 or cisplatin and irinotecan hydrochloride].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090401

• UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.

  International journal of clinical oncology 20090401

• Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.

  Canadian journal of surgery. Journal canadien de chirurgie 20090401

• What's new in ... colorectal cancer. Meaningful progress in therapy options.

  JAAPA : official journal of the American Academy of Physician Assistants 20090401

• Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.

  British journal of cancer 20090324

• Irinotecan toxicity: genes or intestinal microflora?

  British journal of cancer 20090324

• Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320

• The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090315

• Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090310

• Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090302

• A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.

  Journal of cancer research and clinical oncology 20090301

• Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090301

• Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan, and irinotecan.

  Environmental and molecular mutagenesis 20090301

• Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090301

• Successful treatment of small-cell lung cancer with irinotecan in a hemodialysis patient with end-stage renal disease.

  The Korean journal of internal medicine 20090301

• FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.

  The oncologist 20090301

• Manifestation of alveolar rhabdomyosarcoma as primary cutaneous lesions in a neonate with Beckwith-Wiedemann syndrome.

  Journal of pediatric surgery 20090301

• [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].

  Bulletin du cancer 20090301

• Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine.

  Cancer research 20090215

• Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090210

• A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090210

• Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090210

• Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer.

  Cancer letters 20090208

• Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

  Cancer chemotherapy and pharmacology 20090201

• Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.

  Cancer chemotherapy and pharmacology 20090201

• Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.

  Cancer chemotherapy and pharmacology 20090201

• Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan.

  Clinical pharmacology and therapeutics 20090201

• Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090201

• Experience with irinotecan for the treatment of malignant glioma.

  Neuro-oncology 20090201

• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090201

• Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090201

• Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

  Journal of neuro-oncology 20090201

• Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.

  Pharmaceutical research 20090201

• Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention.

  Annals of surgical oncology 20090201

• Irinotecan in cancer patients with end-stage renal failure.

  The Annals of pharmacotherapy 20090201

• Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.

  American journal of clinical oncology 20090201

• [A case of recurrence after curative total gastrectomy for gastric cancer successfully treated by combination chemotherapy with CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090201

• Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer.

  International journal of clinical oncology 20090201

• Role of glucocorticoid receptor in the regulation of cellular sensitivity to irinotecan hydrochloride.

  Journal of pharmacological sciences 20090201

• The CAIRO and FOCUS studies: which lesson is to be learned?

  The oncologist 20090201

• The European contribution to 'Sugarbaker's protocol' for the treatment of colorectal peritoneal carcinomatosis.

  Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20090201

• Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.

  British journal of cancer 20090127

• Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090115

• Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.

  British journal of cancer 20090113

• Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090110

• Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20090101

• Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?

  Cancer chemotherapy and pharmacology 20090101

• Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

  Medical oncology (Northwood, London, England) 20090101

• Primary small cell carcinoma of the breast.

  Breast cancer (Tokyo, Japan) 20090101

• Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20090101

• How can we ameliorate irinotecan-associated diarrhea in children with poor compliance for oral cephalosporin?

  Pediatric blood & cancer 20090101

• 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

  Molecular pharmacology 20090101

• Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.

  Annals of surgical oncology 20090101

• Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.

  Acta oncologica (Stockholm, Sweden) 20090101

• A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients.

  Chemotherapy 20090101

• The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.

  Medical oncology (Northwood, London, England) 20090101

• Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.

  Chemotherapy 20090101

• Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.

  Cancer 20090101

• Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.

  Radiology 20090101

• Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.

  Journal of hepato-biliary-pancreatic surgery 20090101

• Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

  Genetics in medicine : official journal of the American College of Medical Genetics 20090101

• Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.

  Genetics in medicine : official journal of the American College of Medical Genetics 20090101

• Chemotherapy for small-bowel Adenocarcinoma at a single institution.

  Surgery today 20090101

• The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.

  The oncologist 20090101

• Pharmacogenetics and pharmacogenomics of anticancer agents.

  CA: a cancer journal for clinicians 20090101

• The role of capecitabine in the management of tumors of the digestive system.

  Reviews on recent clinical trials 20090101

• [Advanced gastric cancer showing complete response to neoadjuvant chemotherapy with CPT-11 and S-1-a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090101

• [A case of simultaneous double cancers with multiple liver metastases responding to S-1+CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090101

• Does celecoxib have a role in the treatment of patients with colorectal cancer?

  Clinical colorectal cancer 20090101

• Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.

  Clinical colorectal cancer 20090101

• Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.

  Oncology 20090101

• Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.

  Oncology 20090101

• Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.

  Anticancer research 20090101

• Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer.

  American journal of therapeutics 20090101

• A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.

  BMC cancer 20090101

• Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer.

  Tumori 20090101

• Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.

  BMC cancer 20090101

• Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study.

  In vivo (Athens, Greece) 20090101

• Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.

  BMC cancer 20090101

• Early assessment of therapeutic response using FDG PET in small cell lung cancer.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20090101

• Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20090101

• A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.

  BMC cancer 20090101

• [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20090101

• [Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20090101

• Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity.

  Drug metabolism and pharmacokinetics 20090101

• Evolving treatment of advanced colon cancer.

  Annual review of medicine 20090101

• Allometric scaling of a metabolically complex camptothecin analog: differences in scaling of irinotecan and its active metabolite, SN-38.

  Arzneimittel-Forschung 20090101

• Evaluation of the possible benefits of post-radiotherapy surgery after concomitant chemoradiotherapy with a new radio-sensitizing regimen (irinotecan / CPT-11, interferon A2b and amifostine) for advanced-stage cervical carcinoma. Preliminary results of a pilot phase-II study.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20090101

• [Pre-clinical study of combined aranosa, cisplatin and irinotecan in the treatment of experimental lung cancer].

  Voprosy onkologii 20090101

• UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).

  Molecular diagnosis & therapy 20090101

• Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.

  BMC cancer 20090101

• Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.

  Oncology 20090101

• The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.

  Oncology 20090101

• Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

  BMC cancer 20090101

• Single-step therapy -- feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies.

  In vivo (Athens, Greece) 20090101

• Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.

  Oncology research 20090101

• A pilot study of irinotecan combined with 5-fluorouracil and leucovorin for the treatment of Chinese patients with locally advanced and metastatic gastric cancer.

  Tumori 20090101

• Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report.

  World journal of surgical oncology 20090101

• Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature.

  European journal of gynaecological oncology 20090101

• Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.

  Journal of gastrointestinal cancer 20090101

• Chemo-diversion strategy for unresectable colorectal carcinoma: report of two cases.

  Hepato-gastroenterology 20090101

• A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.

  Chemotherapy 20090101

• Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20090101

• Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.

  The Kurume medical journal 20090101

• Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer.

  Journal of cancer research and therapeutics 20090101

• Preparation and characterization of poly lactide-co-glycolide nanoparticles of SN-38.

  PDA journal of pharmaceutical science and technology 20090101

• Irinotecan plus S-1 for liver metastases of gastric cancer.

  Hepato-gastroenterology 20090101

• Semi-synthesis and biological activity of gamma-lactones analogs of camptothecin.

  Bioorganic & medicinal chemistry letters 20081215

• Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081215

• A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.

  Cancer chemotherapy and pharmacology 20081201

• Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.

  Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 20081201

• Irinotecan in the treatment of elderly patients with advanced colorectal cancer.

  Critical reviews in oncology/hematology 20081201

• Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats.

  Cancer biology & therapy 20081201

• Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081201

• Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.

  Japanese journal of clinical oncology 20081201

• Polymeric micellar delivery systems in oncology.

  Japanese journal of clinical oncology 20081201

• What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?

  Current opinion in neurology 20081201

• Pharmacogenomics of tamoxifen and irinotecan therapies.

  Clinics in laboratory medicine 20081201

• First-line therapeutic strategies in metastatic colorectal cancer.

  Oncology (Williston Park, N.Y.) 20081130

• Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120

• Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120

• Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.

  Cancer 20081115

• Efficient one-cycle affinity selection of binding proteins or peptides specific for a small-molecule using a T7 phage display pool.

  Bioorganic & medicinal chemistry 20081115

• A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081115

• Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081115

• Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.

  Cancer research 20081115

• Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.

  Journal of medicinal chemistry 20081113

• Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines.

  British journal of cancer 20081104

• Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.

  Cancer chemotherapy and pharmacology 20081101

• Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.

  Cancer chemotherapy and pharmacology 20081101

• Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.

  Cancer chemotherapy and pharmacology 20081101

• Clinical and pharmacogenetic factors associated with irinotecan toxicity.

  Cancer treatment reviews 20081101

• A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

  Journal of neuro-oncology 20081101

• Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.

  Cancer science 20081101

• A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).

  European journal of cancer (Oxford, England : 1990) 20081101

• Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.

  Japanese journal of clinical oncology 20081101

• Antiangiogenic therapy in malignant gliomas.

  Current opinion in oncology 20081101

• Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081101

• Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).

  Biological & pharmaceutical bulletin 20081101

• Low-dose protracted irinotecan as a palliative chemotherapy for advanced neuroblastoma.

  Journal of pediatric hematology/oncology 20081101

• [A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [Marked response to combination chemotherapy using S-1, CPT-11 for lymph node metastasis of gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [A case of metastatic lung and liver tumors from rectal cancer treated with oral UFT and CPT-11 by hepatic arterial infusion followed by FOLFOX and FOLFIRI].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• Race does not explain genetic heterogeneity in pharmacogenomic pathways.

  Pharmacogenomics 20081101

• Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.

  Clinical colorectal cancer 20081101

• [New perspectives in predicting response to chemotherapy in colorectal cancer].

  Gastroenterologia y hepatologia 20081101

• [Third-line treatment of intermittent hepatic arterial infusion for unresectable liver metastases from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [A case of unresectable advanced gastric cancer successfully treated with continuous S-1 + CPT-11 chemotherapy accompanied by dose reduction against grade 4 hematological adverse event].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [A case of advanced sigmoid colon cancer performed resection of liver metastases after long-term control by S-1 and CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [A case of ovarian cancer in which a remarkable effect was seen with intrathoracic administration of CDDP and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.

  British journal of cancer 20081021

• Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.

  British journal of cancer 20081021

• Clinical determinants of response to irinotecan-based therapy derived from cell line models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081015

• A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081015

• Management and survival trends in advanced colorectal cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20081001

• Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081001

• Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.

  Cancer 20081001

• Bevacizumab: a treatment option for recurrent glioblastoma multiforme.

  The Annals of pharmacotherapy 20081001

• Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

  Journal of pharmacokinetics and pharmacodynamics 20081001

• Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.

  Oncology reports 20081001

• New lessons from 'old' chemotherapy in colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081001

• Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081001

• A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.

  American journal of clinical oncology 20081001

• Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.

  Japanese journal of clinical oncology 20081001

• Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.

  Molecular cancer therapeutics 20081001

• An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.

  Journal of the National Comprehensive Cancer Network : JNCCN 20081001

• [Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081001

• [A fatal case of small cell type undifferentiated carcinoma of the esophagus with sudden diarrhea and bloody discharge by CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081001

• [A case of successful control for primary duodenal cancer with combined CPT-11, CDDP and DOC chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081001

• In vivo chemotherapeutic profile of human gallbladder small cell carcinoma.

  Biomedical research (Tokyo, Japan) 20081001

• [Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view].

  Bulletin du cancer 20081001

• [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].

  Bulletin du cancer 20081001

• Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.

  Journal of chemotherapy (Florence, Italy) 20081001

• Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies.

  Talanta 20080915

• Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080910

• Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.

  Critical reviews in oncology/hematology 20080901

• Pharmacogenetic pathway analysis of irinotecan.

  Clinical pharmacology and therapeutics 20080901

• CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.

  Journal of neuro-oncology 20080901

• Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.

  Molecular pharmacology 20080901

• Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.

  International journal of oncology 20080901

• Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma.

  Oncology reports 20080901

• Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.

  Oncology 20080901

• Modifications of human carboxylesterase for improved prodrug activation.

  Expert opinion on drug metabolism & toxicology 20080901

• Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080901

• Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?

  Expert review of anticancer therapy 20080901

• Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080901

• Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.

  Japanese journal of clinical oncology 20080901

• Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.

  The oncologist 20080901

• An autopsy case of acute pulmonary toxicity related to irinotecan.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20080901

• [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• [A case of advanced gastric cancer with pulmonary carcinomatous lymphangitis and paraaortic lymph node metastases responding to combination chemotherapy of S-1 and irinotecan(CPT-11)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• [Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• PEGylated nanographene oxide for delivery of water-insoluble cancer drugs.

  Journal of the American Chemical Society 20080820

• Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.

  British journal of cancer 20080819

• Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.

  Life sciences 20080815

• Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080815

• Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080815

• Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.

  Chemico-biological interactions 20080811

• Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.

  British journal of cancer 20080805

• Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.

  The pharmacogenomics journal 20080801

• Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20080801

• A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors.

  Cancer chemotherapy and pharmacology 20080801

• Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.

  Cancer chemotherapy and pharmacology 20080801

• Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080801

• Renal function as a predictor of irinotecan-induced neutropenia.

  Clinical pharmacology and therapeutics 20080801

• Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).

  Annals of oncology : official journal of the European Society for Medical Oncology 20080801

• Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.

  Journal of neuro-oncology 20080801

• Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.

  Nature clinical practice. Oncology 20080801

• Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080801

• Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study.

  Anti-cancer drugs 20080801

• Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20080801

• A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study.

  European journal of cancer (Oxford, England : 1990) 20080801

• Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.

  Neoplasia (New York, N.Y.) 20080801

• Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.

  Journal of neurosurgery 20080801

• Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080801

• Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting.

  The oncologist 20080801

• [Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080801

• UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.

  British journal of cancer 20080722

• Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.

  Cancer 20080715

• Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.

  Cancer chemotherapy and pharmacology 20080701

• Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.

  Cancer chemotherapy and pharmacology 20080701

• Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.

  Cancer chemotherapy and pharmacology 20080701

• Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.

  Cancer immunology, immunotherapy : CII 20080701

• Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080701

• Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.

  Lung cancer (Amsterdam, Netherlands) 20080701

• Activated charcoal to prevent irinotecan-induced diarrhea in children.

  Pediatric blood & cancer 20080701

• Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.

  Pharmaceutical research 20080701

• A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).

  Annals of oncology : official journal of the European Society for Medical Oncology 20080701

• Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers.

  Pharmaceutical research 20080701

• Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.

  Cancer 20080701

• Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.

  Archives of toxicology 20080701

• Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs.

  Cancer biology & therapy 20080701

• Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080701

• Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.

  Onkologie 20080701

• A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.

  Nature clinical practice. Urology 20080701

• Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?

  The oncologist 20080701

• [Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• [Long survival of advanced gastric cancer patient after total gastrectomy and postoperative treatment with S-1 despite S-1+CDDP+CPT-11 causing perforation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• [A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models.

  Molecular cancer therapeutics 20080701

• Regional chemotherapy for liver-limited metastatic colorectal cancer.

  Clinical colorectal cancer 20080701

• A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.

  Clinical colorectal cancer 20080701

• [Case report of malignant sertoli cell tumor].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20080701

• Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.

  World journal of gastroenterology 20080628

• Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.

  The pharmacogenomics journal 20080601

• Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.

  Cancer chemotherapy and pharmacology 20080601

• Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20080601

• Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080601

• Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.

  Investigational new drugs 20080601

• Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• Advances in neoadjuvant therapy for colorectal cancer with liver metastases.

  Cancer treatment reviews 20080601

• Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.

  Cancer biology & therapy 20080601

• Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.

  Cancer science 20080601

• Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20080601

• Determination of anticarcinogenic and rescue therapy drugs in urine by photoinduced spectrofluorimetry using multivariate calibration: comparison of several second-order methods.

  Analytical and bioanalytical chemistry 20080601

• Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor.

  Cancer science 20080601

• Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20080601

• Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.

  European journal of cancer (Oxford, England : 1990) 20080601

• Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.

  Journal of surgical oncology 20080601

• Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential.

  Oncology reports 20080601

• Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells.

  International journal of oncology 20080601

• Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080601

• Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?

  Pharmacotherapy 20080601

• Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080601

• Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience.

  Japanese journal of clinical oncology 20080601

• Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.

  American journal of clinical oncology 20080601

• Population-based phase I trial of irinotecan and epirubicin.

  American journal of clinical oncology 20080601

• The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice.

  Journal of chemotherapy (Florence, Italy) 20080601

• Neoadjuvant chemoradiation for rectal cancer: is more better?

  Oncology (Williston Park, N.Y.) 20080601

• [Prevention of irinotecan hydrochloride-induced diarrhea by oral administration of Lactobacillus casei strain Shirota in rats].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080601

• [CR obtained by CPT-11 and CDDP combination-therapy in a small-cell lung-cancer patient through effective pharmaceutical care].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080601

• [A case of interstitial pneumonia induced by S-1/irinotecan combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080601

• [A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080601

• [A case of small cell carcinoma of the ureter].

  Hinyokika kiyo. Acta urologica Japonica 20080601

• Poly (amino acid) micelle nanocarriers in preclinical and clinical studies.

  Advanced drug delivery reviews 20080522

• Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.

  British journal of cancer 20080520

• Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.

  Cancer 20080515

• EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510

• Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510

• Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080501

• Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080501

• Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.

  International journal of cancer 20080501

• A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080501

• UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.

  Cancer 20080501

• Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.

  Cancer 20080501

• Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.

  Expert opinion on pharmacotherapy 20080501

• A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis.

  International journal of oncology 20080501

• Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women.

  Oncology reports 20080501

• Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation.

  Journal of neurosurgery 20080501

• The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20080501

• Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.

  Pharmacogenomics 20080501

• Topoisomerase I inhibitors for the treatment of brain tumors.

  Expert review of anticancer therapy 20080501

• Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.

  Expert review of anticancer therapy 20080501

• Systemic treatment of colorectal cancer.

  Gastroenterology 20080501

• Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.

  Neoplasia (New York, N.Y.) 20080501

• [A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080501

• [Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080501

• Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).

  Onkologie 20080501

• Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.

  Clinical colorectal cancer 20080501

• Colon cancer: update on adjuvant therapy.

  Clinical colorectal cancer 20080501

• A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

  British journal of cancer 20080422

• Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study.

  British journal of cancer 20080408

• Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases.

  Journal of controlled release : official journal of the Controlled Release Society 20080407

• Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.

  Cancer chemotherapy and pharmacology 20080401

• Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.

  Cancer chemotherapy and pharmacology 20080401

• Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.

  Clinical pharmacology and therapeutics 20080401

• Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080401

• Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.

  Basic & clinical pharmacology & toxicology 20080401

• Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.

  Current medical research and opinion 20080401

• Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.

  Neuro-oncology 20080401

• Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.

  Oncology reports 20080401

• Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.

  Bioconjugate chemistry 20080401

• [Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20080401

• Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080401

• The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.

  Cancer research 20080401

• DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080401

• Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080401

• Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.

  American journal of clinical oncology 20080401

• Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.

  Leukemia & lymphoma 20080401

• [Combined irinotecan (CPT-11) and nedaplatin (254-S) therapy for advanced and/or recurrent cervical cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080401

• [Multiple hepatic metastases and ovarian metastases of colon cancer responding to combined therapy with S-1 and CPT-11--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080401

• [Antibody treatment in colorectal cancer--what the surgeon needs to know].

  Zentralblatt fur Chirurgie 20080401

• Chemotherapy in elderly patients with colorectal cancer.

  The oncologist 20080401

• Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.

  International journal of clinical oncology 20080401

• UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.

  Journal of chemotherapy (Florence, Italy) 20080401

• Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.

  Cancer letters 20080318

• Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression.

  Cancer research 20080315

• Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080315

• Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080315

• Osteosarcoma metastatic to the kidney and iatrogenic hemorrhage.

  Pediatric blood & cancer 20080301

• Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.

  Pediatric blood & cancer 20080301

• Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.

  Cancer chemotherapy and pharmacology 20080301

• Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20080301

• Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene.

  Cancer chemotherapy and pharmacology 20080301

• Response of a thymic mucoepidermoid carcinoma to combination chemotherapy with cisplatin and irinotecan: a case report.

  Lung cancer (Amsterdam, Netherlands) 20080301

• A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20080301

• ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080301

• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080301

• Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20080301

• An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.

  Cancer gene therapy 20080301

• Carboxylesterase 2 is downregulated in colorectal cancer following progression of the disease.

  Cancer investigation 20080301

• Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.

  European journal of cancer (Oxford, England : 1990) 20080301

• Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20080301

• U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080301

• Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080301

• Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy.

  Onkologie 20080301

• [A case of multidrug-resistant squamous cell lung carcinoma responding to S-1 plus CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080301

• [A long survival case of advanced colon cancer with lung metastasis and cancerous pleuritis responding to CPT-11 and S-1 combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080301

• Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20080301

• Sequential vs combination colorectal cancer therapy sparks debate.

  British journal of hospital medicine (London, England : 2005) 20080301

• Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

  Clinical colorectal cancer 20080301

• Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.

  Clinical colorectal cancer 20080301

• Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.

  Clinical genitourinary cancer 20080301

• [Current therapeutic options for liver metastasis].

  Revista medica de Chile 20080301

• [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20080301

• Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.

  British journal of cancer 20080226

• Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.

  British journal of cancer 20080226

• Bevacizumab plus irinotecan in recurrent glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080220

• Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes.

  Cancer letters 20080218

• Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases.

  Cancer 20080215

• Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080215

• Spectrofluorimetric determination of irinotecan in the presence of oxidant agents and metal ions.

  Talanta 20080215

• Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

  Journal of the National Cancer Institute 20080206

• Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20080201

• A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20080201

• Reducing irinotecan-associated diarrhea in children.

  Pediatric blood & cancer 20080201

• Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.

  Cancer chemotherapy and pharmacology 20080201

• Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan.

  Cancer gene therapy 20080201

• Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.

  Cancer investigation 20080201

• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201

• The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition.

  Cancer research 20080201

• Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.

  Molecular cancer therapeutics 20080201

• [CPT-11 (Irinotecan)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080201

• [Clinical experience of second-line chemotherapy with S-1/CPT-11 for highly advanced gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080201

• [A case of long-term survival of postoperative brain metastasis of small cell lung cancer effectively treated with chemotherapy, whole brain radiotherapy and stereotactic radiosurgery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080201

• Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

  The oncologist 20080201

• Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.

  British journal of cancer 20080129

• [Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080117

• Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080110

• Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080110

• The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20080101

• A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.

  Cancer chemotherapy and pharmacology 20080101

• Pneumatosis intestinalis and portal venous gas without bowel ischemia in a patient treated with irinotecan and cisplatin.

  Digestive diseases and sciences 20080101

• Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080101

• A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080101

• Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.

  Annals of surgical oncology 20080101

• Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.

  Acta oncologica (Stockholm, Sweden) 20080101

• Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.

  Acta oncologica (Stockholm, Sweden) 20080101

• Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.

  Acta oncologica (Stockholm, Sweden) 20080101

• Carbon beam therapy in recurrent ovarian cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080101

• Treatment of metastatic urachal carcinoma in an elderly woman.

  Nature clinical practice. Oncology 20080101

• Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.

  Acta oncologica (Stockholm, Sweden) 20080101

• Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.

  Journal of the American College of Surgeons 20080101

• Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080101

• Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080101

• [A pilot study of irinotecan hydrochloride(CPT-11)and cisplatin(CDDP)combination chemotherapy for previously treated non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080101

• [Irinotecan plus gemcitabine(IRINOGEM)in the treatment of biliary malignancies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080101

• Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.

  Gan to kagaku ryoho. Cancer & chemotherapy 20080101

• [An elderly case of recurrent colon cancer responding to weekly S-1 chemotherapy leading to partial response].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080101

• [Predictive factors of response to anti-EGFR treatments in colorectal cancer].

  Bulletin du cancer 20080101

• Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.

  The oncologist 20080101

• Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin.

  Clinical & experimental metastasis 20080101

• Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20080101

• Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.

  Clinical colorectal cancer 20080101

• Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation.

  Clinical colorectal cancer 20080101

• Chemotherapy for brain metastases in small-cell lung cancer.

  Clinical lung cancer 20080101

• Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer.

  Chemotherapy 20080101

• Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.

  Medical oncology (Northwood, London, England) 20080101

• Small cell carcinoma of the extrahepatic bile duct diagnosed with EUS-FNA and effectively treated with chemoradiation.

  Internal medicine (Tokyo, Japan) 20080101

• Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer.

  Anticancer research 20080101

• Successful treatment with S-1 plus CPT-11 for lymph node metastasis from colon cancer: report of a case.

  Anticancer research 20080101

• Cellular response to irinotecan in colon cancer cell lines showing differential response to 5-fluorouracil.

  Anticancer research 20080101

• Dose escalation study of amrubicin in combination with fixed-dose irinotecan in patients with extensive small-cell lung cancer.

  Oncology 20080101

• A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.

  BMC cancer 20080101

• Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.

  Oncology 20080101

• Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.

  PloS one 20080101

• [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].

  Revue neurologique 20080101

• Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.

  BMC cancer 20080101

• A phase I trial of CPT-11 and S-1 combination chemotherapy in patients with metastatic colorectal cancer.

  Hepato-gastroenterology 20080101

• Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units.

  Anticancer research 20080101

• Complete response obtained and maintained by combination of S-1 and CPT-11 in hepatic metastases of colon cancer: a case report.

  Anticancer research 20080101

• Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.

  Anticancer research 20080101

• Diminishing impact of preoperative carcinoembryonic antigen (CEA) in prognosis of Dukes' C colorectal cancer.

  Anticancer research 20080101

• Weekly irinotecan plus protracted venous fluorouracil infusion (WI-FI) in advanced colorectal cancer: a phase II study.

  Anticancer research 20080101

• Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer.

  Oncology 20080101

• Bortezomib as a therapeutic candidate for neuroblastoma.

  Journal of experimental therapeutics & oncology 20080101

• Intestinal permeability and toxicity of second-line therapeutic agents in ovarian cancer.

  Tumori 20080101

• Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.

  Chemotherapy 20080101

• Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.

  Cancer journal (Sudbury, Mass.) 20080101

• Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.

  Oncology 20080101

• Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan.

  Journal of gastroenterology 20080101

• Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).

  Anticancer research 20080101

• Phase I study of irinotecan combined with mitomycin-C and 5-fluorouracil for gynecological malignancies: the JGOG study.

  Anticancer research 20080101

• Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients.

  Anticancer research 20080101

• Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.

  Anticancer research 20080101

• A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.

  Cancer treatment reviews 20080101

• Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20080101

• Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.

  Anticancer research 20080101

• The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.

  Acta chirurgica Iugoslavica 20080101

• TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects.

  Hepato-gastroenterology 20080101

• Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.

  Journal of gastrointestinal cancer 20080101

• Docetaxel and irinotecan as first-line chemotherapy in patients with advanced non-small-cell lung cancer: a pilot study.

  Le Journal medical libanais. The Lebanese medical journal 20080101

• A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.

  Cancer 20071215

• Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.

  World journal of gastroenterology 20071214

• Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.

  International journal of cancer 20071201

• Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.

  Lung cancer (Amsterdam, Netherlands) 20071201

• A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071201

• A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071201

• Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.

  International journal of radiation oncology, biology, physics 20071201

• Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071201

• A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.

  Oncology reports 20071201

• [Systemic treatment of peritoneal metastases].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20071201

• Treatment of advanced colorectal cancer in the elderly.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20071201

• Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20071201

• AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 1.

  IDrugs : the investigational drugs journal 20071201

• Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071201

• Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071201

• Bi-weekly irinotecan hydrochloride and cisplatin as a second-line chemotherapy for patients with advanced gastric cancer.

  Gan to kagaku ryoho. Cancer & chemotherapy 20071201

• [Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071201

• [A case report--combination chemotherapy with oral UFT and CPT-11, 5-FU, l-LV by hepatic arterial infusion for multiple hepatic metastasis from sigmoid colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071201

• Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.

  Neoplasia (New York, N.Y.) 20071201

• Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.

  Journal of chemotherapy (Florence, Italy) 20071201

• Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.

  Journal of chemotherapy (Florence, Italy) 20071201

• Experimental evidence for the efficacy of combined therapy of CPT-11 and hyperthermia for squamous cell carcinoma of the esophagus.

  Hepato-gastroenterology 20071201

• Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.

  Clinical colorectal cancer 20071201

• Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.

  Clinical colorectal cancer 20071201

• A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.

  Clinical colorectal cancer 20071201

• Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.

  Journal of experimental & clinical cancer research : CR 20071201

• [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20071201

• Drug-eluting particles for interventional pharmacology.

  Techniques in vascular and interventional radiology 20071201

• Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?

  The EMBO journal 20071114

• [Long- term remission survival with a case of rectal carcinoid tumor with metastasis in the soft tissue effectively treated with the combination therapy of irinotecan/5-fluorouracil/levofolinate followed by resection].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20071110

• A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.

  Cancer chemotherapy and pharmacology 20071101

• Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20071101

• Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071101

• The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.

  European journal of cancer (Oxford, England : 1990) 20071101

• Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071101

• A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071101

• [Results of chemotherapy using new anti-cancer drugs since S-1 for advanced or recurrent gastric cancer in our institute].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [A case of cytology-positive, stage IV gastric cancer, alive with no recurrence for 4 years, curatively treated with combination chemotherapy using S-1, CPT-11 and subsequent total gastrectomy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• Cetuximab efficacy in patients treated routinely in university hospitals.

  Gastroenterologie clinique et biologique 20071101

• Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20071101

• [A long-term surviving patient with unresectable lung metastasis from colon cancer treated with intravenous administration of activated autologous lymphocytes and low-dose chemotherapy--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [Transarterial chemoembolization with irinotecan (CPT-11) and degradable starch microspheres (DSM) in patients with liver metastases from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [A case of multiple liver metastases from rectal cancer in poor performance status successfully treated with hepatic arterial infusion chemotherapy plus CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [Evaluation of bronchial arterial infusion (BAI) for lung cancer with carcinomatous pleuritis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [Carboplatin and CPT-11 chemotherapy in a hemodialysis patient with small-cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [Three successful cases with CPT-11 + CDDP chemotherapy where S-1 failed to respond to recurrent gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [A case of unresectable gastric cancer successfully treated with combination chemotherapy of S-1 + CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [A case of S-1 resistant multiple lung metastases after curative total gastrectomy for gastric cancer successfully treated by S-1 combined with CPT-11 as the third-line chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [Prediction of adverse drug reactions based on genomic information].

  Nihon rinsho. Japanese journal of clinical medicine 20071028

• Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.

  British journal of cancer 20071022

• Taming glioblastoma: targeting angiogenesis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy.

  International journal of cancer 20071015

• The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.

  Cancer research 20071015

• Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071010

• Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071010

• Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071010

• Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations.

  The pharmacogenomics journal 20071001

• Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model.

  Cancer chemotherapy and pharmacology 20071001

• MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism.

  Digestive diseases and sciences 20071001

• Isolated metastasis of lung cancer to the thyroid gland.

  Lung cancer (Amsterdam, Netherlands) 20071001

• Expression and characterization of a human carboxylesterase 2 splice variant.

  The Journal of pharmacology and experimental therapeutics 20071001

• Haplotypes and a novel defective allele of CES2 found in a Japanese population.

  Drug metabolism and disposition: the biological fate of chemicals 20071001

• Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.

  Neuro-oncology 20071001

• Acute toxicity of irinotecan in the ex-vivo isolated perfused human lung model--high-dose therapy during isolated perfusion without acute toxic lung edema.

  Interactive cardiovascular and thoracic surgery 20071001

• Effect of betulinic acid on anticancer drug-resistant colon cancer cells.

  Basic & clinical pharmacology & toxicology 20071001

• Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.

  Therapeutic drug monitoring 20071001

• Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071001

• [A case of unresectable gastric cancer complicated by serious pyloric stenosis in which S-1 administration after gastrojejunostomy proved effective].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071001

• [Neoadjuvant chemotherapy with combination of S-1 and CPT-11 in advanced rectal cancer - a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071001

• FOLFIRI chemotherapy for metastatic colorectal cancer patients.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20071001

• Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay.

  Journal of chemotherapy (Florence, Italy) 20071001

• Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.

  Journal of chemotherapy (Florence, Italy) 20071001

• The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.

  Journal of chemotherapy (Florence, Italy) 20071001

• Local-regional approach to diffuse malignant peritoneal mesothelioma.

  Gastroenterologie clinique et biologique 20071001

• Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy.

  Gastroenterologie clinique et biologique 20071001

• Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

  Journal of the National Cancer Institute 20070905

• Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.

  Cancer chemotherapy and pharmacology 20070901

• Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.

  Molecular pharmacology 20070901

• Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20070901

• [Role of pharmacogenetics in chemotherapy of colorectal cancers].

  La Revue de medecine interne 20070901

• Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.

  Cancer science 20070901

• A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.

  Anti-cancer drugs 20070901

• Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.

  Anti-cancer drugs 20070901

• Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.

  Cancer 20070901

• Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece.

  Current medical research and opinion 20070901

• Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901

• Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070901

• Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070901

• Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070901

• Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.

  Biological & pharmaceutical bulletin 20070901

• Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.

  Cancer biology & therapy 20070901

• [A case of advanced gastric cancer responding remarkably to neo-adjuvant combination chemotherapy using CPT-11 plus S-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070901

• Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.

  Clinical lung cancer 20070901

• A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.

  Journal of Korean medical science 20070901

• Combined-modality therapy for rectal cancer: future prospects.

  Clinical colorectal cancer 20070901

• Metachronous metastasis to the penis from a rectal adenocarcinoma.

  Clinical colorectal cancer 20070901

• Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.

  British journal of cancer 20070828

• 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.

  Journal of medicinal chemistry 20070823

• A renewed call for equipoise.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070810

• Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070810

• Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.

  British journal of cancer 20070806

• Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20070801

• A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).

  Lung cancer (Amsterdam, Netherlands) 20070801

• Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.

  Gynecologic oncology 20070801

• Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.

  Cancer 20070801

• Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801

• Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.

  Biological & pharmaceutical bulletin 20070801

• [A case of small cell carcinoma of the esophagus with remarkable response to chemotherapy with CPT-11 and CDDP].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20070801

• [Bevacizumab (Avastin)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• [Cetuximab].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• [Neuroendocrine carcinoma of the prostate effectively treated by cisplatin and irinotecan--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• [Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20070801

• The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.

  Molecular cancer therapeutics 20070801

• Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.

  International journal of clinical oncology 20070801

• Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor.

  Journal of pediatric surgery 20070801

• Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.

  American journal of clinical oncology 20070801

• Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer.

  American journal of clinical oncology 20070801

• Optimizing combination chemotherapy by controlling drug ratios.

  Molecular interventions 20070801

• [Chemotherapy in lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20070801

• Targeted therapy in rectal cancer.

  Oncology (Williston Park, N.Y.) 20070801

• TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070715

• Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?

  Lancet (London, England) 20070714

• Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

  Lancet (London, England) 20070714

• Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

  Lancet (London, England) 20070714

• Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20070701

• Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

  Cancer 20070701

• Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses.

  Oncology reports 20070701

• Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

  Pharmacogenetics and genomics 20070701

• Cigarette smoking and the personalization of irinotecan therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070701

• Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070701

• Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis.

  Journal of pharmacological sciences 20070701

• Radiotherapy for localized rectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070701

• [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070701

• [Irinotecan+cisplatin and irradiation are effective for brain metastases of gastric cancer--two case reports].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070701

• [Complete remission of hepatic metastasis of gastric cancer with CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070701

• Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.

  Japanese journal of clinical oncology 20070701

• Capecitabine and irinotecan in advanced gastric cancer.

  The Lancet. Oncology 20070701

• Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.

  Clinical colorectal cancer 20070701

• Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102.

  Japanese journal of clinical oncology 20070701

• Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.

  Anti-cancer drugs 20070701

• Hydroxycamptothecin deactivation rates and binding to model membranes and HSA determined by fluorescence spectra analysis.

  Combinatorial chemistry & high throughput screening 20070701

• C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.

  Biochemical pharmacology 20070630

• UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070620

• Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes.

  International journal of pharmaceutics 20070607

• Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.

  Cancer chemotherapy and pharmacology 20070601

• Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.

  Cancer chemotherapy and pharmacology 20070601

• A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.

  Investigational new drugs 20070601

• Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.

  Investigational new drugs 20070601

• Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.

  Annals of surgical oncology 20070601

• Chemotherapy of advanced gastric cancer.

  Cancer treatment reviews 20070601

• A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20070601

• Enhanced antitumor activity of irinotecan combined with propolis and its polyphenolic compounds on Ehrlich ascites tumor in mice.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20070601

• Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.

  Anti-cancer drugs 20070601

• DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation.

  Cancer science 20070601

• Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphism.

  Clinical biochemistry 20070601

• The interactive transcript abundance index [c-myc*p73alpha]/[p21*Bcl-2] correlates with baseline level of apoptosis and response to CPT-11 in human bronchogenic carcinoma cell lines.

  International journal of oncology 20070601

• UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070601

• Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers.

  Basic & clinical pharmacology & toxicology 20070601

• Insights, challenges, and future directions in irinogenetics.

  Therapeutic drug monitoring 20070601

• Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070601

• Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.

  American journal of clinical oncology 20070601

• [Second-line chemotherapy in gastric cancer following S-1 with CPT-11 chemotherapy performed as clinical trial].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070601

• [Evaluation of combination chemotherapy with 5-FU, CDDP and CPT-11 for human gastric carcinoma transplanted into nude mice - comparative study of in vivo chemosensitivity test].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070601

• [A case of unresectable advanced pancreatic cancer treated by S-1 with concurrent radiotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070601

• [Long survival of a colon cancer case with multiple liver metastases cured by multidisciplinary therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070601

• Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases.

  Archives of surgery (Chicago, Ill. : 1960) 20070601

• UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.

  Current opinion in molecular therapeutics 20070601

• Chemotherapy-induced mucositis: focusing on diarrhea.

  The journal of supportive oncology 20070601

• In vitro simulation study of individualized chemotherapy in lung cancer.

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20070601

• Extensive colonic ischemia following treatment with bevacizumab, fluouracil and CPT-11 in a young patient with advanced adenocarcinoma of the rectum.

  The Israel Medical Association journal : IMAJ 20070601

• Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.

  Acta chirurgica Belgica 20070601

• Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.

  Journal of experimental & clinical cancer research : CR 20070601

• A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.

  British journal of cancer 20070521

• Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.

  Cancer research 20070515

• A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.

  British journal of cancer 20070507

• Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review.

  International journal of colorectal disease 20070501

• Thrombotic microangiopathy and anti-VEGF agents.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070501

• Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.

  Annals of surgical oncology 20070501

• Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.

  Biochemical pharmacology 20070501

• Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: application to cellular metabolism and accumulation studies.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070501

• Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.

  Cancer 20070501

• CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.

  Virchows Archiv : an international journal of pathology 20070501

• Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.

  Oncology reports 20070501

• Sensitivity to CPT-11 and platinum derivatives of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.

  Oncology reports 20070501

• Sensitivity to CPT-11 and platinum derivatives of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.

  Oncology reports 20070501

• Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501

• Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501

• Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.

  Leukemia & lymphoma 20070501

• [A case of ascending colon cancer with enlarged metastatic lymph nodes around superior mesenteric arterial root that responded dramatically to S-1 and CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070501

• [Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070501

• Integration of novel agents into combined-modality treatment for rectal cancer patients.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20070501

• Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.

  Molecular cancer therapeutics 20070501

• Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.

  Human gene therapy 20070501

• Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.

  Japanese journal of clinical oncology 20070501

• Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach.

  Human cell 20070501

• Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

  Clinical colorectal cancer 20070501

• Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer.

  Japanese journal of clinical oncology 20070501

• Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells.

  FEBS letters 20070417

• [Diagnosis of and therapy for pancreatic neoplasms].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070410

• Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.

  Pediatric blood & cancer 20070401

• Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.

  Cancer chemotherapy and pharmacology 20070401

• Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.

  Journal of neuro-oncology 20070401

• Mediastinal signet-ring cell carcinoma of unknown primary: long-term survival by treatment with S-1, a novel derivative of 5-fluorouracil.

  Lung cancer (Amsterdam, Netherlands) 20070401

• Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070401

• St. John's wort and irinotecan-induced diarrhea.

  Toxicology and applied pharmacology 20070401

• Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.

  Cancer 20070401

• Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.

  Pharmacogenomics 20070401

• A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.

  Onkologie 20070401

• Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).

  The journal of gene medicine 20070401

• Cetuximab plus irinotecan in refractory colorectal cancer patients.

  Expert review of anticancer therapy 20070401

• S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.

  Molecular cancer therapeutics 20070401

• [Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [Outpatient chemotherapy for lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [A case report of gastric small cell carcinoma with long survival time by adjuvant chemotherapy--reports of chemotherapy regimens for gastric small cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [A case of TS-1 resistant recurrent gastric cancer with lung metastasis responding to TS-1 and irinotecan combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [Second-or third-line chemotherapy with CPT-11+TS-1 for 5 cases of metastatic and recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [A case of effective regimen of tegafur and uracil (UFT)/leucovorin (LV) plus irinotecan (CPT-11) for advanced rectal carcinoma with severe pelvic infiltration to be performed curative resection].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• Adjuvant treatment of colon cancer: past, present and future.

  Journal of chemotherapy (Florence, Italy) 20070401

• Adjuvant therapy for stage II and III colorectal cancer.

  Seminars in oncology 20070401

• Developing strategies for liver metastases from colorectal cancer.

  Seminars in oncology 20070401

• Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.

  Scandinavian journal of gastroenterology 20070401

• Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats.

  Cancer biology & therapy 20070401

• Size matters. What can we learn from a small randomized trial?

  Onkologie 20070401

• A case of small cell carcinoma of the kidney.

  Hinyokika kiyo. Acta urologica Japonica 20070401

• [Preparation and characterization of 7-ethyl-10-hydroxycamptothecin-loaded hypomicron of amphiphilic block copolymer].

  Yao xue xue bao = Acta pharmaceutica Sinica 20070401

• Irinotecan toxicity.

  Current opinion in supportive and palliative care 20070401

• A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.

  British journal of cancer 20070326

• Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11.

  Journal of molecular biology 20070316

• Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20070301

• A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer.

  Cancer chemotherapy and pharmacology 20070301

• Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20070301

• FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070301

• Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series.

  Biochemical pharmacology 20070301

• Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.

  Biochimica et biophysica acta 20070301

• Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.

  Cancer science 20070301

• Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.

  Diseases of the colon and rectum 20070301

• Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.

  Anti-cancer drugs 20070301

• Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.

  Oncology reports 20070301

• Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070301

• [Lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070301

• [Chemotherapy for elderly patients with colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070301

• [A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070301

• [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070301

• Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.

  Journal of neurosurgery 20070301

• Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.

  The oncologist 20070301

• Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070301

• Validation of rapid polymerase chain reaction-based detection of all length polymorphisms in the UGT 1A1 gene promoter.

  Diagnostic molecular pathology : the American journal of surgical pathology, part B 20070301

• Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20070301

• Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.

  Clinical colorectal cancer 20070301

• [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070301

• A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.

  British journal of cancer 20070226

• Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis.

  British journal of cancer 20070226

• The thermodynamic dissociation constants of the anticancer drugs camptothecine, 7-ethyl-10-hydroxycamptothecine, 10-hydroxycamptothecine and 7-ethylcamptothecine by the least-squares nonlinear regression of multiwavelength spectrophotometric pH-titration data.

  Analytica chimica acta 20070219

• Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070215

• Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070215

• Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.

  British journal of cancer 20070212

• [Standard chemotherapy for colonic neoplasms].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070210

• Morphology control of polylactide microspheres enclosing irinotecan hydrochloride with polylactide based polymer surfactant for reduction of initial burst.

  International journal of pharmaceutics 20070207

• Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.

  Pediatric blood & cancer 20070201

• Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.

  Cancer chemotherapy and pharmacology 20070201

• A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer.

  Cancer chemotherapy and pharmacology 20070201

• Irinotecan changes gene expression in the small intestine of the rat with breast cancer.

  Cancer chemotherapy and pharmacology 20070201

• Comparison of antitumor activities in tumor xenograft treatment.

  Contemporary clinical trials 20070201

• Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

  Investigational new drugs 20070201

• Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070201

• Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070201

• Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070201

• Effects of green tea compounds on irinotecan metabolism.

  Drug metabolism and disposition: the biological fate of chemicals 20070201

• Role of p53 in irinotecan-induced intestinal cell death and mucosal damage.

  Anti-cancer drugs 20070201

• Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070201

• Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070201

• [Basic strategies on first- and second-line chemotherapy for advanced gastric cancers].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20070201

• [Up to date chemotherapy for colon cancer].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20070201

• [Clinical development of chemotherapy for advanced gastric cancer].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20070201

• Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070201

• [Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070201

• A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort.

  Current drug metabolism 20070201

• [Small cell carcinoma of the urinary bladder treated with neo-adjuvant cp chemotherapy (CPT-11 and CDDP): a case report].

  Hinyokika kiyo. Acta urologica Japonica 20070201

• [Pre-operative chemotherapy for patients with hepatic metastases from colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070201

• Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.

  British journal of cancer 20070129

• Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.

  British journal of cancer 20070115

• Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.

  British journal of cancer 20070115

• A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070115

• A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.

  Cancer chemotherapy and pharmacology 20070101

• Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.

  Cancer chemotherapy and pharmacology 20070101

• Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.

  The Journal of pharmacology and experimental therapeutics 20070101

• Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20070101

• Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.

  European journal of cancer (Oxford, England : 1990) 20070101

• Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma.

  Cancer science 20070101

• Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.

  Journal of surgical oncology 20070101

• Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.

  European journal of cancer (Oxford, England : 1990) 20070101

• Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin.

  Neuro-oncology 20070101

• Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

  Cancer 20070101

• Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.

  Clinical pharmacology and therapeutics 20070101

• The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.

  Journal of clinical pharmacology 20070101

• Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat.

  Experimental biology and medicine (Maywood, N.J.) 20070101

• Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.

  Cancer research 20070101

• [Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• [Superficial small cell carcinoma of esophagus treated by endoscopic mucosal resection combined with chemoradiotherapy--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• [A case of stage IV gastric cancer treated sequentially for over two years by TS-1, paclitaxel, and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• [Successful CPT-11 treatment in a patient with pancreatic cancer associated with multiple liver metastases and chronic renal failure].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• [A case of recurrent colon cancer with urinary bladder, para-aortic lymph nodes, and spleen metastases successfully treated with CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• [CR of rectal cancer and synchronous liver and lung metastases obtained with TS-1 plus CPT-11 combination therapy--case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro.

  Pharmacogenetics and genomics 20070101

• Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101

• Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101

• Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.

  Clinical colorectal cancer 20070101

• Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity.

  Anticancer research 20070101

• Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features.

  Anticancer research 20070101

• Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.

  Chemotherapy 20070101

• Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.

  Digestive diseases (Basel, Switzerland) 20070101

• [A prevalent genetic variety of UDP-glycuronosyl transferase predicts high risk of irinotecan toxicity].

  Medicina 20070101

• Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070101

• The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer.

  Anticancer research 20070101

• CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression.

  Anticancer research 20070101

• Multicenter phase II study of irinotecan plus bolus fluorouracil/l-leucovorin for metastasic colorectal cancer.

  Anticancer research 20070101

• Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis.

  Anticancer research 20070101

• Panitumumab in metastatic colorectal cancer.

  Clinical advances in hematology & oncology : H&O 20070101

• Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.

  Chemotherapy 20070101

• Adjuvant treatment of colorectal cancer.

  CA: a cancer journal for clinicians 20070101

• Development and clinical indications of cetuximab.

  The International journal of biological markers 20070101

• Cetuximab in colon cancer.

  The International journal of biological markers 20070101

• A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine.

  Cancer investigation 20070101

• Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors.

  Journal of experimental therapeutics & oncology 20070101

• Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.

  Acta oncologica (Stockholm, Sweden) 20070101

• [Irinotecan and liver dysfunctions].

  Therapie 20070101

• Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer.

  Anticancer research 20070101

• Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070101

• HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.

  Cancer treatment and research 20070101

• Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.

  Cancer treatment and research 20070101

• Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug.

  Angewandte Chemie (International ed. in English) 20070101

• A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.

  Tumori 20070101

• Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma.

  Anticancer research 20070101

• Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer.

  Anticancer research 20070101

• Complete remission of ovarian small cell carcinoma treated with irinotecan and cisplatin: a case report.

  Anticancer research 20070101

• Neoadjuvant chemotherapy with irinotecan and mitomycin-C for locally advanced squamous cell carcinoma of the uterine cervix.

  Anticancer research 20070101

• A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.

  Anticancer research 20070101

• Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.

  Anticancer research 20070101

• Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases.

  Anticancer research 20070101

• Irinotecan and S-1 neoadjuvant chemoradiation therapy in patients with advanced rectal cancer.

  Hepato-gastroenterology 20070101

• Establishment of a single-dose irinotecan model of gastrointestinal mucositis.

  Chemotherapy 20070101

• Evaluation of HI-6 oxime: potential use in protection of human acetylcholinesterase inhibited by antineoplastic drug irinotecan and its cyto/genotoxicity in vitro.

  Acta biochimica Polonica 20070101

• Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20070101

• Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.

  Cancer journal (Sudbury, Mass.) 20070101

• A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer.

  Medical oncology (Northwood, London, England) 20070101

• Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.

  Oncology research 20070101

• Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20070101

• Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient.

  Chemotherapy 20070101

• [Angiogenesis targeting in gastro-intestinal cancers].

  Bulletin du cancer 20070101

• Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma.

  Oncology 20070101

• Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.

  Oncology 20070101

• Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.

  International surgery 20070101

• Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.

  Oncology 20070101

• Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study.

  In vivo (Athens, Greece) 20070101

• Long-term survivors after chemotherapy in advanced non-small cell lung cancer.

  Anticancer research 20070101

• A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.

  Oncology 20070101

• Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).

  Oncology 20070101

• Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.

  Oncology 20070101

• [The choice of treatment in advanced gastric cancer].

  Tumori 20070101

• Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.

  Acta clinica Belgica 20070101

• [Combination chemotherapy with newly-developed cytostatics for disseminated small cell lung cancer].

  Voprosy onkologii 20070101

• Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.

  Oncology 20070101

• XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.

  Oncology 20070101

• ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.

  Drug metabolism letters 20070101

• A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.

  British journal of cancer 20061218

• Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.

  British journal of cancer 20061218

• Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta.

  Annals of oncology : official journal of the European Society for Medical Oncology 20061201

• Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.

  International journal of radiation oncology, biology, physics 20061201

• Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20061201

• A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20061201

• Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation.

  Pharmaceutical research 20061201

• A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.

  Cancer 20061201

• Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.

  Oncology reports 20061201

• Adding pharmacogenetics information to drug labels: lessons learned.

  Pharmacogenetics and genomics 20061201

• Consistent liver metastases in a rat model by portal injection of microencapsulated cancer cells.

  Cancer research 20061201

• Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.

  The American journal of pathology 20061201

• [Thymic basaloid carcinoma].

  Kyobu geka. The Japanese journal of thoracic surgery 20061201

• Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.

  Pharmacogenomics 20061201

• [Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• [A recurrent endocrine cell cancer of the stomach showing almost complete remission after chemotherapy for 1 year].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).

  Onkologie 20061201

• Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.

  Journal of gastroenterology 20061201

• [Outpatient chemotherapy in gynecologic oncology].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases.

  Journal of controlled release : official journal of the Controlled Release Society 20061128

• A bacterial protein enhances the release and efficacy of liposomal cancer drugs.

  Science (New York, N.Y.) 20061124

• Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061120

• Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061120

• Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061120

• Molecular determinants of irinotecan efficacy.

  International journal of cancer 20061115

• Pharmacogenetics and irinotecan therapy.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061115

• Searching for the Holy Grail of oncology.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061115

• Fractionated administration of irinotecan and cisplatin in Japanese patients with extensive-stage-disease small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061110

• BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20061101

• Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.

  Cancer chemotherapy and pharmacology 20061101

• Irinotecan in the treatment of colorectal cancer.

  Cancer treatment reviews 20061101

• Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

  Cancer science 20061101

• Real-time imaging and quantification of brain delivery of liposomes.

  Pharmaceutical research 20061101

• Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report.

  Oncology reports 20061101

• [A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• [What happened during these 12 years since CPT-11 was launched in Japan ?].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• Pharmacogenetic approach for cancer treatment-tailored medicine in practice.

  Annals of the New York Academy of Sciences 20061101

• 5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20061101

• [Evaluation of bronchial arterial infusion (BAI) for lung cancer with brain metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• [A case report of small cell carcinoma of the esophagus successfully treated by irinotecan and cisplatin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases.

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• [A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• [A treatment for pulmonary metastases from colorectal cancer by pre-operative CPT-11/5'-DFUR combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101

• Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer.

  World journal of gastroenterology 20061028

• Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061020

• Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061020

• St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis.

  Toxicology and applied pharmacology 20061015

• Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.

  Cancer research 20061015

• Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.

  Cancer chemotherapy and pharmacology 20061001

• A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.

  The Journal of pharmacology and experimental therapeutics 20061001

• Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20061001

• Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20061001

• Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement by Bartlett et al.

  Annals of surgical oncology 20061001

• Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.

  Annals of surgical oncology 20061001

• Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061001

• Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer.

  Clinical pharmacology and therapeutics 20061001

• Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

  Cancer research 20061001

• Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.

  American journal of clinical oncology 20061001

• New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.

  Future oncology (London, England) 20061001

• [A case of advanced gastric cancer with long-term survival treated by chemotherapy and surgical cytoreduction].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061001

• [Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemotherapy with 5-FU].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061001

• [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061001

• Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.

  Journal of chemotherapy (Florence, Italy) 20061001

• A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.

  Journal of chemotherapy (Florence, Italy) 20061001

• Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease.

  Journal of chemotherapy (Florence, Italy) 20061001

• [Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20061001

• [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20061001

• Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061001

• CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.

  British journal of cancer 20060918

• Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.

  British journal of cancer 20060918

• Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060910

• Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060910

• A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

  British journal of cancer 20060904

• Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.

  Cancer chemotherapy and pharmacology 20060901

• Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.

  The Journal of pharmacology and experimental therapeutics 20060901

• Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.

  Cancer science 20060901

• A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.

  International journal of radiation oncology, biology, physics 20060901

• Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060901

• Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.

  Oncology reports 20060901

• Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.

  Oncology reports 20060901

• Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.

  Japanese journal of clinical oncology 20060901

• A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060901

• Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.

  Pharmacogenetics and genomics 20060901

• A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat.

  Cancer biology & therapy 20060901

• Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.

  Anti-cancer drugs 20060901

• Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901

• Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901

• [Pharmacokinetic study of cancer chemotherapy].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20060901

• Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

  The oncologist 20060901

• [Malignant mesothelioma--diagnosis and treatment strategies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [Hepatic arterial infusion chemotherapy for liver metastases from digestive cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [A case of advanced gastric cancer with liver metastasis completely responding to CPT-11+low-dose 5-FU+CDDP chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [A case of non-curatively resected colon cancer with liver and lymph node metastases treated by TS-1/CPT-11 combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [A case of local recurrence of rectal cancer in long-term responding to combined therapy of low-dose CPT-11 and 5'-DFUR].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.

  Cancer biology & therapy 20060901

• Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder.

  International journal of urology : official journal of the Japanese Urological Association 20060901

• Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.

  Molecular cancer therapeutics 20060901

• Highlights from: 42nd Annual Meeting of the American Society of Clinical Oncology.

  Clinical colorectal cancer 20060901

• [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060901

• Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060901

• Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.

  Current clinical pharmacology 20060901

• A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy.

  Cancer 20060815

• Hexosomes formed from glycerate surfactants--formulation as a colloidal carrier for irinotecan.

  International journal of pharmaceutics 20060802

• [Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20060801

• A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20060801

• Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20060801

• Predicting the outcome of chemotherapy for colorectal cancer.

  Current opinion in pharmacology 20060801

• Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.

  Lung cancer (Amsterdam, Netherlands) 20060801

• First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060801

• Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060801

• Determinants of chemosensitivity in gastric cancer.

  Current opinion in pharmacology 20060801

• Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.

  Current opinion in pharmacology 20060801

• A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060801

• Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060801

• TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

  Trends in pharmacological sciences 20060801

• Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan.

  Pediatric transplantation 20060801

• A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination.

  Cancer research 20060801

• In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060801

• [Lung cancer with bone metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060801

• [A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060801

• [Multiple hepatic metastases of colon cancer responding to combined therapy with TS-1 and CPT-11--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060801

• Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.

  Anti-cancer drugs 20060801

• Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20060801

• The role of targeted therapy in the treatment of colorectal cancer.

  Clinical advances in hematology & oncology : H&O 20060801

• [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060801

• [Application of Camptosar in neoadjuvant chemotherapy for rectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060801

• Turning point for colorectal cancer clinical trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720

• Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720

• Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720

• Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.

  Cancer chemotherapy and pharmacology 20060701

• The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.

  Drug metabolism and disposition: the biological fate of chemicals 20060701

• A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060701

• Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.

  Molecular pharmacology 20060701

• Salvage chemotherapy with CPT-11 for recurrent meningioma.

  Journal of neuro-oncology 20060701

• Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.

  Lung cancer (Amsterdam, Netherlands) 20060701

• Irinotecan-eluting stents inhibited neointimal proliferation in hypercholesterolemic rabbit aortas.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20060701

• Biological agents versus chemotherapy in the treatment of colorectal cancer.

  Expert opinion on pharmacotherapy 20060701

• The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060701

• Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.

  Expert review of molecular diagnostics 20060701

• [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060701

• [24 hour infusion of CPT-11/oral UFT/LV].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060701

• [A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060701

• The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.

  British journal of clinical pharmacology 20060701

• [Adjuvant treatment of colorectal cancer].

  Bulletin du cancer 20060701

• The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.

  Molecular cancer therapeutics 20060701

• Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

  Molecular cancer therapeutics 20060701

• [Present status and prospect of irinotecan application in adjuvant therapy for colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060701

• Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060615

• Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060615

• Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.

  International journal of cancer 20060601

• Expression of drug pathway proteins is independent of tumour type.

  The Journal of pathology 20060601

• Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

  Virchows Archiv : an international journal of pathology 20060601

• Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway.

  Cancer research 20060601

• FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• [Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [A patient with hepatic, pulmonary, and nodal metastases of colon cancer responding to CPT-11/TS-1 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Advanced rectal cancer in an older patient, in whom metastatic liver lesions were effectively controlled with oral UFT+LV and venous CPT-11 administration--case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Collision cancer of squamous cell carcinoma and small cell carcinoma of the lung; report of a case].

  Kyobu geka. The Japanese journal of thoracic surgery 20060601

• Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.

  Molecular cancer therapeutics 20060601

• A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.

  Digestive diseases and sciences 20060601

• [S-1 for gastric cancer-S-1 monotherapy and its progress].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Combination chemotherapy of S-1 +CPT-11 (q 4-5 w) for metastatic gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [S-1 as a single agent for colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Long-term repeatable chemotherapy for patients with advanced pancreatic cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.

  Oncogene 20060525

• Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.

  British journal of cancer 20060522

• Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.

  British journal of cancer 20060522

• Irinogenetics: what is the right star?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060520

• Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060520

• Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer.

  Cancer 20060515

• A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.

  British journal of cancer 20060508

• A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.

  British journal of cancer 20060508

• Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.

  British journal of cancer 20060508

• Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar).

  The Medical letter on drugs and therapeutics 20060508

• HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38.

  Journal of pharmaceutical and biomedical analysis 20060503

• Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.

  Investigational new drugs 20060501

• Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.

  Head & neck 20060501

• Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.

  European journal of haematology 20060501

• Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060501

• Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.

  Cancer treatment reviews 20060501

• Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.

  Oncology reports 20060501

• Individualizing chemotherapeutic treatment of colorectal cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060501

• Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060501

• [The present state and future of home care for gastric cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [Lung carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [Outpatient based colorectal cancer treatment--the current status, challenges and future outlook].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [A case of gastric cancer presenting with obstructive jaundice and responding to biweekly CPT-11 and CDDP combination administration].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.

  Current drug metabolism 20060501

• [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20060501

• [Irinotecan for the treatment of metastatic colorectal cancer].

  Bulletin du cancer 20060501

• MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

  Neurology 20060425

• Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.

  British journal of cancer 20060424

• Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.

  Oncogene 20060420

• New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060420

• Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060415

• Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones.

  Biochemical pharmacology 20060414

• Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study.

  British journal of cancer 20060410

• A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060401

• Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).

  Lung cancer (Amsterdam, Netherlands) 20060401

• The antitumor effect of a novel differentiation inducer, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), in combinatory therapy on human colon cancer.

  International journal of oncology 20060401

• The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.

  Oncology reports 20060401

• Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.

  Oncology reports 20060401

• A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

  Neuro-oncology 20060401

• Chemotherapy for advanced pancreatic cancer.

  Best practice & research. Clinical gastroenterology 20060401

• Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

  Expert opinion on pharmacotherapy 20060401

• Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.

  American journal of clinical oncology 20060401

• Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.

  American journal of clinical oncology 20060401

• [A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060401

• Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20060401

• [Non-surgical treatment for pancreatic cancer].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20060401

• [A case report: simultaneous bilateral testicular tumors with different cell types--complete response after combination chemotherapy of cisplatin and irrinotecan hydrochloride--].

  Hinyokika kiyo. Acta urologica Japonica 20060401

• [Prevention of anticancer drug-induced premature ovarian failure].

  Nihon rinsho. Japanese journal of clinical medicine 20060401

• [Molecular targets in colon cancer].

  Therapeutische Umschau. Revue therapeutique 20060401

• Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.

  Drug metabolism and pharmacokinetics 20060401

• Individualizing cancer chemotherapy.

  Clinical advances in hematology & oncology : H&O 20060401

• Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

  Oncology (Williston Park, N.Y.) 20060401

• Nondermatologic adverse events associated with anti-EGFR therapy.

  Oncology (Williston Park, N.Y.) 20060401

• Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.

  Oncology (Williston Park, N.Y.) 20060401

• DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.

  The Journal of biological chemistry 20060331

• Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.

  British journal of cancer 20060327

• Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

  Cancer research 20060315

• From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060315

• Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060315

• Correspondence re: Cecchin et al., Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 2005;11:6901-7.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060315

• [Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials].

  Deutsche medizinische Wochenschrift (1946) 20060310

• Role of pharmacogenetics in irinotecan therapy.

  Cancer letters 20060308

• [The modern treatment of colorectal cancer. Present and future].

  Orvosi hetilap 20060305

• Irinotecan (CPT-11) combined with cisplatin for small cell carcinoma of the nasal cavity.

  Auris, nasus, larynx 20060301

• Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060301

• Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.

  International journal of radiation oncology, biology, physics 20060301

• Pharmacogenetics of irinotecan metabolism and transport: an update.

  Toxicology in vitro : an international journal published in association with BIBRA 20060301

• Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060301

• Recent developments in the use of chemotherapy in brain tumours.

  European journal of cancer (Oxford, England : 1990) 20060301

• Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level.

  European journal of cancer (Oxford, England : 1990) 20060301

• Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

  Cancer 20060301

• Direct activation of the human major vault protein gene by DNA-damaging agents.

  Oncology reports 20060301

• Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations.

  Expert opinion on drug safety 20060301

• Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.

  Cancer research 20060301

• [A case of small-cell lung cancer responding remarkably to CPT-11 and CDDP combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060301

• [A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060301

• [Chemotherapy for lung cancer patients].

  Journal of UOEH 20060301

• Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.

  Cancer science 20060301

• Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells.

  Molecular cancer therapeutics 20060301

• Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.

  Clinical colorectal cancer 20060301

• Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.

  Clinical colorectal cancer 20060301

• Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.

  Clinical lung cancer 20060301

• Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20060301

• Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20060301

• Irinotecan for children with relapsed solid tumors.

  Pediatric hematology and oncology 20060301

• Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060301

• Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060301

• Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems.

  International journal of pharmaceutics 20060217

• Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma.

  Cancer 20060215

• A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060215

• Intestinal microflora and digestive toxicity of irinotecan in mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060215

• Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060210

• A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20060201

• Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.

  Journal of neuro-oncology 20060201

• Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.

  International journal of radiation oncology, biology, physics 20060201

• Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060201

• The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.

  Gynecologic oncology 20060201

• A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060201

• Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma.

  Cancer 20060201

• in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.

  International journal of oncology 20060201

• PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.

  Technology in cancer research & treatment 20060201

• Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes.

  Pharmacogenetics and genomics 20060201

• Identification and immunotherapeutic targeting of antigens induced by chemotherapy.

  Nature biotechnology 20060201

• Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060201

• Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060201

• A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.

  Japanese journal of clinical oncology 20060201

• Central nervous system toxicity induced by irinotecan.

  Journal of the National Cancer Institute 20060201

• Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20060201

• Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.

  American journal of clinical oncology 20060201

• Designer combination therapy for cancer.

  Nature biotechnology 20060201

• [Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].

  Bulletin du cancer 20060201

• [Progress in therapy for testicular tumors].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060201

• [A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060201

• [Mechanisms of substrate transport by ABC transporter, MRP1/ABCC1].

  Seikagaku. The Journal of Japanese Biochemical Society 20060201

• Novel single nucleotide polymorphism of UGT1A7 gene in Japanese.

  Drug metabolism and pharmacokinetics 20060201

• Novel single nucleotide polymorphism of UGT1A9 gene in Japanese.

  Drug metabolism and pharmacokinetics 20060201

• Administration of anti-EGFR therapy: a practical review.

  Seminars in oncology nursing 20060201

• [Is small cell lung cancer an orphan disease?].

  Revue de pneumologie clinique 20060201

• [From ASCO and WCLC 2005 to clinical practice: 'conventional' treatments].

  Revue de pneumologie clinique 20060201

• SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.

  British journal of cancer 20060116

• Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.

  Cancer 20060115

• Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

• Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

• Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.

  Oncogene 20060112

• A phase I study of irinotecan administered on a weekly schedule in pediatric patients.

  Pediatric blood & cancer 20060101

• Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.

  Cancer chemotherapy and pharmacology 20060101

• Characterization of secretory intestinal transport of the lactone form of CPT-11.

  Cancer chemotherapy and pharmacology 20060101

• Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.

  Cancer chemotherapy and pharmacology 20060101

• Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060101

• Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.

  The Journal of clinical endocrinology and metabolism 20060101

• Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer.

  Anti-cancer drugs 20060101

• A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20060101

• Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20060101

• Unresectable hepatic colorectal metastases: need for new surgical strategies.

  Annals of surgical oncology 20060101

• Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.

  Annals of surgical oncology 20060101

• Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.

  Surgery today 20060101

• Adjuvant therapy for colon cancer 2005: new options in the twenty-first century.

  Surgical oncology clinics of North America 20060101

• Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.

  Human gene therapy 20060101

• [Management of chemotherapy-induced mucositis and diarrhea].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060101

• [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060101

• Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid.

  Molecular cancer therapeutics 20060101

• Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.

  Molecular cancer therapeutics 20060101

• Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer.

  Japanese journal of clinical oncology 20060101

• [Irinotecan chemotherapy for patients with advanced or relapsed pancreatic neoplasm].

  Nihon rinsho. Japanese journal of clinical medicine 20060101

• Influence of irinotecan and SN-38 on the irradiation response of WHO3 human oesophageal tumour cells under hypoxic conditions.

  Anticancer research 20060101

• Circumvention of camptothecin-induced resistance during the adaptive cellular stress response.

  Anticancer research 20060101

• Small cell lung cancer: an update on therapeutic aspects.

  The Indian journal of chest diseases & allied sciences 20060101

• Metastatic ovarian carcinoma one year after surgical removal of colon carcinoma during pregnancy: a case report.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Chylous ascites following operation for para-aortic lymph node dissection in a patient with cervical cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Phospholipid fatty acid composition and diamine oxidase activity of intestinal mucosa from rats treated with irinotecan hydrochloride (CPT-11) under vegetable oil-enriched diets: comparison between perilla oil and corn oil.

  JPEN. Journal of parenteral and enteral nutrition 20060101

• Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

  Bioconjugate chemistry 20060101

• [Myelotoxity of the nuclear enzyme inhibitors irinotecan and etoposide].

  Eksperimental'naia i klinicheskaia farmakologiia 20060101

• Irinotecan as a new agent for urachal cancer.

  Urologia internationalis 20060101

• Second-line combination chemotherapy of oral S-1 with cisplatin and irinotecan for colorectal cancer resistant to 5-FU.

  Hepato-gastroenterology 20060101

• A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer.

  Hepato-gastroenterology 20060101

• Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs.

  Anticancer research 20060101

• In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab.

  Anticancer research 20060101

• Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer.

  Anticancer research 20060101

• Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.

  Anticancer research 20060101

• Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.

  Oncology 20060101

• A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.

  Oncology 20060101

• Neoadjuvant chemotherapy in cervical cancer: a 67 patients experience.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line.

  Molecular pharmaceutics 20060101

• Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.

  Molecular cancer 20060101

• Stable disease in advanced colorectal cancer: therapeutic implications.

  Anticancer research 20060101

• Both bronchial and vascular stenting followed by chemoradiotherapy for locally advanced non-small cell lung cancer.

  Anticancer research 20060101

• Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis.

  Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20060101

• A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer.

  Cancer investigation 20060101

• Mechanism of central nervous system toxicity by irinotecan.

  Medical hypotheses 20060101

• Survival of patients with colorectal cancer liver metastases treated by regional chemotherapy.

  Hepato-gastroenterology 20060101

• Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.

  Cancer investigation 20060101

• Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.

  Anticancer research 20060101

• A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients.

  Anticancer research 20060101

• Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.

  Anticancer research 20060101

• Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.

  Chemotherapy 20060101

• Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.

  Drug metabolism reviews 20060101

• Decreasing dosage of irinotecan, 5-flurouracil (5-FU) and leucovorin (LV) in the treatment of advanced and/or metastatic colorectal cancer: a phase II study.

  Chang Gung medical journal 20060101

• Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20060101

• A case report and discussion of cetuximab-induced folliculitis.

  American journal of clinical dermatology 20060101

• Combined chemotherapy of irinotecan and low-dose cisplatin (I/low-P) against metastatic biliary tract cancer.

  Journal of hepato-biliary-pancreatic surgery 20060101

• Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience.

  Medical oncology (Northwood, London, England) 20060101

• Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin.

  Tumori 20060101

• Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer.

  Tumori 20060101

• In vitro thermochemotherapy of colon cancer cell lines with irinotecan alone and combined with mitomycin C.

  Hepato-gastroenterology 20060101

• Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results.

  Anticancer research 20060101

• Recent progress in target therapy in colorectal cancer.

  Anticancer research 20060101

• Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.

  The oncologist 20060101

• Complete response of highly advanced colon cancer with multiple lymph node metastases to irinotecan combined with UFT: report of a case.

  Surgery today 20060101

• Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition.

  Tumori 20060101

• Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy evaluation. A phase I-II study.

  Tumori 20060101

• Development of a tumor-selective approach to treat metastatic cancer.

  PloS one 20060101

• Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer.

  Anticancer research 20060101

• Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.

  Anticancer research 20060101

• Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer.

  Anticancer research 20060101

• Hepatic metastases of colorectal cancer: locoregional intra-arterial treatment.

  Anticancer research 20060101

• [Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].

  Magyar onkologia 20060101

• Genome-wide cDNA microarray screening of genes related to the benefits of paclitaxel and irinotecan chemotherapy in patients with advanced non-small cell lung cancer.

  Journal of experimental therapeutics & oncology 20060101

• [Metastatic colorectal cancer: adjournments from ESMO 2006].

  Tumori 20060101

• [A review of chemotherapy for metastatic colon cancer].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.

  Annals of medicine 20060101

• Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.

  International journal of gastrointestinal cancer 20060101

• Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

• Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents.

  Bioorganic & medicinal chemistry 20051215

• Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.

  Chemico-biological interactions 20051215

• The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase.

  Chemico-biological interactions 20051215

• Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.

  Cancer 20051215

• A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.

  British journal of cancer 20051212

• Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.

  Cancer chemotherapy and pharmacology 20051201

• A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.

  Cancer chemotherapy and pharmacology 20051201

• Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan.

  Drug metabolism and disposition: the biological fate of chemicals 20051201

• [Which role do new therapeutic options play in palliative care of colorectal cancer?].

  Der Internist 20051201

• Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.

  Cancer biology & therapy 20051201

• Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.

  Investigational new drugs 20051201

• Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11.

  European journal of cancer care 20051201

• Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.

  Journal of pharmacokinetics and pharmacodynamics 20051201

• Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.

  Japanese journal of clinical oncology 20051201

• A multicenter phase II study of 'adjuvant' irinotecan following resection of colorectal hepatic metastases.

  American journal of clinical oncology 20051201

• Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.

  American journal of clinical oncology 20051201

• Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).

  American journal of clinical oncology 20051201

• [Progression of adjuvant chemotherapy for colon cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20051201

• [Recent progress of chemotherapy for colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051201

• [CPT-11-induced diarrhea treated with indisetron hydrochloride--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051201

• Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.

  Journal of Korean medical science 20051201

• Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.

  The Laryngoscope 20051201

• Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma.

  International journal of clinical oncology 20051201

• Intravenous irinotecan plus oral ciclosporin.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20051201

• Irinotecan with bolus and infusional 5-flurouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-flurouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20051201

• Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.

  Seminars in oncology 20051201

• The role of bevacizumab as first-line therapy for colon cancer.

  Seminars in oncology 20051201

• Second-line treatment of patients with metastatic colorectal cancer.

  Seminars in oncology 20051201

• Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.

  Seminars in oncology 20051201

• Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.

  Seminars in oncology 20051201

• A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.

  Digestive diseases and sciences 20051201

• A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.

  Cancer biology & therapy 20051201

• A case of esophageal small cell carcinoma with multiple liver metastases responding to chemotherapy with irinotecan plus cisplatin.

  Journal of experimental & clinical cancer research : CR 20051201

• Liposomalization of SN-38 as active metabolite of CPT-11.

  Journal of controlled release : official journal of the Controlled Release Society 20051128

• Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.

  British journal of cancer 20051128

• The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB.

  Cancer letters 20051118

• Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan.

  AIDS (London, England) 20051118

• Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial.

  British journal of cancer 20051114

• [Drug therapy of patients with metastatic colorectal cancer].

  Ugeskrift for laeger 20051107

• Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma.

  AIDS (London, England) 20051104

• Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.

  Cancer chemotherapy and pharmacology 20051101

• Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution.

  Cancer chemotherapy and pharmacology 20051101

• S-phase modulation by irinotecan: pilot studies in advanced solid tumors.

  Cancer chemotherapy and pharmacology 20051101

• Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20051101

• Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial.

  Cancer 20051101

• Human multidrug resistance associated protein 4 confers resistance to camptothecins.

  Pharmaceutical research 20051101

• Combination effects of irradiation and irinotecan on cervical squamous cell carcinoma cells in vitro.

  Oncology reports 20051101

• The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.

  Anti-cancer drugs 20051101

• Irinotecan (CPT-11) in the treatment of mycosis fungoides.

  The British journal of dermatology 20051101

• Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.

  Nature clinical practice. Oncology 20051101

• Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051101

• [SNPs associated with adverse effects].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• [A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• [A case of rectal cancer treated by preoperative chemoradiation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• Successful treatment of chemoresistant stage 3 neuroblastoma using irinotecan as a single agent.

  Journal of pediatric hematology/oncology 20051101

• Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.

  Clinical colorectal cancer 20051101

• Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.

  Clinical colorectal cancer 20051101

• Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.

  Clinical colorectal cancer 20051101

• Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.

  Clinical colorectal cancer 20051101

• UGT1A1 genotyping in patients undergoing treatment with irinotecan.

  Clinical advances in hematology & oncology : H&O 20051101

• Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.

  Gastroenterologie clinique et biologique 20051101

• The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.

  Biochemical pharmacology 20051015

• Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.

  British journal of cancer 20051003

• Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20051001

• Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.

  Lung cancer (Amsterdam, Netherlands) 20051001

• Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).

  Drug metabolism and disposition: the biological fate of chemicals 20051001

• Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.

  Cancer 20051001

• MRP1 mutated in the L0 region transports SN-38 but not leukotriene C4 or estradiol-17 (beta-D-glucuronate).

  Biochemical pharmacology 20051001

• Systemic therapy for pancreatic cancer.

  Seminars in radiation oncology 20051001

• Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051001

• Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.

  Cancer research 20051001

• [A case of advanced gastric cancer with obstructive jaundice that responded to TS-1/CPT-11 combination therapy after percutaneous transhepatic cholangio drainage].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of small cell carcinoma of the stomach].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• Advanced colorectal cancer: current treatment and nursing management with economic considerations.

  Clinical journal of oncology nursing 20051001

• [Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].

  Kyobu geka. The Japanese journal of thoracic surgery 20051001

• In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.

  International journal of clinical oncology 20051001

• Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.

  The oncologist 20051001

• Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.

  IDrugs : the investigational drugs journal 20051001

• [Host immunity in colorectal cancer patients treated with TS-1 plus CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [Chemotherapy for patients with advanced/recurrent gastric cancer and the practice at our institute].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [Chemotherapy for liver metastasis of colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of an increase in resectability with preoperative chemotherapy TS-1 combined with CPT-11 for unresectable rectal cancer in downstaging].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of metastatic colon cancer treated with oxaliplatin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of chemoradiation with tissue expander for local reccurence of rectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [Two cases of postoperative local skin recurrence of breast cancer successfully treated with chemotherapy of irinotecan hydrochloride (CPT-11)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives.

  Journal of pharmaceutical and biomedical analysis 20050915

• A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy.

  Cancer 20050915

• Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050915

• Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050915

• Regulation of hepatocyte engraftment and proliferation after cytotoxic drug-induced perturbation of the rat liver.

  Transplantation 20050915

• Dendritic supramolecular assemblies for drug delivery.

  Chemical communications (Cambridge, England) 20050914

• Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.

  British journal of cancer 20050905

• Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.

  International journal of cancer 20050901

• Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.

  European urology 20050901

• Gastric cancer. Treatment of advanced disease and new drugs.

  Frontiers in bioscience : a journal and virtual library 20050901

• The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.

  Lung cancer (Amsterdam, Netherlands) 20050901

• Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.

  Japanese journal of clinical oncology 20050901

• Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.

  International journal of oncology 20050901

• Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.

  Oncology reports 20050901

• Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.

  Oncology reports 20050901

• Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.

  Anti-cancer drugs 20050901

• In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking.

  Anti-cancer drugs 20050901

• Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050901

• Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).

  Japanese journal of clinical oncology 20050901

• Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.

  Pharmacogenomics 20050901

• Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.

  Clinical lung cancer 20050901

• [Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050901

• [Clinical significant of semiquantificating DNA topoisomerase- I mRNA in colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050901

• [A case of colon cancer with liver and lung metastases-efficacy of CPT-11/5-FU/l-LV (IFL) as part of ambulatory treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050901

• Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.

  Journal of neuro-oncology 20050901

• Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.

  Clinical colorectal cancer 20050901

• Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.

  Clinical colorectal cancer 20050901

• [Functional SNPs of the breast cancer resistance protein (ABCG2) gene altering the pharmacokinetics/pharmacodynamics of anticancer agents].

  Seikagaku. The Journal of Japanese Biochemical Society 20050901

• Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL.

  Cancer biology & therapy 20050901

• Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.

  The Korean journal of internal medicine 20050901

• [Successful salvage therapy of continuous low-dose irinotecan for a patient with relapsed and refractory diffuse large B-cell lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050901

• Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• Cetuximab therapy and symptomatic hypomagnesemia.

  Journal of the National Cancer Institute 20050817

• Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death.

  Cancer research 20050815

• Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

• pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation.

  International journal of pharmaceutics 20050811

• [Clinical effects of combination chemotherapy with irinotecan hydrochloride and cisplatin on cervical cancer: study of 46 patients].

  Zhonghua yi xue za zhi 20050810

• Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Whither irinotecan?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.

  International journal of oncology 20050801

• Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.

  Lung cancer (Amsterdam, Netherlands) 20050801

• Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.

  Therapeutic drug monitoring 20050801

• Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.

  European journal of cancer (Oxford, England : 1990) 20050801

• Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.

  Cancer research 20050801

• Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050801

• Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.

  American journal of clinical oncology 20050801

• [Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma].

  Ai zheng = Aizheng = Chinese journal of cancer 20050801

• Analysis of incomplete quality of life data in advanced stage cancer: a practical application of multiple imputation.

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20050801

• [A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050801

• [Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050801

• Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis.

  Journal of chemotherapy (Florence, Italy) 20050801

• Patient with angina secondary to capecitabine.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20050801

• Metastatic colorectal cancer: is there one standard approach?

  Oncology (Williston Park, N.Y.) 20050801

• Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050725

• Role of genomic markers in colorectal cancer treatment.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050710

• Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.

  Cancer chemotherapy and pharmacology 20050701

• Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms.

  Drug metabolism and disposition: the biological fate of chemicals 20050701

• Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.

  Anti-cancer drugs 20050701

• A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050701

• A mouse model for developing treatment for secondary liver tumors.

  International journal of oncology 20050701

• Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy.

  Oncology reports 20050701

• Chemotherapy for metastatic colorectal cancer.

  Journal of the National Comprehensive Cancer Network : JNCCN 20050701

• [Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050701

• [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050701

• [Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050701

• [A case report of bowel obstruction due to peritonitis carcinomatosa using combined administration with CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050701

• [Childhood rhabdomyosarcoma].

  Nihon Geka Gakkai zasshi 20050701

• Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer.

  Clinical colorectal cancer 20050701

• Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.

  Clinical colorectal cancer 20050701

• [Assessment of immunotoxicity of irinotecan determined by the novel method, by which productivity of TNF-alpha from whole blood is stimulated by lipopolysaccharide].

  Rinsho byori. The Japanese journal of clinical pathology 20050701

• [Favorable response obtained by low dose chemotherapy in an elderly patient with extensive small cell lung cancer and renal dysfunction].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050701

• Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20050701

• [New oncolytic agents and immunomodulators and their application].

  Nederlands tijdschrift voor geneeskunde 20050625

• [Chemotherapy of patients with colorectal carcinoma].

  Nederlands tijdschrift voor geneeskunde 20050625

• Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.

  British journal of cancer 20050620

• Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.

  Journal of surgical oncology 20050615

• Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.

  Cancer chemotherapy and pharmacology 20050601

• Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050601

• The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.

  Journal of cancer research and clinical oncology 20050601

• The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.

  Molecular pharmacology 20050601

• Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050601

• A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.

  Investigational new drugs 20050601

• Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.

  Investigational new drugs 20050601

• Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?

  Annals of oncology : official journal of the European Society for Medical Oncology 20050601

• Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.

  Lung cancer (Amsterdam, Netherlands) 20050601

• Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.

  Gynecologic oncology 20050601

• Perioperative adjunctive treatment in the management of operable gastric cancer.

  Journal of surgical oncology 20050601

• Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy.

  The Journal of clinical investigation 20050601

• [Systemic therapy for colorectal cancer].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20050601

• Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.

  Journal of the American College of Surgeons 20050601

• A long-term survival case of small cell lung cancer in an HIV-infected patient.

  Japanese journal of clinical oncology 20050601

• A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• [Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer].

  Pathologie-biologie 20050601

• St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.

  Pharmaceutical research 20050601

• In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells.

  Molecular cancer therapeutics 20050601

• [Chemotherapy for advanced non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• [Treatment of small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• [Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• [A case of peritoneal dissemination of gastric cancer successfully treated by irinotecan combined with cisplatin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• Oxaliplatin (Eloxatin) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma.

  Thyroid : official journal of the American Thyroid Association 20050601

• Modeling antitumor activity in xenograft tumor treatment.

  Biometrical journal. Biometrische Zeitschrift 20050601

• [Molecular biology in clinical cancer research: the example of digestive cancers].

  Revue d'epidemiologie et de sante publique 20050601

• Surface morphology control of polylactide microspheres enclosing irinotecan hydrochloride.

  International journal of pharmaceutics 20050530

• Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints.

  Oncogene 20050526

• Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.

  British journal of cancer 20050523

• A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.

  British journal of cancer 20050523

• Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520

• Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520

• A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050515

• Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues.

  Journal of chromatography. A 20050506

• Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.

  Cancer chemotherapy and pharmacology 20050501

• Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2.

  Cancer chemotherapy and pharmacology 20050501

• Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue.

  Cancer chemotherapy and pharmacology 20050501

• Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells.

  International journal of oncology 20050501

• Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.

  Cancer chemotherapy and pharmacology 20050501

• The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20050501

• New combinations in metastatic colorectal cancer: what are our expectations?

  The oncologist 20050501

• 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.

  Journal of clinical pathology 20050501

• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  The Lancet. Oncology 20050501

• Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

  Pharmacogenetics and genomics 20050501

• Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050501

• Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.

  Cancer research 20050501

• Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.

  Chemotherapy 20050501

• The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells.

  Chemotherapy 20050501

• Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.

  Molecular cancer therapeutics 20050501

• Adjuvant therapy in colon cancer: which treatment in 2005?

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.

  Clinical colorectal cancer 20050501

• Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.

  Clinical colorectal cancer 20050501

• [Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20050501

• [Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20050501

• [Successful treatment of refractory mantle cell lymphoma with irinotecan].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050501

• Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.

  British journal of cancer 20050411

• Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050410

• [Colon cancer: molecular markers].

  Deutsche medizinische Wochenschrift (1946) 20050408

• Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11.

  Journal of medicinal chemistry 20050407

• Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.

  Journal of cancer research and clinical oncology 20050401

• Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.

  Cancer immunology, immunotherapy : CII 20050401

• Tumor necrosis factor enhances SN38-mediated apoptosis in mesothelioma cells: the role of nuclear factor-kappaB pathway activation.

  Cancer 20050401

• Gefitinib ('Iressa', ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.

  Cancer chemotherapy and pharmacology 20050401

• Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.

  Oncology reports 20050401

• Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20050401

• Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.

  British journal of clinical pharmacology 20050401

• Critical evaluation of current treatments in metastatic colorectal cancer.

  The oncologist 20050401

• Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.

  Molecular cancer therapeutics 20050401

• Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.

  Japanese journal of clinical oncology 20050401

• Complete response of brain metastases to irinotecan-based chemotherapy.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20050401

• [A case of recurrent breast cancer with bone metastasis causing pancytopenia--efficacy of low-dose CPT-11+ MPA].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050401

• Irinotecan-induced colitis.

  International journal of surgical pathology 20050401

• Cetuximab in previously treated colorectal cancer.

  Clinical colorectal cancer 20050401

• Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.

  Clinical colorectal cancer 20050401

• [A young patient with invasive small cell carcinoma of the urinary bladder: a case report].

  Hinyokika kiyo. Acta urologica Japonica 20050401

• Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.

  Journal of chemotherapy (Florence, Italy) 20050401

• Current therapies for advanced colorectal cancer.

  Oncology (Williston Park, N.Y.) 20050401

• Docetaxel in the management of advanced pancreatic cancer.

  Seminars in oncology 20050401

• Experience with docetaxel in the treatment of gastric cancer.

  Seminars in oncology 20050401

• Docetaxel in the treatment of esophageal cancer.

  Seminars in oncology 20050401

• Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.

  Clinical advances in hematology & oncology : H&O 20050401

• Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.

  British journal of cancer 20050328

• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320

• Is there a new drug beyond floxuridine for intra-arterial hepatic chemotherapy in liver metastases from colorectal cancer?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320

• A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.

  British journal of cancer 20050314

• Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11.

  British journal of cancer 20050314

• In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy.

  The journal of gene medicine 20050301

• Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American.

  Drug metabolism and disposition: the biological fate of chemicals 20050301

• Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.

  Cancer chemotherapy and pharmacology 20050301

• Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.

  Drug metabolism and disposition: the biological fate of chemicals 20050301

• Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050301

• From molecular characteristics to cellular events in apoptosis-resistant HL-60 cells.

  International journal of oncology 20050301

• Gene expression profiling of the irinotecan pathway in colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050301

• Advances in colon cancer chemotheapy: nursing implications.

  Home healthcare nurse 20050301

• Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

  Molecular cancer therapeutics 20050301

• Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.

  Chemotherapy 20050301

• Gastrointestinal Cancers--Second Annual Symposium. 27-29 January 2005, Hollywood, FL, USA.

  IDrugs : the investigational drugs journal 20050301

• [Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050301

• The effect of granisetron on in vitro metabolism of doxorubicin, irinotecan and etoposide.

  Current medical research and opinion 20050301

• Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.

  Clinical therapeutics 20050301

• Synthesis and antitumor activity of A-ring modified hexacyclic analogues of camptothecin.

  Yao xue xue bao = Acta pharmaceutica Sinica 20050301

• Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.

  British journal of cancer 20050227

• Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050220

• Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050220

• Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.

  Cancer 20050215

• Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

  Cancer research 20050215

• Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050215

• Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050215

• MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050215

• Identification of a novel cardenolide (2''-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses.

  Journal of medicinal chemistry 20050210

• A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38).

  Journal of pharmaceutical and biomedical analysis 20050207

• Systemic therapy for colorectal cancer.

  The New England journal of medicine 20050203

• Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.

  Cancer 20050201

• A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050201

• Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050201

• Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201

• Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.

  Japanese journal of clinical oncology 20050201

• UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050201

• Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.

  Seminars in oncology 20050201

• Adjuvant therapy of colon cancer.

  Seminars in oncology 20050201

• Combined modality treatment for rectal cancer.

  Seminars in oncology 20050201

• Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.

  Seminars in oncology 20050201

• Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.

  Seminars in oncology 20050201

• Inhibitory effects of asiatic acid and CPT-11 on growth of HT-29 cells.

  The journal of medical investigation : JMI 20050201

• Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.

  Annals of surgical oncology 20050201

• Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil.

  Journal of chemotherapy (Florence, Italy) 20050201

• Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.

  British journal of cancer 20050131

• Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

• A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.

  British journal of cancer 20050117

• Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.

  Statistics in medicine 20050115

• Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.

  Cancer 20050115

• Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).

  Cancer 20050101

• Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer.

  Anti-cancer drugs 20050101

• Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.

  Anti-cancer drugs 20050101

• Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050101

• Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.

  The Journal of pharmacy and pharmacology 20050101

• Effect of carboxylesterase inhibition on the anti-tumour effects of irinotecan.

  The Journal of international medical research 20050101

• Synergistic antitumor activity of capecitabine in combination with irinotecan.

  Clinical colorectal cancer 20050101

• Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.

  Clinical colorectal cancer 20050101

• [Second-line chemotherapy for advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• [Second-line chemotherapy for recurrent ovarian cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• [A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.

  Expert opinion on pharmacotherapy 20050101

• Toxicity of the topoisomerase I inhibitors.

  Expert opinion on drug safety 20050101

• Chemoresistance in non-small cell lung cancer.

  Current medicinal chemistry. Anti-cancer agents 20050101

• New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: a single center's experience before and after their introduction.

  International journal of gastrointestinal cancer 20050101

• Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.

  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101

• Small-cell lung cancer: current therapy and novel agents.

  Oncology (Williston Park, N.Y.) 20050101

• Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: a case report.

  Hepato-gastroenterology 20050101

• First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.

  Oncology 20050101

• Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.

  Anticancer research 20050101

• Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients.

  Medical hypotheses 20050101

• Benefit-risk assessment of irinotecan in advanced colorectal cancer.

  Drug safety 20050101

• Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.

  Pharmacogenetics and genomics 20050101

• Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20050101

• New chemotherapeutic strategies in colorectal cancer.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20050101

• Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.

  Anticancer research 20050101

• Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.

  Anticancer research 20050101

• Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy.

  Anticancer research 20050101

• (Neo-)adjuvant treatments in colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050101

• Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study.

  Medical oncology (Northwood, London, England) 20050101

• Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.

  Cancer journal (Sudbury, Mass.) 20050101

• Novel agents that potentially inhibit irinotecan-induced diarrhea.

  Current medicinal chemistry 20050101

• Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.

  In vivo (Athens, Greece) 20050101

• The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.

  Oncology 20050101

• Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.

  Oncology 20050101

• Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.

  Oncology 20050101

• Cancer cell adaptation to chemotherapy.

  BMC cancer 20050101

• Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.

  Acta oncologica (Stockholm, Sweden) 20050101

• Capecitabine as third line therapy in patients with advanced colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20050101

• Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer.

  Anticancer research 20050101

• Exogenous expression of hRFI induces multidrug resistance through escape from apoptosis in colorectal cancer cells.

  Anticancer research 20050101

• Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer.

  Anticancer research 20050101

• Nuclear area is a prognostic determinant in advanced colorectal cancer.

  Anticancer research 20050101

• Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.

  Oncology 20050101

• A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.

  Oncology 20050101

• Transfection assays with allele-specific constructs: functional analysis of UDP-glucuronosyltransferase variants.

  Methods in molecular biology (Clifton, N.J.) 20050101

• Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy.

  Anticancer research 20050101

• Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: case reports.

  Anticancer research 20050101

• Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.

  Anticancer research 20050101

• Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer.

  Anticancer research 20050101

• A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.

  Medical oncology (Northwood, London, England) 20050101

• Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.

  Medical oncology (Northwood, London, England) 20050101

• [Utilizing synergism].

  Krankenpflege Journal 20050101

• Clinical trial designs for prospective validation of biomarkers.

  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101

• Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan.

  Acta oncologica (Stockholm, Sweden) 20050101

• Clinical pharmacogenetics of irinotecan (CPT-11).

  Drug metabolism reviews 20050101

• Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics.

  International journal of toxicology 20050101

• Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?

  Nature clinical practice. Oncology 20050101

• Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?

  Nature clinical practice. Gastroenterology & hepatology 20050101

• Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG).

  Tumori 20050101

• High salt culture conditions suppress proliferation of rat C6 glioma cell by arresting cell-cycle progression at S-phase.

  Journal of molecular neuroscience : MN 20050101

• An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.

  Oncology 20050101

• [Biotherapy in colorectal cancer].

  Journal de chirurgie 20050101

• Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.

  Oncology 20050101

• Same-day pegfilgrastim and chemotherapy.

  Cancer investigation 20050101

• Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.

  Oncology 20050101

• Survival after oxaliplatin therapy of irinotecan-pretreated advanced colorectal cancer patients.

  Hepato-gastroenterology 20050101

• Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study.

  European journal of gynaecological oncology 20050101

• Chemotherapy for colorectal cancer.

  Digestive surgery 20050101

• Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines.

  Oncology research 20050101

• [New chances in therapy of gastrointestinal tumors].

  Krankenpflege Journal 20050101

• [The results of cetuximab treatment of a patient with multiple pretreated, irinotecan resistant metastatic colorectal cancer].

  Magyar onkologia 20050101

• Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.

  Oncology research 20050101

• [Chemotherapy of advanced stomach cancer].

  Zhonghua yi xue za zhi 20041217

• Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.

  Cancer research 20041215

• HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.

  Cancer research 20041215

• Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20041201

• Two schedules of second-line irinotecan for metastatic colon carcinoma.

  Cancer 20041201

• Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy.

  International journal of oncology 20041201

• Suppressive effect of CPT-11 on rat esophageal tumorigenesis induced by N-nitrosomethylbenzylamine.

  Oncology reports 20041201

• First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041201

• Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041201

• Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

  Annals of surgery 20041201

• Which drug combination for colorectal cancer?

  Expert opinion on pharmacotherapy 20041201

• Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

  Cancer research 20041201

• [Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20041201

• Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041201

• Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38.

  Clinical pharmacology and therapeutics 20041201

• [Colorectal cancer: current treatment options].

  Zeitschrift fur Gastroenterologie 20041201

• A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.

  Bulletin du cancer 20041201

• [Topoisomerase I inhibitor (irinotecan hydrochloride)].

  Nihon rinsho. Japanese journal of clinical medicine 20041201

• Irinotecan and other agents in the management of multiple tumor types. Highlights from the 6th University of Texas M. D. Anderson Cancer Center Investigators' Workshop. July 16-20, 2003, Amelia Island, Florida, USA.

  Oncology (Williston Park, N.Y.) 20041201

• Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.

  Oncology (Williston Park, N.Y.) 20041201

• Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.

  Oncology (Williston Park, N.Y.) 20041201

• Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.

  Oncology (Williston Park, N.Y.) 20041201

• Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma.

  Oncology (Williston Park, N.Y.) 20041201

• Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.

  Oncology (Williston Park, N.Y.) 20041201

• Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.

  Oncology (Williston Park, N.Y.) 20041201

• Combined-modality therapy of rectal cancer with irinotecan-based regimens.

  Oncology (Williston Park, N.Y.) 20041201

• Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer.

  Journal of experimental therapeutics & oncology 20041201

• [Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy].

  MMW Fortschritte der Medizin 20041118

• Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.

  Cancer 20041115

• Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041115

• Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

  Journal of the National Cancer Institute 20041103

• Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine.

  International journal of colorectal disease 20041101

• Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.

  Investigational new drugs 20041101

• The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.

  International journal of colorectal disease 20041101

• Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• Palliative chemotherapy for advanced gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041101

• A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.

  Clinical pharmacology and therapeutics 20041101

• Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11).

  Clinical pharmacology and therapeutics 20041101

• Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma.

  Journal of pediatric hematology/oncology 20041101

• Intergroup trial fails to demonstrate a benefit with the addition of irinotecan to bolus 5-fluorouracil/leucovorin in stage III colon cancer.

  Clinical colorectal cancer 20041101

• [A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041101

• [CPT-11 combined chemotherapy for metastatic gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041101

• [A case of liver metastatic recurrence of gastric cancer effectively treated by combined chemotherapy of CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041101

• Pemetrexed in advanced colorectal cancer.

  Oncology (Williston Park, N.Y.) 20041101

• Limited potential of hepatic arterial infusion of irinotecan.

  Journal of chemotherapy (Florence, Italy) 20041101

• Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.

  Journal of chemotherapy (Florence, Italy) 20041101

• Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents.

  Journal of medicinal chemistry 20041021

• Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.

  British journal of cancer 20041018

• A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.

  British journal of cancer 20041018

• Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.

  British journal of cancer 20041018

• Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX.

  British journal of cancer 20041018

• Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.

  Cancer 20041015

• Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.

  Cancer research 20041015

• Bevacizumab in colorectal cancer.

  The New England journal of medicine 20041014

• Cetuximab in colon cancer.

  The New England journal of medicine 20041007

• Cetuximab in colon cancer.

  The New England journal of medicine 20041007

• Excited-state proton transfer reactions of 10-hydroxycamptothecin.

  Journal of the American Chemical Society 20041006

• Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.

  Journal of the National Cancer Institute 20041006

• Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.

  Cancer chemotherapy and pharmacology 20041001

• New approaches to prevent intestinal toxicity of irinotecan-based regimens.

  Cancer treatment reviews 20041001

• New options and old dilemmas in the treatment of patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041001

• Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041001

• Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.

  Gynecologic oncology 20041001

• [Advances in palliative and adjuvant chemotherapy of colon cancer].

  Deutsche medizinische Wochenschrift (1946) 20041001

• Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.

  Anti-cancer drugs 20041001

• Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.

  The Annals of thoracic surgery 20041001

• Pharmacogenetics of irinotecan toxicity.

  Pharmacogenomics 20041001

• Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• [Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20041001

• [Chemotherapy using nedaplatin for advanced gynecologic cancers].

  Nihon rinsho. Japanese journal of clinical medicine 20041001

• [Treatment of platinum-resistant ovarian cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20041001

• [Kampo therapy for side effects of gynecologic carcinomatous chemotherapy].

  Nihon rinsho. Japanese journal of clinical medicine 20041001

• Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.

  International journal of clinical oncology 20041001

• Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma.

  International journal of clinical oncology 20041001

• [Successful treatment of liver metastasis and extrahepatic metastasis with hepatic arterial infusion of CDDP, CPT-11, and 5-FU].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• [Case report--Complete response of liver metastasis of rectal cancer after combination chemotherapy of CPT-11 + UFT-E].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• [CPT-11 hepatic arterial infusion chemotherapy for metastatic liver tumor from gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• [Evaluation of bronchial arterial infusion (BAI) for metastatic lung tumor from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• [A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?

  Journal of chemotherapy (Florence, Italy) 20041001

• Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours.

  International journal of clinical practice 20041001

• Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer.

  American journal of clinical oncology 20041001

• Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040915

• Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.

  Cancer research 20040915

• No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.

  British journal of cancer 20040913

• Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer.

  British journal of cancer 20040913

• Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients.

  Oncology reports 20040901

• Integration of novel agents in the treatment of colorectal cancer.

  Cancer chemotherapy and pharmacology 20040901

• Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20040901

• Pharmacogenomics and stomach cancer.

  Pharmacogenomics 20040901

• ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040901

• Gefitinib reverses breast cancer resistance protein-mediated drug resistance.

  Molecular cancer therapeutics 20040901

• Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.

  Clinical colorectal cancer 20040901

• Evidence-based update of chemotherapy options for metastatic colorectal cancer.

  ANZ journal of surgery 20040901

• [Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• [A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• [A case of 5-FU-resistant recurrent colon cancer treated with low-dose CPT-11/CDDP on an outpatient basis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.

  Pharmacogenetics 20040901

• Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study.

  Anti-cancer drugs 20040901

• Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.

  Anti-cancer drugs 20040901

• The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.

  Neoplasia (New York, N.Y.) 20040901

• Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).

  Journal of experimental & clinical cancer research : CR 20040901

• The treatment of colorectal carcinoma: standard chemotherapy and beyond.

  Clinical advances in hematology & oncology : H&O 20040901

• Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.

  Journal of the National Comprehensive Cancer Network : JNCCN 20040901

• Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.

  International journal of cancer 20040820

• Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.

  British journal of cancer 20040816

• UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.

  British journal of cancer 20040816

• Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

  Cancer research 20040815

• Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.

  British journal of cancer 20040802

• ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.

  The Journal of pharmacology and experimental therapeutics 20040801

• Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.

  Investigational new drugs 20040801

• Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.

  Journal of cancer research and clinical oncology 20040801

• Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.

  European urology 20040801

• Cisplatin enhances the p53-independent apoptosis induced by a topoisomerase I inhibitor (CPT-11) in the lens epithelial tumors in transgenic mice.

  Oncology reports 20040801

• Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.

  Oncology reports 20040801

• UGT1A1*28 polymorphism in ovarian cancer patients.

  Oncology reports 20040801

• Developments in combination chemotherapy for colorectal cancer.

  Expert review of anticancer therapy 20040801

• Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer.

  Journal of the American College of Surgeons 20040801

• Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040801

• Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040801

• Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay.

  Clinical chemistry 20040801

• Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.

  Journal of surgical oncology 20040801

• A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040801

• Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

  Journal of clinical pharmacology 20040801

• Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

  Gynecologic oncology 20040801

• Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040801

• Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.

  Molecular cancer therapeutics 20040801

• Treatment issues in pediatric gastric adenocarcinoma.

  Journal of pediatric surgery 20040801

• [A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040801

• [A successfully resected case of colorectal cancer with multiple liver metastases treated with systemic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040801

• [Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].

  Zentralblatt fur Chirurgie 20040801

• The price tag on progress--chemotherapy for colorectal cancer.

  The New England journal of medicine 20040722

• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  The New England journal of medicine 20040722

• New treatment options for colorectal cancer.

  The New England journal of medicine 20040722

• Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: an application in a clinical trial of unresectable non-small-cell lung cancer.

  Statistics in medicine 20040715

• Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040715

• Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer.

  Cancer research 20040715

• Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.

  Journal of cancer research and clinical oncology 20040701

• Treatment options for small cell lung cancer.

  Current oncology reports 20040701

• The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).

  Biochemical pharmacology 20040701

• A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20040701

• Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20040701

• Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer--experience from a prematurely closed phase II study.

  Lung cancer (Amsterdam, Netherlands) 20040701

• Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040701

• Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040701

• Irinotecan chemotherapy associated with transient dysarthria and aphasia.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040701

• Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.

  Anti-cancer drugs 20040701

• The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.

  European journal of biochemistry 20040701

• Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours.

  Expert opinion on pharmacotherapy 20040701

• Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression.

  Molecular pharmacology 20040701

• [A case of TS-1 resistant recurrent gastric cancer responding to TS-1 +CPT-11 combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040701

• Chemotherapy in gastric cancer: a brief chronicle with emphasis on recent developments.

  The Israel Medical Association journal : IMAJ 20040701

• Circadian rhythm of irinotecan tolerability in mice.

  Chronobiology international 20040701

• Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• Two new drugs for colon cancer.

  The Medical letter on drugs and therapeutics 20040607

• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  The New England journal of medicine 20040603

• Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.

  Cancer chemotherapy and pharmacology 20040601

• Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.

  Molecular pharmacology 20040601

• An immediate hemolytic reaction induced by repeated administration of oxaliplatin.

  Transfusion 20040601

• Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.

  Cancer 20040601

• Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.

  Anti-cancer drugs 20040601

• Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.

  Anti-cancer drugs 20040601

• Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.

  American journal of clinical oncology 20040601

• 'Irinogenetics' and UGT1A: from genotypes to haplotypes.

  Clinical pharmacology and therapeutics 20040601

• UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.

  Clinical pharmacology and therapeutics 20040601

• A novel mouse model of rectal cancer established by orthotopic implantation of colon cancer cells.

  Cancer science 20040601

• In vitro conversion of irinotecan to SN-38 in human plasma.

  Cancer science 20040601

• [Management of chemotherapy induced diarrhea].

  Zeitschrift fur Gastroenterologie 20040601

• Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.

  Gynecologic oncology 20040601

• Current approaches to first-line treatment of advanced colorectal cancer.

  Clinical colorectal cancer 20040601

• Current status of second-line therapy for metastatic colorectal cancer.

  Clinical colorectal cancer 20040601

• Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies.

  Clinical colorectal cancer 20040601

• Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.

  International journal of clinical oncology 20040601

• [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040601

• [Successful downstaging by a low-dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin in peritoneal lavage cytology positive, 5-fluorouracil refractory advanced gastric cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040601

• Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.

  The Journal of pharmacy and pharmacology 20040601

• Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.

  Onkologie 20040601

• [New therapy options in colorectal carcinoma].

  Therapeutische Umschau. Revue therapeutique 20040601

• Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.

  Oncology (Williston Park, N.Y.) 20040601

• Irinotecan in advanced lung cancer: focus on North American trials.

  Oncology (Williston Park, N.Y.) 20040601

• Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.

  Oncology (Williston Park, N.Y.) 20040601

• Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.

  Experimental oncology 20040601

• A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy.

  Japanese journal of clinical oncology 20040601

• Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

  British journal of cancer 20040517

• Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040515

• ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.

  International journal of cancer 20040510

• Modeling antitumor activity by using a non-linear mixed-effects model.

  Mathematical biosciences 20040501

• Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.

  Analytical biochemistry 20040501

• Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.

  Drug metabolism and disposition: the biological fate of chemicals 20040501

• A flow cytometric assay for simultaneous assessment of drug efflux, proliferation, and apoptosis.

  Cytometry. Part B, Clinical cytometry 20040501

• Irinotecan-induced interstitial pneumonia.

  The Lancet. Oncology 20040501

• In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.

  Cancer research 20040501

• The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11.

  Cancer science 20040501

• [Chemotherapy for small cell lung cancer].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20040501

• [A case of gastric metastasis of small cell cancer of the lung, regression of the gastric lesion after chemotherapy].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20040501

• [Chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040501

• [A case of colon carcinoma with unresectable multiple liver metastases responding to various combined chemotherapies centering on hepatic arterial infusion therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040501

• Reactivation of hepatitis C virus after chemotherapy for colon cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20040501

• Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.

  Clinical colorectal cancer 20040501

• Progress in the development of novel treatments for colorectal cancer.

  Oncology (Williston Park, N.Y.) 20040501

• Current strategies in previously untreated advanced colorectal cancer.

  Oncology (Williston Park, N.Y.) 20040501

• A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases.

  Japanese journal of clinical oncology 20040501

• [Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040501

• Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.

  British journal of cancer 20040419

• Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.

  British journal of cancer 20040419

• Irinotecan pharmacogenetics: is it time to intervene?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040415

• A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.

  Investigational new drugs 20040401

• Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction.

  Journal of cancer research and clinical oncology 20040401

• Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20040401

• Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040401

• Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040401

• Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040401

• Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

  Cancer research 20040401

• Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040401

• Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.

  International journal of clinical oncology 20040401

• [Screening of DNA topoisomerase inhibitors].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• [Screening for inhibitors of tumor invasion into basement membranes].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• [Structure-activity relationship analysis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• [Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

  Neuro-oncology 20040401

• Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

  Neuro-oncology 20040401

• Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma.

  International journal of hematology 20040401

• Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.

  Journal of experimental therapeutics & oncology 20040401

• Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040315

• Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040315

• Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line.

  Oncogene 20040304

• Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.

  Cancer chemotherapy and pharmacology 20040301

• Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.

  European journal of cancer (Oxford, England : 1990) 20040301

• Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040301

• Quantification of tumor tissue populations by multispectral analysis.

  Magnetic resonance in medicine 20040301

• Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?

  Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20040301

• A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040301

• Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.

  Anti-cancer drugs 20040301

• [Two cases of metastatic or recurrent rectal cancer responding to combined chemotherapy of low-dose CPT-11 and 5'-DFUR as second-line chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040301

• [A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040301

• [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040301

• Chemotherapy-induced lung disease.

  Clinics in chest medicine 20040301

• Chemotherapy of small cell lung cancer: state of the art.

  Current opinion in oncology 20040301

• Systemic treatment of advanced colorectal carcinoma.

  European journal of gastroenterology & hepatology 20040301

• [Resection of liver metastasis of colorectal origin following chemotherapy with irinotecan].

  Annales de chirurgie 20040301

• Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a model.

  Biochemistry 20040224

• Pheophorbide a is a specific probe for ABCG2 function and inhibition.

  Cancer research 20040215

• p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.

  Oncogene 20040212

• Development and characterization of a novel liposome-based formulation of SN-38.

  International journal of pharmaceutics 20040211

• Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.

  American journal of clinical oncology 20040201

• First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?

  Annals of oncology : official journal of the European Society for Medical Oncology 20040201

• Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.

  Cancer research 20040201

• Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex.

  Cancer research 20040201

• Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040201

• Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040201

• Focus on gastric cancer.

  Cancer cell 20040201

• Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failure.

  Internal medicine (Tokyo, Japan) 20040201

• A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.

  Journal of neuro-oncology 20040201

• New developments in the treatment of esophageal cancer.

  Clinical advances in hematology & oncology : H&O 20040201

• UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.

  British journal of cancer 20040126

• Biliary excretion of irinotecan and its metabolites.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20040123

• Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ('Iressa') and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.

  International journal of cancer 20040120

• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040115

• Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.

  Cancer 20040115

• Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).

  British journal of cancer 20040112

• Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.

  Cancer chemotherapy and pharmacology 20040101

• Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.

  International journal of cancer 20040101

• Enzyme-prodrug systems: carboxylesterase/CPT-11.

  Methods in molecular medicine 20040101

• Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.

  Biochemical pharmacology 20040101

• Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• First-line treatment strategies to improve survival in patients with advanced colorectal cancer.

  Drugs 20040101

• Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.

  European journal of cancer (Oxford, England : 1990) 20040101

• Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040101

• [Principles of postoperative therapy in rectal carcinoma].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20040101

• Biological characterization of MLN944: a potent DNA binding agent.

  Molecular cancer therapeutics 20040101

• Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.

  Gynecologic oncology 20040101

• FDA drug approval summaries: oxaliplatin.

  The oncologist 20040101

• Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

  Neuro-oncology 20040101

• Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

  Neuro-oncology 20040101

• Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer.

  Surgery today 20040101

• Treatment of colorectal cancer metastasis: the role of chemotherapy.

  Cancer metastasis reviews 20040101

• Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.

  Japanese journal of clinical oncology 20040101

• The role of new agents in the treatment of colorectal cancer.

  Oncology 20040101

• Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content.

  Oncology 20040101

• [Combined treatment of esophageal cancer: a review].

  Medicina (Kaunas, Lithuania) 20040101

• [The guidelines for diagnostics and treatment of cervical cancer].

  Medicina (Kaunas, Lithuania) 20040101

• Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).

  Oncology 20040101

• Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.

  Oncology 20040101

• Effect of human noxa on irinotecan-induced apoptosis in human gastric carcinoma cell lines.

  Hepato-gastroenterology 20040101

• 5-Fluorouracil: identification of novel downstream mediators of tumour response.

  Anticancer research 20040101

• Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.

  Anticancer research 20040101

• [Capecitabine and irinotecan].

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20040101

• A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.

  Oncology 20040101

• Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.

  BMC cancer 20040101

• Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors.

  The International journal of biological markers 20040101

• Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.

  BMC cancer 20040101

• Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.

  BMC cancer 20040101

• [Liver resection after downstaging with neoadjuvant chemotherapy for 'unresectable' colorectal metastases].

  Chirurgia italiana 20040101

• [Present-day potential of medication for disseminated cervical carcinoma].

  Voprosy onkologii 20040101

• First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.

  Oncology 20040101

• A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.

  Oncology 20040101

• Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.

  Medical oncology (Northwood, London, England) 20040101

• Role of DNA mismatch repair in apoptotic responses to therapeutic agents.

  Environmental and molecular mutagenesis 20040101

• Current perspectives in the treatment of metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.

  Cancer investigation 20040101

• Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy.

  Anticancer research 20040101

• UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers.

  Anticancer research 20040101

• Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer.

  Oncology 20040101

• Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.

  The oncologist 20040101

• Role of new agents in the treatment of colorectal cancer.

  Surgical oncology 20040101

• Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.

  Cancer investigation 20040101

• Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.

  Cancer investigation 20040101

• [Recent results of irinotecan therapy in colorectal cancer].

  Magyar onkologia 20040101

• Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan.

  Tumori 20040101

• Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.

  Oncology 20040101

• Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.

  Anticancer research 20040101

• Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.

  Anticancer research 20040101

• Progress in treatment of small-cell lung cancer: role of CPT-11.

  British journal of cancer 20031215

• Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.

  International journal of cancer 20031210

• Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy.

  Cancer chemotherapy and pharmacology 20031201

• Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.

  Cancer chemotherapy and pharmacology 20031201

• Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.

  Journal of cancer research and clinical oncology 20031201

• A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

  Annals of oncology : official journal of the European Society for Medical Oncology 20031201

• Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.

  Expert opinion on investigational drugs 20031201

• Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.

  Pharmacogenetics 20031201

• A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN38).

  Biomedical chromatography : BMC 20031201

• Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.

  International journal of clinical oncology 20031201

• Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.

  International journal of clinical oncology 20031201

• Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20031201

• Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20031201

• A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031201

• Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.

  Cancer research 20031201

• Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

  International journal of clinical pharmacology and therapeutics 20031201

• [Concurrent chemoradiation experience of recurrent gastric cancers resistant to TS-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031201

• [Novel molecular approaches in the therapy of advanced colorectal carcinoma].

  Onkologie 20031201

• The toxicity rates of two different regimens of irinotecan.

  Hepato-gastroenterology 20031201

• A phase II irinotecan-cisplatin combination in advanced pancreatic cancer.

  British journal of cancer 20031117

• A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.

  British journal of cancer 20031117

• Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.

  British journal of cancer 20031103

• Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.

  Cancer chemotherapy and pharmacology 20031101

• Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.

  Clinical chemistry 20031101

• Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.

  Investigational new drugs 20031101

• Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes.

  Investigational new drugs 20031101

• Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031101

• [Chemotherapy for gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• [Chemotherapy for colorectal carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• [A case of advanced cancer with liver metastasis and paraaortic lymph node metastasis responding remarkably to combination chemotherapy of low-dose CDDP, 5-FU and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• [A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• Presentations from the Walter Reed Army Medical Center. Case 1: rectal carcinoma.

  Oncology (Williston Park, N.Y.) 20031101

• [Campto (CPT-11) treatment of advanced large intestinal cancer: clinical experience].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20031101

• Overview of chemotherapy-induced diarrhea.

  Seminars in oncology nursing 20031101

• Development of new agents for the treatment of advanced colorectal cancer.

  Clinical colorectal cancer 20031101

• A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.

  Clinical colorectal cancer 20031101

• Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.

  Clinical colorectal cancer 20031101

• Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.

  Japanese journal of clinical oncology 20031101

• [A case of isolated hepatic malignant lymphoma representing characteristic findings on radiological imaging].

  Fukuoka igaku zasshi = Hukuoka acta medica 20031101

• Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

  British journal of cancer 20031020

• Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031015

• Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031015

• A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031015

• Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031015

• A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.

  Cancer research 20031015

• Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20031005

• A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20031001

• Colorectal cancer: integrating oxaliplatin.

  Current treatment options in oncology 20031001

• Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.

  The Journal of pharmacology and experimental therapeutics 20031001

• Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).

  Annals of oncology : official journal of the European Society for Medical Oncology 20031001

• Review article: colorectal cancer chemotherapy.

  Alimentary pharmacology & therapeutics 20031001

• Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.

  Gynecologic oncology 20031001

• Apoptotic pathways of epothilone BMS 310705.

  Gynecologic oncology 20031001

• Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?

  Anti-cancer drugs 20031001

• Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.

  Anti-cancer drugs 20031001

• Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan.

  Southern medical journal 20031001

• [Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].

  Nihon Geka Gakkai zasshi 20031001

• [The platelet-sparing effect of carboplatin and docetaxel combination chemotherapy for lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.

  Seminars in radiation oncology 20031001

• Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.

  Seminars in radiation oncology 20031001

• Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients.

  Journal of chemotherapy (Florence, Italy) 20031001

• Irinotecan (Campto) in the treatment of pancreatic cancer.

  Expert review of anticancer therapy 20031001

• [Experimental study on intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [A case of resected spinal metastasis following colectomy and hepatectomy for descending colon carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [A case of unresectable liver metastases from rectosigmoid colon cancer with survival for over 3 years after multidisciplinary treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [A case of spinal infarction related to hepatic arterial infusion chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [Long-term survival after neck lymph node metastases from sigmoid colon cancer--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• Current treatment and future directions in neuroblastoma.

  Indian journal of pediatrics 20031001

• Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.

  Methods and findings in experimental and clinical pharmacology 20031001

• Are there any better camptothecins than the ones we have?

  Clinical advances in hematology & oncology : H&O 20031001

• Pharmacogenomics: road to anticancer therapeutics nirvana?

  Oncogene 20030929

• Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.

  British journal of cancer 20030915

• Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.

  British journal of cancer 20030915

• Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.

  British journal of cancer 20030915

• Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.

  British journal of cancer 20030915

• Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030915

• Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.

  Cancer research 20030915

• Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.

  Journal of gastroenterology and hepatology 20030901

• Comment: Usefulness of herbal and dietary supplement references.

  The Annals of pharmacotherapy 20030901

• Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030901

• Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030901

• Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.

  Anti-cancer drugs 20030901

• [Controversial issues in chemotherapy for inoperable gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030901

• [Controversy of treatment for advanced colorectal cancer--intermedisine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030901

• PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy.

  Molecular cancer therapeutics 20030901

• Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.

  Leukemia & lymphoma 20030901

• Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction.

  Oncology (Williston Park, N.Y.) 20030901

• Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.

  Oncology (Williston Park, N.Y.) 20030901

• Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.

  Oncology (Williston Park, N.Y.) 20030901

• Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer.

  Oncology (Williston Park, N.Y.) 20030901

• Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.

  Oncology (Williston Park, N.Y.) 20030901

• Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.

  Oncology (Williston Park, N.Y.) 20030901

• Irinotecan in esophageal cancer.

  Oncology (Williston Park, N.Y.) 20030901

• Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.

  Oncology (Williston Park, N.Y.) 20030901

• [Polymorphism in colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Chemotherapy for colon cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Application and problems in hepatic arterial infusion chemotherapy].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Home chemotherapy and outpatient treatment for metastatic colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [5-fluorouracil and leucovorin therapy for advanced colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Present status of chemotherapy for colorectal cancer in countries outside of Japan].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Toxicities associated with chemotherapy in colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Radiotherapy for locally relapsed rectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Guidance and informed consent in colon cancer therapy].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model.

  Japanese journal of clinical oncology 20030901

• Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors.

  Journal of controlled release : official journal of the Controlled Release Society 20030828

• Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer.

  Journal of the National Cancer Institute 20030820

• Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.

  British journal of cancer 20030818

• Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.

  British journal of cancer 20030818

• Irinotecan pathway genotype analysis to predict pharmacokinetics.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030815

• Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.

  The Journal of pharmacology and experimental therapeutics 20030801

• Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20030801

• Advanced NSCLC: new cytostatic agents.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.

  Molecular pharmacology 20030801

• Intestinal permeability in colorectal cancer patients treated by raltitrexed or irinotecan.

  Journal of clinical gastroenterology 20030801

• Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study.

  International journal of radiation oncology, biology, physics 20030801

• A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030801

• Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030801

• Missing evidence for the adequacy of a 1-cm distal margin in resected rectal cancer.

  Annals of surgical oncology 20030801

• Tailoring chemotherapy in advanced colorectal cancer.

  Current opinion in pharmacology 20030801

• Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.

  Cancer research 20030801

• Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Expression and functional analyses of breast cancer resistance protein in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• [A case of multiple lung metastases from colon cancer after sigmoidectomy treated effectively by chemotherapy].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20030801

• [A patient with peritoneal metastasis from gastric cancer who responded to weekly chemotherapy with paclitaxel on the third line and could take meal].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030801

• [A case of effective weekly paclitaxel administration for metastatic gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030801

• Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.

  Molecular cancer therapeutics 20030801

• Validation of the role of angiogenesis as a chemotherapeutic target.

  Clinical colorectal cancer 20030801

• Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.

  Clinical colorectal cancer 20030801

• Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.

  Clinical colorectal cancer 20030801

• 5-fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line.

  Anti-cancer drugs 20030801

• CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians.

  Journal of chemotherapy (Florence, Italy) 20030801

• New perspectives in the management of pancreas cancer.

  Seminars in oncology 20030801

• Current and ongoing trials with irinotecan in the United States.

  Seminars in oncology 20030801

• Alternative schedules with irinotecan.

  Seminars in oncology 20030801

• Induction therapy in patients with metastatic colorectal cancer.

  Seminars in oncology 20030801

• Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.

  Seminars in oncology 20030801

• Evolving role of irinotecan in small-cell lung cancer.

  Clinical advances in hematology & oncology : H&O 20030801

• Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.

  European journal of pharmacology 20030725

• Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.

  Statistics in medicine 20030715

• Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38).

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030705

• Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20030701

• Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11).

  Medical and pediatric oncology 20030701

• A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.

  International journal of colorectal disease 20030701

• Is liver disease an octreotide side effect?

  Journal of clinical gastroenterology 20030701

• A phase II study of irinotecan in patients with advanced renal cell carcinoma.

  Cancer 20030701

• A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030701

• Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030701

• Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

• Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study.

  Chemotherapy 20030701

• Population-based maximum tolerated dose of irinotecan and carboplatin.

  Oncology (Williston Park, N.Y.) 20030701

• Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20030701

• Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20030701

• Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20030701

• The global role of irinotecan in the treatment of lung cancer: 2003 update.

  Oncology (Williston Park, N.Y.) 20030701

• A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.

  The Journal of surgical research 20030701

• Pharmacology of intraperitoneal CPT-11.

  Surgical oncology clinics of North America 20030701

• Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.

  The Netherlands journal of medicine 20030701

• Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.

  Clinical lung cancer 20030701

• Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

  British journal of cancer 20030616

• Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601

• Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030601

• Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.

  American journal of clinical oncology 20030601

• Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.

  Gynecologic oncology 20030601

• Optimal use of the combination of irinotecan and 5-fluorouracil.

  Seminars in oncology 20030601

• Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.

  Pharmaceutical research 20030601

• [Recent advances in chemotherapy for digestive cancers with special references to gastric and colonic cancers].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20030601

• [Chemotherapy-induced diarrhea].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030601

• [A case of gastric cancer with multiple liver metastasis responding to combination therapy of CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030601

• Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.

  Journal of chemotherapy (Florence, Italy) 20030601

• Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study.

  Journal of chemotherapy (Florence, Italy) 20030601

• Advances in colon cancer.

  Drug news & perspectives 20030601

• IPM chemotherapy in cytokine refractory renal cell cancer.

  British journal of cancer 20030519

• High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030505

• Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20030501

• Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).

  Annals of oncology : official journal of the European Society for Medical Oncology 20030501

• Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030501

• Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.

  Cancer 20030501

• The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.

  Cancer 20030501

• Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.

  Cancer 20030501

• Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.

  Cancer 20030501

• Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

  Cancer 20030501

• Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.

  Cancer gene therapy 20030501

• Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.

  Annals of surgical oncology 20030501

• Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030501

• Pharmacogenetics of irinotecan.

  Current medicinal chemistry. Anti-cancer agents 20030501

• [A case of colon cancer with liver metastases and lymph node metastases successfully treated with surgery followed by CPT-11 and 5-FU chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030501

• Irinotecan: promising activity in the treatment of malignant glioma.

  Oncology (Williston Park, N.Y.) 20030501

• Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.

  Oncology (Williston Park, N.Y.) 20030501

• Rationale for mitomycin and irinotecan use in advanced breast cancer.

  Oncology (Williston Park, N.Y.) 20030501

• Japanese ovarian trials: focus on irinotecan.

  Oncology (Williston Park, N.Y.) 20030501

• Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.

  Oncology (Williston Park, N.Y.) 20030501

• Phase I. Trial of irinotecan plus carboplatin in two dose schedules.

  Oncology (Williston Park, N.Y.) 20030501

• Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.

  Oncology (Williston Park, N.Y.) 20030501

• Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.

  Oncology (Williston Park, N.Y.) 20030501

• Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.

  Oncology (Williston Park, N.Y.) 20030501

• Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20030501

• Phlebitis due to irinotecan.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20030501

• [Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus].

  Gastroenterologie clinique et biologique 20030501

• Concurrent radiation therapy and irinotecan in stage IIIB cervical cancer.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20030501

• Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.

  British journal of cancer 20030422

• Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030401

• Lipid membrane with low proton permeability.

  Biochimica et biophysica acta 20030401

• Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.

  Lung cancer (Amsterdam, Netherlands) 20030401

• Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma.

  Diseases of the colon and rectum 20030401

• Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.

  Molecular cancer therapeutics 20030401

• Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage.

  American journal of clinical oncology 20030401

• [A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030401

• Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer.

  Japanese journal of clinical oncology 20030401

• Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.

  British journal of cancer 20030324

• Cancer pharmacogenomics: current and future applications.

  Biochimica et biophysica acta 20030317

• Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030315

• Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy.

  Bioorganic & medicinal chemistry letters 20030310

• CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype.

  Leukemia research 20030301

• Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030301

• An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030301

• Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030301

• Concern about similarity of manuscripts.

  Clinical pharmacology and therapeutics 20030301

• [A case of metastatic liver tumor of colorectal cancer responding to low-dose CPT-11 chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030301

• Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.

  Japanese journal of clinical oncology 20030301

• Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.

  Japanese journal of clinical oncology 20030301

• [Severe acute cytomegalovirus colitis after administration of irinotecan and raltitrexed chemotherapy].

  Gastroenterologie clinique et biologique 20030301

• [A case of paraneoplastic syndrome improved following chemoradiotherapy for lung cancer].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20030301

• [A symphony for the camptothecins].

  Bulletin du cancer 20030301

• Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.

  The Prostate 20030215

• Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.

  British journal of cancer 20030210

• Successful clinical response to irinotecan in relapsed neuroblastoma.

  Medical and pediatric oncology 20030201

• Limited stage small cell lung cancer: treatment and therapy.

  Current treatment options in oncology 20030201

• p53-mediated regulation of expression of a rabbit liver carboxylesterase confers sensitivity to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11).

  The Journal of pharmacology and experimental therapeutics 20030201

• High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma.

  Therapeutic drug monitoring 20030201

• Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.

  Cancer research 20030201

• Hepatic artery infusion for liver metastases from colorectal cancer.

  Lancet (London, England) 20030201

• Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.

  Lung cancer (Amsterdam, Netherlands) 20030201

• Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.

  Leukemia 20030201

• Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.

  International journal of clinical oncology 20030201

• [Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030201

• [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030201

• The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.

  Clinical colorectal cancer 20030201

• Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.

  Clinical colorectal cancer 20030201

• Chemotherapy for small cell lung cancer.

  Seminars in oncology 20030201

• [Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].

  Bulletin du cancer 20030201

• Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.

  Journal of neuro-oncology 20030201

• [Chemotherapy for colorectal cancers].

  Journal de chirurgie 20030201

• Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.

  Life sciences 20030124

• Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030115

• Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy.

  Oncology reports 20030101

• Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity.

  Drug metabolism and disposition: the biological fate of chemicals 20030101

• Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.

  Drug metabolism and disposition: the biological fate of chemicals 20030101

• Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.

  International journal of radiation oncology, biology, physics 20030101

• Antitumor properties of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol).

  Biological & pharmaceutical bulletin 20030101

• Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.

  Anti-cancer drugs 20030101

• Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20030101

• Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer.

  Oncology 20030101

• Lessons learned from the irinotecan metabolic pathway.

  Current medicinal chemistry 20030101

• A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703).

  Japanese journal of clinical oncology 20030101

• The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases.

  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20030101

• Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer.

  Medical oncology (Northwood, London, England) 20030101

• Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study.

  Anticancer research 20030101

• Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft.

  Urologic oncology 20030101

• Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.

  Oncology reports 20030101

• Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil.

  Oncology reports 20030101

• The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents.

  Oncology reports 20030101

• [Cytoreductive surgery of liver metastasis from colorectal cancer: principles of intra-arterial regional chemotherapy].

  Khirurgiia 20030101

• Palliative treatment of patients with colorectal cancer.

  Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society 20030101

• A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.

  Hepato-gastroenterology 20030101

• Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer.

  Oncology 20030101

• Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study.

  Oncology 20030101

• Metastatic colorectal cancer: systemic treatment in the new millennium.

  Cancer control : journal of the Moffitt Cancer Center 20030101

• Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports.

  European journal of gynaecological oncology 20030101

• Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Irinotecan in the treatment of gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Current treatments and future perspectives in colorectal and gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study.

  Anticancer research 20030101

• Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.

  Anticancer research 20030101

• Chemotherapy for advanced pancreatic cancer.

  International journal of radiation oncology, biology, physics 20030101

• Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: efficacy and prognostic factors.

  Tumori 20030101

• Irinotecan enhances IL-12 production by OK-432-activated murine macrophages.

  Anticancer research 20030101

• Epidermal growth factor receptor inhibition induces trichomegaly.

  Acta oncologica (Stockholm, Sweden) 20030101

• Treatment of advanced disease and new drugs.

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20030101

• Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer.

  Anticancer research 20030101

• Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.

  Anticancer research 20030101

• Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.

  Oncology 20030101

• Current chemotherapy for glioblastoma.

  Cancer journal (Sudbury, Mass.) 20030101

• SNP analysis by using ferrocenyl naphthalene diimide (FND)-based electrochemical hybridization assay (EHA).

  Nucleic acids research. Supplement (2001) 20030101

• Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20030101

• The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours.

  Oncology reports 20030101

• [The update on pancreatic cancer chemotherapy].

  Medicina (Kaunas, Lithuania) 20030101

• Clinical studies of camptothecin and derivatives.

  The Alkaloids. Chemistry and biology 20030101

• Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study.

  Tumori 20030101

• Single-agent irinotecan as second-line treatment for advanced gastric cancer.

  Tumori 20030101

• Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.

  Cancer investigation 20030101

• Combined modality therapy in esophageal cancer: the Memorial experience.

  Seminars in surgical oncology 20030101

• Palliative cytostatic treatment of cervical carcinoma.

  European journal of gynaecological oncology 20030101

• Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.

  Anticancer research 20030101

• Unexpected interactions between nicotinamide and CPT-11 in a rhabdomyosarcoma tumor model.

  Anticancer research 20030101

• A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.

  Cancer investigation 20030101

• New developments in systemic chemotherapy in advanced colorectal cancer.

  Scandinavian journal of gastroenterology. Supplement 20030101

• [Systemic treatment of colorectal cancers--factual standards and perspectives].

  Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 20030101

• [Novel combinations of irinotecan with molecular-targeted drugs in the treatment of colorectal carcinoma].

  Tumori 20030101

• Erbitux trial flawed from the beginning, committee finds.

  Journal of the National Cancer Institute 20021218

• Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021215

• Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.

  Archives of gynecology and obstetrics 20021201

• Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20021201

• Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021201

• Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021201

• Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021201

• Pharmacokinetics of irinotecan and its metabolites.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021201

• Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.

  Expert opinion on investigational drugs 20021201

• Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.

  Pharmacogenetics 20021201

• Novel therapeutic approaches in the treatment of children with hepatoblastoma.

  Journal of pediatric hematology/oncology 20021201

• Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).

  American journal of clinical oncology 20021201

• Challenging the platinum combinations in the chemotherapy of NSCLC.

  Lung cancer (Amsterdam, Netherlands) 20021201

• Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20021201

• Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.

  Clinical pharmacology and therapeutics 20021201

• Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.

  Oncology (Williston Park, N.Y.) 20021201

• Current status of capecitabine in the treatment of colorectal cancer.

  Oncology (Williston Park, N.Y.) 20021201

• [Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021201

• Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.

  Zeitschrift fur Gastroenterologie 20021201

• The role of pemetrexed in the treatment of colorectal cancer.

  Seminars in oncology 20021201

• Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.

  Seminars in oncology 20021201

• Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.

  Cytokine 20021124

• Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.

  British journal of cancer 20021118

• Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.

  The Journal of biological chemistry 20021115

• Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.

  International journal of oncology 20021101

• The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.

  The Journal of pharmacology and experimental therapeutics 20021101

• Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors.

  Cancer 20021101

• Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021101

• Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021101

• Non-platinum gemcitabine combinations in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20021101

• Unexpected pleural effusions in 3 pediatric patients treated with STI-571.

  Journal of pediatric hematology/oncology 20021101

• Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.

  Anti-cancer drugs 20021101

• High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20021101

• [Glutamate transporter mediated increase of antitumor activity by theanine, an amino acid in green tea].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20021101

• [A case of AFP-producing gastric cancer with multiple liver metastases responding to CPT-11 and cisplatin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Dysarthria during irinotecan administration].

  La Revue de medecine interne 20021101

• Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.

  Clinical colorectal cancer 20021101

• Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.

  Clinical colorectal cancer 20021101

• Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.

  Clinical colorectal cancer 20021101

• Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.

  Clinical colorectal cancer 20021101

• [A case of postoperative liver metastasis of alpha-fetoprotein producing gastric cancer successfully treated with intrahepatic chemotherapy (adriamycin, cisplatin, irinotecan hydrochloride)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [A case of ovarian cancer in which a remarkable effect was seen with low-dose CDDP intratumoral injection of CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Hepatic arterial infusion with irinotecan for the colorectal cancer patient with liver metastasis--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [A case of stage IV diffusely infiltrating colon cancer treated by surgical resection and chemoradiation therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [A case of gastric cancer associated with synchronous liver metastasis successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Gastrointestinal toxicity caused by irinotecan in the case of preexistent passage problems].

  Nederlands tijdschrift voor geneeskunde 20021026

• Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.

  Biochemical pharmacology 20021015

• Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

  Cancer research 20021015

• Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.

  Cancer research 20021015

• Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.

  British journal of cancer 20021007

• Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.

  Cancer 20021001

• Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021001

• Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.

  Cancer chemotherapy and pharmacology 20021001

• SN-38 induces cell cycle arrest and apoptosis in human testicular cancer.

  European urology 20021001

• Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 20021001

• Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021001

• A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021001

• Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer: a phase II study.

  American journal of clinical oncology 20021001

• Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.

  American journal of clinical oncology 20021001

• [A case of colon metastasis to the lung treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021001

• The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.

  Seminars in oncology 20021001

• Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.

  Seminars in oncology 20021001

• Epithelial growth factor receptor interacting agents.

  Hematology/oncology clinics of North America 20021001

• Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.

  British journal of cancer 20020923

• Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020915

• Secreted and tumour targeted human carboxylesterase for activation of irinotecan.

  British journal of cancer 20020909

• Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer.

  Panminerva medica 20020901

• Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity.

  Molecular pharmacology 20020901

• Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).

  Molecular pharmacology 20020901

• Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020901

• Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020901

• Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 20020901

• Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients.

  Cancer research 20020901

• Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status.

  International journal of cancer 20020901

• Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.

  Chemotherapy 20020901

• Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models.

  Biometrics 20020901

• Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20020901

• Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.

  Clinical pharmacology and therapeutics 20020901

• Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.

  Journal of neuro-oncology 20020901

• Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.

  Journal of cancer research and clinical oncology 20020901

• [Randomized controlled trials in Japan--lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020901

• Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs.

  Japanese journal of cancer research : Gann 20020901

• Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20020901

• Camptothecin and taxane regimens for small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20020901

• Irinotecan plus cisplatin in small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20020901

• Current role of irinotecan in the treatment of non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20020901

• Efficacy and tolerability of irinotecan in patients with advanced colorectal cancer in Singapore.

  Annals of the Academy of Medicine, Singapore 20020901

• Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

  Pharmaceutical research 20020901

• O6-benzylguanine-mediated enhancement of chemotherapy.

  Molecular cancer therapeutics 20020901

• Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.

  Human cell 20020901

• St. John's Wort: more implications for cancer patients.

  Journal of the National Cancer Institute 20020821

• Effects of St. John's wort on irinotecan metabolism.

  Journal of the National Cancer Institute 20020821

• Nitric oxide-induced Cl- secretion in isolated rat colon is mediated by the release of thromboxane A2.

  The Journal of physiology 20020815

• Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.

  International journal of oncology 20020801

• Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.

  Lung cancer (Amsterdam, Netherlands) 20020801

• Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020801

• Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020801

• Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020801

• Targeting vascular endothelial growth factor in colorectal cancer.

  Oncology (Williston Park, N.Y.) 20020801

• Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report.

  Oncology (Williston Park, N.Y.) 20020801

• Mitomycin as a modulator of irinotecan anticancer activity.

  Oncology (Williston Park, N.Y.) 20020801

• Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.

  Oncology (Williston Park, N.Y.) 20020801

• Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.

  Oncology (Williston Park, N.Y.) 20020801

• Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.

  Internal medicine (Tokyo, Japan) 20020801

• [Three patients with advanced nonresectable and recurrent gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by CPT-11 administration].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020801

• [CPT-11 hepatic arterial injection plus oral UFT administration for liver metastasis of rectal cancer--report of two cases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020801

• Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.

  Onkologie 20020801

• [Gemcitabine-based combinations in inoperable pancreatic cancers].

  Bulletin du cancer 20020801

• Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.

  Clinical colorectal cancer 20020801

• N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.

  Clinical colorectal cancer 20020801

• The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.

  Clinical colorectal cancer 20020801

• Irinotecan in 5-fluorouracil-refractory colorectal cancer.

  Clinical colorectal cancer 20020801

• Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.

  Clinical colorectal cancer 20020801

• Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.

  British journal of cancer 20020729

• Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation.

  The Journal of biological chemistry 20020719

• Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.

  British journal of cancer 20020715

• Modulation of irinotecan metabolism by ketoconazole.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020715

• Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.

  Cancer research 20020715

• GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.

  International journal of oncology 20020701

• Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.

  International journal of oncology 20020701

• Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.

  Drug metabolism and disposition: the biological fate of chemicals 20020701

• Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020701

• Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020701

• Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.

  International journal of cancer 20020701

• Another NICE mess.

  The Lancet. Oncology 20020701

• [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020701

• Chemotherapy for metastatic colorectal cancer.

  Drug and therapeutics bulletin 20020701

• Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 and oxaliplatin.

  Anti-cancer drugs 20020701

• Non-linear pharmacokinetics of irinotecan in mice.

  Anti-cancer drugs 20020701

• Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.

  British journal of cancer 20020617

• Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.

  British journal of cancer 20020605

• Determination of drug interactions occurring with the metabolic pathways of irinotecan.

  Drug metabolism and disposition: the biological fate of chemicals 20020601

• Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020601

• Thalidomide and irinotecan-associated diarrhea.

  American journal of clinical oncology 20020601

• Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.

  European journal of cancer (Oxford, England : 1990) 20020601

• Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.

  Anti-cancer drugs 20020601

• Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.

  Japanese journal of cancer research : Gann 20020601

• [A case of advanced colon cancer with para-aortic lymph node metastasis responding greatly to treatment by adjuvant chemotherapy of low-dose CPT-11 on an outpatient basis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020601

• New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.

  Expert review of anticancer therapy 20020601

• ERBITUX as a single agent and in combination in colorectal carcinoma.

  Expert review of anticancer therapy 20020601

• Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020601

• Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.

  Seminars in oncology 20020601

• Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

  Current cancer drug targets 20020601

• C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

  Molecular cancer therapeutics 20020601

• Loss of one allele of the p53 gene in the lens epithelial tumor in transgenic mice suppresses apoptosis induced by a topoisomerase I inhibitor (CPT-11).

  Cancer letters 20020528

• [Irinotekan in spread small cell lung cancer. More studies are required to change the practice].

  Lakartidningen 20020523

• Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.

  Oncogene 20020516

• Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs.

  British journal of cancer 20020506

• Irinotecan in small-cell lung cancer.

  The New England journal of medicine 20020502

• An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry.

  Biomedical chromatography : BMC 20020501

• New developments in the treatment of esophageal cancer.

  Current oncology reports 20020501

• Structural insights into CPT-11 activation by mammalian carboxylesterases.

  Nature structural biology 20020501

• Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

• Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

• Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

• Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination.

  Chemotherapy 20020501

• Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.

  Japanese journal of cancer research : Gann 20020501

• [Current status of the chemotherapy for lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020501

• [A case of rectal cancer with multiple liver metastases that responded dramatically to pharmacokinetic modulating chemotherapy/CPT-11 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020501

• [Usefulness of low-dose irinotecan for multiple lung metastases of cholangiocellular carcinoma after operation--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020501

• [Small cell lung cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• [Irinotecan].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• [Recent progress in the treatment of ED small cell lung cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• [New treatment strategy for stage III non-small-cell lung cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• Irinotecan, cisplatin, and radiation in esophageal cancer.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan and gemcitabine in patients with solid tumors: phase I trial.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan in epithelial ovarian cancer.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan for the treatment of cervical cancer.

  Oncology (Williston Park, N.Y.) 20020501

• Combined-modality therapy for rectal cancer using irinotecan.

  Oncology (Williston Park, N.Y.) 20020501

• Preoperative chemoradiation for locally advanced rectal cancer: emerging treatment strategies.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.

  Clinical colorectal cancer 20020501

• Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20020501

• Lessons learned from the Saltz and Mayo Clinic regimens.

  Clinical colorectal cancer 20020501

• Chemoradiation with novel agents for rectal cancer.

  Clinical colorectal cancer 20020501

• Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.

  Cancer 20020415

• Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.

  International journal of oncology 20020401

• Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.

  Drug metabolism and disposition: the biological fate of chemicals 20020401

• Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin.

  Molecular pharmacology 20020401

• Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.

  Cancer chemotherapy and pharmacology 20020401

• Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.

  Cancer chemotherapy and pharmacology 20020401

• Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.

  Neuro-oncology 20020401

• Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

  American journal of clinical oncology 20020401

• Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.

  Clinical pharmacology and therapeutics 20020401

• [Antitumor activity of combination treatment combining gemcitabine with topotecin against human lung cancer xenografted in nude mice].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020401

• [A case of recurrent rectal cancer responding to weekly low-dose CPT-11/isovorin/5-fluorouracil].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020401

• [Chemotherapy for the patients with esophageal cancer].

  Nihon Geka Gakkai zasshi 20020401

• Update on European adjuvant trials with irinotecan for colorectal cancer.

  Oncology (Williston Park, N.Y.) 20020401

• Irinotecan/thalidomide in metastatic colorectal cancer.

  Oncology (Williston Park, N.Y.) 20020401

• Capecitabine/irinotecan combination regimens in colorectal cancer.

  Oncology (Williston Park, N.Y.) 20020401

• Irinotecan therapy for small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20020401

• Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice.

  British journal of cancer 20020318

• Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.

  British journal of cancer 20020318

• Stability of irinotecan hydrochloride in aqueous solutions.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020315

• DNA damage is able to induce senescence in tumor cells in vitro and in vivo.

  Cancer research 20020315

• Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.

  Lung cancer (Amsterdam, Netherlands) 20020301

• Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020301

• Combined chemotherapy trials require combined pharmacogenetic approaches.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020301

• Promising drug is victim of bad business.

  Nature medicine 20020301

• Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination.

  Mutagenesis 20020301

• Fighting wars, winning battles.

  Annals of surgical oncology 20020301

• Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases.

  Annals of surgical oncology 20020301

• [A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020301

• Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.

  Japanese journal of cancer research : Gann 20020301

• Factors influencing the cellular accumulation of SN-38 and camptothecin.

  Cancer chemotherapy and pharmacology 20020301

• [Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20020301

• Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020301

• Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020215

• Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.

  Biochemical pharmacology 20020215

• Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer.

  British journal of cancer 20020212

• Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.

  Biochemistry 20020205

• Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts.

  International journal of oncology 20020201

• Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.

  Therapeutic drug monitoring 20020201

• Nothing succeeds like failure.

  Nature biotechnology 20020201

• Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.

  American journal of clinical oncology 20020201

• Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020201

• Future treatment options with capecitabine in solid tumours.

  European journal of cancer (Oxford, England : 1990) 20020201

• ImClone BLA is declined.

  Nature biotechnology 20020201

• Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.

  Cancer 20020201

• CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.

  Cancer 20020201

• [Globalization of anti-cancer therapies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020201

• [Apoptosis as a measure of chemosensitivity to anti-cancer drugs in gynecological cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020201

• [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020201

• Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.

  Gan to kagaku ryoho. Cancer & chemotherapy 20020201

• Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.

  Journal of chemotherapy (Florence, Italy) 20020201

• Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure.

  Onkologie 20020201

• Gemcitabine-based combination treatment of pancreatic cancer.

  Seminars in oncology 20020201

• Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.

  Seminars in oncology 20020201

• Altered irinotecan metabolism in a patient receiving phenytoin.

  Anti-cancer drugs 20020201

• Prediction of the response of colorectal cancer to systemic therapy.

  The Lancet. Oncology 20020201

• [Developed new agents for lung cancer].

  Nihon Geka Gakkai zasshi 20020201

• Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.

  Journal of pediatric hematology/oncology 20020201

• Influence of phenytoin on the disposition of irinotecan: a case report.

  Journal of pediatric hematology/oncology 20020201

• Clinical trials using irinotecan.

  Journal of pediatric hematology/oncology 20020201

• Phase I study of irinotecan in pediatric patients with malignant solid tumors.

  Journal of pediatric hematology/oncology 20020201

• Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor.

  Journal of neuro-oncology 20020201

• A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.

  Hematology/oncology clinics of North America 20020201

• Adjuvant therapy of colon cancer: a review.

  Clinical colorectal cancer 20020201

• [The new chemotherapy of colorectal cancers].

  Presse medicale (Paris, France : 1983) 20020126

• Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

  The New England journal of medicine 20020110

• Lung cancer--time to move on from chemotherapy.

  The New England journal of medicine 20020110

• Irinotecan dosing: does the CPT in CPT-11 stand for 'Can't Predict Toxicity'?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101

• Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101

• Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101

• Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.

  Cancer research 20020101

• Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020101

• O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.

  Japanese journal of cancer research : Gann 20020101

• Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20020101

• Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test.

  Oncology reports 20020101

• Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.

  Cancer investigation 20020101

• Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.

  BMC cancer 20020101

• Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.

  Anti-cancer drugs 20020101

• Chronotherapy of colorectal cancer.

  Chronobiology international 20020101

• Third Wave, Daiichi to develop personalized cancer treatment.

  Expert review of molecular diagnostics 20020101

• UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.

  The pharmacogenomics journal 20020101

• Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20020101

• Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme.

  Journal of neuro-oncology 20020101

• An HIV treatment the world may never see.

  Positively aware : the monthly journal of the Test Positive Aware Network 20020101

• In vitro schedule-dependent interaction between irinotecan and vinorelbine in NCI H460 non-small cell lung cancer cell line.

  Anticancer research 20020101

• Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.

  Anticancer research 20020101

• A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.

  Oncology 20020101

• Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil.

  Oncology reports 20020101

• Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases.

  Hepato-gastroenterology 20020101

• Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer.

  Hepato-gastroenterology 20020101

• A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.

  Anticancer research 20020101

• Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer.

  Oncology 20020101

• Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.

  Oncology 20020101

• Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects.

  Cancer detection and prevention 20020101

• Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.

  Oncology 20020101

• Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.

  Clinical & experimental metastasis 20020101

• In vivo advantage of combined administration with CPT-11 and 5-fluorouracil in rats.

  Journal of experimental therapeutics & oncology 20020101

• CDK inhibitors: cell cycle arrest versus apoptosis.

  Cell cycle (Georgetown, Tex.) 20020101

• The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.

  Cancer investigation 20020101

• Irinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases.

  Surgery today 20020101

• Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.

  Anticancer research 20020101

• Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer.

  Anticancer research 20020101

• Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.

  Anticancer research 20020101

• Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.

  Cancer biology & therapy 20020101

• Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats.

  Drug metabolism and drug interactions 20020101

• CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.

  International journal of gastrointestinal cancer 20020101

• A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.

  International journal of gastrointestinal cancer 20020101

• Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20011201

• Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20011201

• Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study.

  Toxicology and applied pharmacology 20011201

• Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20011201

• Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20011201

• Radiosensitization with chemotherapeutic agents.

  Lung cancer (Amsterdam, Netherlands) 20011201

• CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.

  Japanese journal of cancer research : Gann 20011201

• Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• [Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011201

• [Chemotherapy of colorectal carcinoma].

  Der Internist 20011201

• Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.

  Cancer chemotherapy and pharmacology 20011201

• Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011201

• Quantitation of camptothecin and related compounds.

  Journal of chromatography. B, Biomedical sciences and applications 20011125

• Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011115

• Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.

  Biochemical and biophysical research communications 20011109

• A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.

  Drug metabolism and disposition: the biological fate of chemicals 20011101

• Unique action determinants of double acting topoisomerase inhibitor, TAS-103.

  International journal of oncology 20011101

• Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells.

  Cancer research 20011101

• Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011101

• Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.

  Japanese journal of cancer research : Gann 20011101

• [A case of lung metastasis from colon cancer treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011101

• Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes.

  Cancer immunology, immunotherapy : CII 20011101

• Toxicity of irinotecan in patients with colorectal cancer.

  The New England journal of medicine 20011101

• A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011101

• Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011101

• [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].

  Revue de pneumologie clinique 20011101

• Perspectives in colorectal cancer meeting. Miami, Florida. September 28-29, 2001.

  Clinical colorectal cancer 20011101

• Capecitabine combinations in the treatment of advanced colorectal cancer.

  Clinical colorectal cancer 20011101

• Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.

  Clinical colorectal cancer 20011101

• Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011015

• Downregulation of topoisomerase I in differentiating human intestinal epithelial cells.

  International journal of cancer 20011015

• [New therapeutic options in chemotherapy of advanced colorectal cancer].

  Medizinische Klinik (Munich, Germany : 1983) 20011015

• High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells.

  Analytical biochemistry 20011001

• Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer.

  The British journal of surgery 20011001

• Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.

  Anti-cancer drugs 20011001

• [Standard therapy of CPT-11 for colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin.

  Xenobiotica; the fate of foreign compounds in biological systems 20011001

• [Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• [Sigmoid colon cancer with multiple liver metastasis (H3) effectively treated with CPT-11 and DSM (degradable starch microsphere) HAI therapy and intensive high dosage 5-FU HAI therapy--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• [Four cases of multiple liver metastasis of colorectal cancer treated with hepatic resection after chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• [Two cases of multiple liver metastases of colon cancer with systemic irinotecan and hepatic arterial injection of 5-FU].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• Irinotecan-induced dysarthria.

  Journal of the National Cancer Institute 20010919

• Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

  Cancer research 20010915

• Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010915

• Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20010901

• Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE).

  British journal of pharmacology 20010901

• [A case of esophageal small-cell carcinoma responding to chemotherapy with CTP-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010901

• Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.

  Cancer chemotherapy and pharmacology 20010901

• Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010901

• The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.

  Human cell 20010901

• Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.

  Molecular pharmacology 20010801

• Phase I clinical trial of weekly combined topotecan and irinotecan.

  American journal of clinical oncology 20010801

• Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010801

• Two unusual sites of colon cancer metastases and a rare thyroid lymphoma. Case 2. Chemotherapy-responsive right artial metastasis from colon carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010801

• Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction.

  Anti-cancer drugs 20010801

• Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010801

• High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes.

  Biomedical chromatography : BMC 20010801

• Temozolomide in combination with other cytotoxic agents.

  Seminars in oncology 20010801

• Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20010801

• [Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer].

  Bulletin du cancer 20010801

• Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.

  Japanese journal of clinical oncology 20010801

• Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20010801

• Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165.

  Acta pharmacologica Sinica 20010801

• Irinotecan in the treatment of small cell lung cancer.

  Expert review of anticancer therapy 20010801

• Therapeutic advances in the management of metastatic colorectal cancer.

  Expert review of anticancer therapy 20010801

• Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.

  Clinical colorectal cancer 20010801

• Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.

  Clinical colorectal cancer 20010801

• Review of the role of CPT-11 in the treatment of colorectal cancer.

  Clinical colorectal cancer 20010801

• Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

  The New England journal of medicine 20010712

• Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

  The New England journal of medicine 20010712

• Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase.

  Cancer research 20010701

• A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11.

  Cancer research 20010701

• Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 20010701

• Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group.

  British journal of cancer 20010701

• Researchers urge caution with standard regimen for metastatic colorectal cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010701

• [Usefulness of chemotherapy with CPT-11 in clinic for three colorectal cancer in terminal stage].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010701

• Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.

  Cancer chemotherapy and pharmacology 20010701

• The emerging world role of irinotecan in lung cancer.

  Oncology (Williston Park, N.Y.) 20010701

• Irinotecan and radiation in combined-modality therapy for solid tumors.

  Oncology (Williston Park, N.Y.) 20010701

• Rationale for non-platinum chemotherapy in advanced NSCLC.

  Oncology (Williston Park, N.Y.) 20010701

• Topoisomerase I inhibitors in the treatment of head and neck cancer.

  Oncology (Williston Park, N.Y.) 20010701

• Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.

  Oncology (Williston Park, N.Y.) 20010701

• Role of topoisomerase I inhibitors in small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20010701

• Recent advances in the chemotherapy of non-small cell lung cancer.

  Japanese journal of clinical oncology 20010701

• Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study.

  Annals of hematology 20010701

• Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver.

  Journal of pharmaceutical sciences 20010601

• Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.

  Anti-cancer drugs 20010601

• Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer.

  American journal of clinical oncology 20010601

• Control of irinotecan-induced diarrhea by octreotide after loperamide failure.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20010601

• [A case of advanced gastric cancer treated with neoadjuvant chemotherapy of low-dose CPT-11 + CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010601

• [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010601

• Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.

  Seminars in oncology 20010601

• [Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20010601

• Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.

  The Surgical clinics of North America 20010601

• Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.

  Pharmaceutical research 20010601

• Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.

  Seminars in oncology 20010601

• In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.

  Osaka city medical journal 20010601

• Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010515

• Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.

  International journal of oncology 20010501

• Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20010501

• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  Cancer research 20010501

• Impact on survival following successful neoadjuvant chemotherapy and radical surgery for Stage IIb bulky and Stage IIIb cervical cancer.

  Gynecologic oncology 20010501

• Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010501

• CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.

  Japanese journal of cancer research : Gann 20010501

• [Platinum compounds in cancer therapy--past, present, and future].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010501

• [A modified administrated schedule for combination therapy with irinotecan and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical cancer--a report of 2 cases as a pilot study].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010501

• Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer.

  Cancer chemotherapy and pharmacology 20010501

• Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.

  The Lancet. Oncology 20010501

• 25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.

  Clinical colorectal cancer 20010501

• Advances in the treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20010501

• Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.

  Clinical colorectal cancer 20010501

• Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.

  International journal of cancer 20010415

• Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.

  Cancer letters 20010410

• Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.

  Drug metabolism and disposition: the biological fate of chemicals 20010401

• Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.

  Cancer research 20010401

• [Chemotherapy by combination of low-dose CPT-11 and PSK in an elderly man with liver metastasis from gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010401

• Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan.

  Cancer chemotherapy and pharmacology 20010401

• The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.

  Oncology (Williston Park, N.Y.) 20010401

• A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010401

• Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010401

• 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.

  Journal of cellular biochemistry 20010401

• [Chemotherapy of irinotecan (CPT-11) combined with cisplatin in patients with advanced gastric cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• [Irinotecan (CPT-11) therapy for advanced gastric cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• [Home chemotherapy and/or outpatient chemotherapy for patient with advanced gastric cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• [New chemotherapies for colorectal cancer treatment].

  Gastroenterologie clinique et biologique 20010401

• Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.

  The Journal of biological chemistry 20010316

• Determinants of prognosis and response to therapy in colorectal cancer.

  Current oncology reports 20010301

• Oxaliplatin: a new agent for colorectal cancer.

  Current oncology reports 20010301

• Topoisomerase I targeting agents in small-cell lung cancer.

  Current oncology reports 20010301

• Irinotecan in the treatment of colorectal cancer: clinical overview.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010301

• [A case of AFP-producing gastric cancer responding to low-dose CPT-11 and low-dose cisplatin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010301

• Cisplatin and irinotecan in upper gastrointestinal malignancies.

  Oncology (Williston Park, N.Y.) 20010301

• Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.

  Oncology (Williston Park, N.Y.) 20010301

• Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma.

  Oncology (Williston Park, N.Y.) 20010301

• Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.

  Biochimica et biophysica acta 20010216

• Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010215

• Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma.

  Cancer 20010215

• Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.

  Cancer 20010215

• Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

  Biochemical and biophysical research communications 20010209

• Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.

  British journal of cancer 20010201

• Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb / 3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II.

  Japanese journal of cancer research : Gann 20010201

• Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer.

  American journal of clinical oncology 20010201

• [Weekly low dose CPT-11 for multiple lung metastases of colon cancer on an out-patient treatment: a case report].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20010201

• Adjuvant therapy of colon cancer.

  Seminars in oncology 20010201

• North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.

  Seminars in oncology 20010201

• [Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?].

  Onkologie 20010201

• A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.

  Anti-cancer drug design 20010201

• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  The New England journal of medicine 20010125

• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  The New England journal of medicine 20010125

• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  The New England journal of medicine 20010125

• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  The New England journal of medicine 20010125

• Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.

  Cancer research 20010115

• The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

  Cancer research 20010115

• The changing face of chemotherapy in colorectal cancer.

  British journal of cancer 20010101

• A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.

  Cancer 20010101

• Gemcitabine: progress in the treatment of pancreatic cancer.

  Oncology 20010101

• Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.

  British journal of pharmacology 20010101

• Irinotecan: a new agent comes of age.

  The oncologist 20010101

• Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond.

  The oncologist 20010101

• Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

  The oncologist 20010101

• Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

  Clinical and experimental immunology 20010101

• [A case of small cell carcinoma of esophagus successfully treated by chemotherapy with CPT-11 and CDDP].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20010101

• In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• Irinotecan in small-cell lung cancer: the US experience.

  Oncology (Williston Park, N.Y.) 20010101

• Establishment of the standard regimen for non-small-cell lung cancer in Japan.

  Oncology (Williston Park, N.Y.) 20010101

• Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule.

  Oncology (Williston Park, N.Y.) 20010101

• Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20010101

• Docetaxel followed by gemcitabine and irinotecan in solid tumors.

  Oncology (Williston Park, N.Y.) 20010101

• Irinotecan: summary and future directions.

  Oncology (Williston Park, N.Y.) 20010101

• Current status of irinotecan in lung cancer.

  Oncology (Williston Park, N.Y.) 20010101

• New state of the art in small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20010101

• Chemoradiation in locally advanced non-small cell lung cancer.

  Cancer treatment and research 20010101

• Lung cancer: therapeutic options for stage IV and recurrent NSCLC.

  Cancer treatment and research 20010101

• Treatment of extensive stage small cell lung cancer.

  Cancer treatment and research 20010101

• Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.

  Oncology 20010101

• Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.

  Investigational new drugs 20010101

• Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.

  Anticancer research 20010101

• [Irinotecan in colorectal cancer].

  Tumori 20010101

• [Molecular factors predictive of response to chemotherapy in advanced stages of colorectal cancer].

  Tumori 20010101

• Adjuvant therapy for colon cancer: the European experience.

  Tumori 20010101

• A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.

  Oncology 20010101

• Morphological classification of dental lesions induced by various antitumor drugs in mice.

  Toxicologic pathology 20010101

• Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.

  Investigational new drugs 20010101

• New adjuvant therapies for esophageal cancer.

  Advances in surgery 20010101

• Optimizing the use of irinotecan in colorectal cancer.

  The oncologist 20010101

• Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report.

  Tumori 20010101

• A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

  Anticancer research 20010101

• Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.

  Bioconjugate chemistry 20010101

• Streptococcal preparation OK-432 enhances the antitumor activity of CPT-11 by increasing Th1-cytokine production in mice.

  Anticancer research 20010101

• Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

  The oncologist 20010101

• The development of camptothecin analogs in childhood cancers.

  The oncologist 20010101

• Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20010101

• [Irinotecan and fluorouracil in combination in colorectal carcinoma: a little clarity].

  Tumori 20010101

• Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report.

  European journal of gynaecological oncology 20010101

• UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.

  AAPS pharmSci 20010101

• Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases--a pilot experience.

  Hepato-gastroenterology 20010101

• [Irinotecan and tomudex in the treatment of patients with advanced cancer of the large intestine].

  Voprosy onkologii 20010101

• Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma.

  Anticancer research 20010101

• Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: results of a phase I clinical study.

  Tumori 20010101

• A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

  Health technology assessment (Winchester, England) 20010101

• [Proceedings of the 3rd National Conference of Medical Oncology. Irinotecan: present and future. Napoli, Italy, 5 November 2001].

  Tumori 20010101

• [Colorectal cancer: irinotecan in combination with newer drugs].

  Tumori 20010101

• [Irinotecan in the treatment of stomach cancer].

  Tumori 20010101

• [Role of irinotecan in the treatment of small cell carcinoma].

  Tumori 20010101

• The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.

  Anti-cancer drug design 20010101

• Irinotecan hydrochloride.

  Clinical journal of oncology nursing 20010101

• New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.

  International journal of cancer 20001015

• Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.

  Cancer research 20000301

• Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

  Cancer research 19991201

• Bradycardia induced by irinotecan: a case report.

  Japanese journal of clinical oncology 19981101

• Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA.

  Cancer research 19981001

• 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.

  Clinical & experimental metastasis 19981001

• Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.

  The Journal of pharmacology and experimental therapeutics 19980701

• Clinical pharmacokinetics of irinotecan.

  Clinical pharmacokinetics 19971001

• Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.

  British journal of cancer 19960801

• Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

  Cancer research 19930615

• Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.

  Cancer chemotherapy and pharmacology 19880101

• Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.

  Cancer chemotherapy and pharmacology 19880101

• Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.

  Cancer research 19871115